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As complex organisms, animals and humans rely on a delicate interplay between many 
connected systems to maintain proper cellular and whole-body function. Oxygen regulation and 
homeostasis are vital for proper function in healthy cells, as are core components of aerobic 
metabolism and efficient ATP generation to supply our energy needs. Maintaining pH 
homeostasis is also of primary importance; cells maintain pH homeostasis through a host of 
active and passive transporters to maintain pH balance both inside and outside of the cell.  
Events of uncontrolled cellular proliferation, also known as cancer, survive and thrive 
under conditions that perturb the delicate balance of both oxygen and pH homeostasis. Because 
tumors rapidly divide, they outgrow the vasculature that supplies them with the nutrients they 
require, including O2. This causes the hypoxia dependent expression of enzymes that shifts the 
tumor microenvironment into anaerobic metabolic states, resulting in the overproduction of lactic 





This thesis is focused on the development of chemical tools to image oxygen 
 and pH (mis)regulation within the tumor microenvironment. To accomplish this, we use 
chemiluminescent 1,2-dioxetane compounds that emit light in response to analytes within their 
chemical environment. Specifically, we developed an activity-based hypoxia sensing 
chemiluminescence probe that emits light under low O2 conditions. HyCL-4-AM provides a 
selective 60,000-fold increase in luminescence emission in the presence of rat liver microsomes 
(RLM), and provides highly sensitive and reproduceable O2 dependent emission in cells. Whole 
animal imaging experiments in muscle tissue and tumor xenografts show that HyCL-4-AM can 
differentiate between well oxygenated muscle tissue and hypoxic tumors, demonstrating 
potential for monitoring tumor reoxygenation via hyperoxic treatment. 
Furthermore, we report a chemiluminescence resonance energy transfer (CRET) 
probe Ratio-pHCL-1, that transfers energy from the dioxetane substrate to a pH responsive 
fluorophore. The probe provides an accurate measurement of pH between 6.8 and 8.4, making it 
a viable tool for measuring pH in biological systems. Using an IVIS Spectrum, pH can be 
measured through tissue with Ratio-pHCL-1, which is shown in vitro and calibrated in 
sacrificed mouse models. Intraperitoneal injections of Ratio-pHCL-1 into live mice show high 
photon outputs and consistent increases in flux ratio when measured at pH 6, 7, and 8. This 
design could ultimately be used to study pH heterogeneity within the tumor microenvironment.  
Finally, we report UVC-454, UVA-454, and Spiro-CL as photoactivatable 
chemiluminescence compounds. UVC-454 and UVA-454 are protected with ortho-nitrobenzyl 
protecting groups that provide irreversible photochemical uncaging of the chemiluminophore 
species through UV light irradiation. UVC-454 and UVA-454 can be selectively activated based 
on uncaging wavelength, and demonstrate ability to be photoactivated in water. Spiro-CL is a 
 vi 
novel chemiluminescent spiropyran that can reversibly interconvert from its stable spiropyran 
form to a metastable merocyanine form through UV or visible light irradiation, respectively. 
Further, this compound exhibits chemiluminescence in its open form upon irradiation with UV 
light in DMSO.
 vii 
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Figure 2-1. Response of HyCL-3 and HyCL-4-AM. Chemiluminescence emission 
spectra of (A) 10 µM HyCL-3 (blue trace) before and (red trace) after treatment 
with 1 µg mL–1 NTR and 0.2 mM NADH and (B) 10 µM HyCL-4-AM (blue 
trace) before and (red trace) after treatment with 1 µg mL–1 NTR, 0.2 mM NADH, 
and 1 U mL–1 PLE. (C) Integrated emission intensity of 10 µM HyCL-4-AM (red 
trace) or HyCL-3 (blue trace) alone or with 200–1000 ng mL–1 NTR and 0.2 mM 
NADH. PLE (1 U mL–1) was added for HyCL-4-AM. (D) Time-course of the 
chemiluminescence emission of 10 µM HyCL-4-AM alone (blue trace) or with 
200, 400, 600, 800, and (red trace) 1000 ng mL–1 NTR, 0.2 mM NADH, and 1 U 
mL–1 PLE. All experiments were performed in 20 mM PBS (pH 7.4) containing ≤ 
1% DMSO. Error bars are ± S.D. 44 
Figure 2-2. Response of HyCL-3. (A) Time-course and (B) integrated emission intensity 
of the chemiluminescence emission of 10 µM HyCL-3 alone (blue trace) or with 
2.5, 5, 7.5, 10, and (red trace) 12.5 mg mL–1 NTR, and 0.4 mM NADH. All 
experiments were performed in 20 mM PBS (pH 7.4) containing ≤ 1% DMSO. 
Values are the average of 3 technical replicates. Error bars are ± S.D. 44 
Figure 2-3. Mass spectrum of the peak assigned to adamantanone from HyCL-3 Inset is 
the NIST standard. 45 
Figure 2-4. Mass spectrum of the peak assigned to hydroxylamine for HyCL-3. 45 
Figure 2-5. Mass spectrum of the peak assigned to adamantanone for HyCL-4-AM. Inset 
is the NIST standard. 46 
Figure 2-6. Mass spectrum of the peak assigned to the hydroxylamine for HyCL-4-AM. 46 
Figure 2-7. Selectivity of HyCL-3 ad HyCL-4-AM. Response of (A) 20 µM HyCL-3 in 
the (blue trace) absence and (red trace) presence of 200 µg mL–1 rat liver 
microsomes (RLM) and 50 µM NADPH and (B) 20 µM HyCL-4-AM in the 
(blue trace) absence and (red trace) presence of 200 µg mL–1 rat liver microsomes 
(RLM) and 50 µM NADPH. Response of (C) 20 µM HyCL-3 and (D) 20 µM 
HyCL-4-AM to the indicated analytes from 0 to (red bars) 50 min at 10-minute 
increments. All experiments were performed in 10 mM PBS (pH 7.4) containing 
≤ 1% DMSO. Error bars are ± S.D. 48 
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Figure 2-8. pH dependence of acrylate dioxetane phenol. Response to 2 µM acrylate 
dioxetane phenol in the presence of 20 mM carbonate, PBS, or Tris buffer (pH 
2.98-10.04) containing 5% DMSO. 49 
Figure 2-9. HyCL-3 Cellular Data. (A) A549 cells were incubated with 0–100 µM 
HyCL-3 for 16 hours and then viability was evaluated using the MTT assay. 
Error bars are ± S.D. from n = 3 replicates. (B) Time-course of the 
chemiluminescence emission of A549 cells incubated with 40 µM HyCL-3 at 
(red trace) 1% O2 or (blue trace) 20% O2. (C) Luminescence intensity of 40 µM 
HyCL-3 at t = 30 min in 1% O2 and 20% O2 in A549 cells. Error bars are ± S.D. 
from n = 9 wells across 3 biological replicates. Statistical significance was 
assessed using a Student's two-tailed t-test. ***** p<5x10–6. 50 
Figure 2-10. HyCL-4-AM MTT assay. A549 cells were incubated with 0–100 µM 
HyCL-3 for 16 hours and then viability was evaluated using the MTT assay. 
Error bars are ± S.D. from n = 3 technical replicates. 51 
Figure 2-11. Measuring hypoxia in living A549 cells. (A)–(C) Time-course of the 
chemiluminescence emission of A549 cells incubated with 40 µM HyCL-4-AM 
at 1% O2, 5% O2 or 20% O2 in the presence or absence of DPI. (D) 
Chemiluminescence emission intensity at 300 min of A549 cells incubated with 
40 µM HyCL-4-AM at 1% O2, 5% O2, and 20% O2. (E) Measured rate constants 
for the cellular response of HyCL-4-AM. (F) Time-course of the 
chemiluminescence emission of A549 cells incubated with 40 µM HyCL-4-AM-
Cont at 20% O2 in the presence or absence of DPI. All experiments were 
performed in F12K containing 10% FBS and ≤ 1% DMSO. Error bars are ± S.D. 
Statistical significance was assessed using a two-tailed Student's t-test. *p<0.05 
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trace) presence and (blue trace) absence of A549 cells at 1% O2 and 37 ºC. Values 
are the average of n = 3 technical replicates, except for the red trace in Figure 2-
12A, which are the average of n = 9 wells across three biological replicates. 52 
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biological pH. (A) Time-course of the chemiluminescent emission of 0, 0.5, 1.0, 
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in 20 mM PBS (pH = 7.4) and ≤ 1% DMSO.  53 
Figure 2-14. Kinetic model. (A) Reactions used to model the chemiluminescence 
emission. (B) Rate equation for the chemiluminescence emission. y-value 
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represents [HyCL-4] generated after k1. (C) Example fit of the chemiluminescence 
response of 40 µM HyCL-4-AM in A549 cells at 1% O2. (D) Example fit of the 
chemiluminescence response of 40 µM HyCL-4-AM in A549 cells at 20% O2. 54 
Figure 2-15. Measuring oxygenation in healthy muscle tissue and tumor xenografts. 
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mice after intramuscular (IM) injection into the flank, intratumoral injection while 
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were breathing 100% O2 (IT, 100%). (D) Photon flux and (E) chemiluminescence 
images of athymic nude mice 60 minutes after IM injection, IT injection while 
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Error bars are ± S.E. from n = 3–6 mice. Statistical significance was assessed 
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5% DMSO) and (red trace) chemiluminescence emission spectra of 20 µM methyl 
acrylate dioxetane phenol67 (100 mM PBS, pH 7.45, 5% DMSO). 95 
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Light is one of the most fundamental aspects of the natural world. Plants process light 
using photosynthesis to create energy, ultimately supplying us with both food to eat and oxygen 
to breathe. Animals,1–3 bacteria,4 and plants5,6 have developed advanced photoreceptors to enable 
them to respond to light stimuli. Light is prevalent all around us, and the ability to create, 
manipulate, and harness light has been integral to the development of the human species.  
 Light comes in many forms; The most common form is the generation of light through 
combustion or heating, also known as incandescence.7 Incandescence arises as a byproduct of 
heating a substance, where molecules will give off energy in the form of a photon as a means of 
reducing their energetic state. These are known as “hot light” sources. Fire is the main example 
of combustion-based light production where cellulose in the presence of oxygen will combust, 
releasing energy stored in the wood to create light, heat, char, carbon monoxide, carbon dioxide, 
and water. Light bulbs are also a source of incandescence, where a carbon filament inside of the 
bulb acts as a resistor in an electrical current, and is heated to a point where a small percentage of 
energy put into the system is released as light. 
 
1.1  Chemiluminescence  
Light, however, does not just occur from “hot light” sources. There are many natural 
examples of “cold light” generation, where photonic emission arises from sources other than 
 2 
heat. One such process is the result of chemiluminescence, where a chemical reaction causes the 
excitation and concomitant emission of a photon. A Jablonski diagram of a chemiluminescence 
reaction is given in Scheme 1-1, showing the requirements of a chemiluminescence reaction.8 
The reaction needs to be sufficiently exothermic to excite the product formed during the reaction 
into an excited state. Upon relaxation back to the ground state, the energy can be released either 
in the form of a quantized emission of a photon, or through heat in the process of thermal 
relaxation. This dissertation will focus on light production through “cold” luminescence sources 
and their applications in science and technology. 
 
Scheme 1-1. Potential energy diagrams for (a) an exothermic reaction and (b) a 




Numerous methods have been shown to produce chemiluminescence, including light generation 
from gas phase reactions between nitric oxide and ozone, sulfur and ozone, and fluorine-based 
chemiluminescence systems.9–13 Other common systems include electrochemiluminescence,14–19 

















1.1.1 Gas phase chemiluminescence 
A few interesting gas phase reactions involving ozone and other species can also generate 
chemiluminescence. Sulfur compounds such as H2S, Me2S, MeSH and others can be oxidized to 
form SO radical, which can be reacted with ozone in the following reaction to form excited SO2 
(Scheme 1-2).9,10 Gas phase detection of NOx can also be detected in a similar manner, where 
generation of NO combined with ozone also creates chemiluminescent emission. These reactions 
have been utilized for detection and quantification of sulfur and nitrogen compounds through GC 
analysis.11,12 Atomic fluorine or CF4 can be reacted with both organic and inorganic hydrides, 
and some hydrocarbons in the gas phase to produce fluorine-based chemiluminescence.13 
 




Electrochemiluminescence, or ECL is luminescence emission caused by the generation of 
excited state species on electrode surfaces, and is a means of converting electrical energy into 
photonic emission.14 Perhaps the most utilized method for ECL generation is through alternating 
voltage potentials on Ru(bpy)32+ to produce electrochemiluminescence emission from the excited 
state Ru(bpy)32+ species (Scheme 1-3.). Ru(bpy)32+ is an example of annihilation induced ECL, 
where an electron transfer reaction occurs between an excited and reduced species generated by 
pulsing voltage potentials at the electrode react, “annihilating” both the oxidized and reduced 
form to produce the emitting compound in the excited state.15 
 
SO O3 SO2* O2+ SO2 + hν+
NO O3 NO2* O2+ NO2 + hν+
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Scheme 1-3. Mechanism of electrogenerated chemiluminescence emission from Tris(2,2’-
bipyridine)ruthenium dichloride.  
 
 
Other forms of ECL generation have been successfully utilized. Coreactant ECL is one 
such form, where a redox active species will be introduced to the system to react with the 
emitter. Common redox active compounds employed as coreactants include the oxalate16,17 and 
peroxydisulfate ions,18 and tri-n-propylamine (TPrA),19  
 Electrochemiluminescence has proven useful in many analytical techniques including 
electrochemical assays for analyte detection. Multitudes of analytes have been successfully 
detected and quantified through ECL including small molecules, drugs, explosives, and viral and 
bacterial DNA and RNA,14 showing extensive utility through accurate quantification methods 
and sensitivity of analytes of down to 10-11M. 
 
1.1.3 1,2-Dioxetanones 
Classical chemiluminescence systems are derived from the breaking of highly energetic 
chemical bonds. Notably, decomposition of strained peroxide bonds including dioxetanes, 
dioxetanones, dioxetanediones, and dioxins, are commonly utilized reactions for 
chemilumincence emission, and examples of these reactions have been produced both 
synthetically and in the natural world. These small molecule chemiluminescence generating 
compounds share a common endoperoxide motif with either a-carbonyl or CR2 groups.  
Ru(bpy)32+ Ru(bpy)33+- e- EºRu2+/3+ = +1.2V
Ru(bpy)32+ Ru(bpy)31++ e- EºRu2+/1+ = -1.4V
Ru(bpy)32+ Ru(bpy)31++ Ru(bpy)3 2+ Ru(bpy)32++
Ru(bpy)3 2+ Ru(bpy)32+ + hν
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Dioxetanones and dioxetanediones are key players in chemiluminescence generation. 
Dioxetanones specifically have an important role to play in nature, as they are the most common 
bioluminescence substrates in luciferin/luciferase pairs.21 D-luciferin derived from the north 
American firefly Photinus pyralis has been the most extensively studied of all luciferins. The 
structure and mechanism of chemiluminescence from D-luciferin are given in Scheme 1-4.22 D-
luciferin is activated to luciferyl adenylate, and will react with superoxide in a single electron 
transfer mechanism23 and displacement of the AMP ester to obtain the dioxetanone intermediate. 
Decomposition of the dioxetanone releases CO2 to generate oxyluciferin in the excited state. 
 




 While oxyluciferin serves as the luminophore, many factors play into determining its 
emission profile. The primary cause of changes in emission is the luciferase itself, where both 
structural differences from protein to protein enact changes in the microenvironment where the 
luminescence reaction is catalyzed, and ultimately influences the electronics of the emitter.24 
Oxyluciferin exists in up to 6 different forms depending on its microenvironment, and each of 
those forms have varying emission profiles ranging from 420–620 nm.25  
 
1.1.4 1,2-Dioxetanediones 
Dioxetanediones represent another key intermediate generated for chemiluminescence 

















































peroxyoxalate, finding that some oxalyl esters26 and oxalyl chloride27 could be reacted with H2O2 
and base (Scheme 1-5) to generate chemiluminescence with quantum yields of up to 23% in 
aqueous solution with the addition of rubrene as the fluorescer. 
 
Scheme 1-5. Mechanism of peroxyoxalate decomposition. 
 
 
1.1.5 1,2-Dioxins  
1,2-dioxins are unstable intermediates that can provide the energetic requirements for 
chemiluminescence emission. Perhaps the most widely recognized form of chemiluminescence 
detection, luminol, is often utilized for the detection of blood samples because heme iron found 
in blood catalyzes luminescent emission from the molecule in the presence of molecular oxygen. 
Luminol first reacts with base to form the dianionic intermediate, followed by the interaction 
with  triplet oxygen in the presence of heme iron to form a 1,2-dioxin upon the release of 
molecular nitrogen. Cleavage of the dioxin will excite the luminophore giving blue emission 



























Scheme 1-6. Chemical structure of luminol and mechanism of heme iron-catalyzed 




1,2-dioxetanes were first synthesized in 1969 in the form of 3,3,4-trimethyl-1,2-
dioxetane30 as a confirmation of theoretical reports stating that the decomposition of such 
compounds should yield an excited state carbonyl product. This was indeed the case, and thermal 
decomposition of the compound yielded chemiluminescence emission near 435 nm. Other early 
dioxetanes were also prepared,31 but had short half-lives. In 1972, Wieringa and coworkers 
postulated that bulky groups could stabilize the dioxetane compounds, and installation of an 
endoperoxide onto adamantylideneadamantane via triplet photosensitization of oxygen provided 
the most stable 1,2-dioxetane to date, exhibiting a half-life of approximately 20 years.32  
 
1.2 Mechanisms of decomposition and luminescence 
1.2.1 Thermal decomposition of 1,2-dioxetanes and relatives 
The thermal stability of 1,2-dioxetanes is determined by the activation energy required to 
initiate uncatalyzed decomposition of the dioxetane, and the mechanism of this decomposition 
has been hotly debated in the literature. Through experimental and theoretical mechanistic 
studies, three separate mechanisms have been proposed, including concerted cleavage, stepwise 







































Scheme 1-7. Proposed mechanisms for unimolecular and uncatalyzed 1,2-dioxetane 
decomposition. From top to bottom: the concerted mechanism, the merged (asynchronous-




The concerted mechanism indicates that both C-C and O-O bond cleavage occur at the 
same time through simultaneous bond lengthening and breaking processes. However, this is 
likely a simplistic mechanistic view, as it does not take into account the inherent weakness of O-
O bonds. The proposed biradical mechanism first involves O-O bond cleavage, leaving a 
biradical intermediate. This intermediate will then rotate 180º about the O-C-C-O dihedral angle 
to the anti-conformer, followed by C-C bond cleavage to generate both excited and ground state 
carbonyl products. The biradical mechanism better fits experimental data exploring the topic,33,34 
however, the concerted mechanism better explains formation of singlet and triplet excited states 
upon decomposition. A combination of the two mechanisms, the asynchronous-concerted, or 
merged mechanism, has been proposed to account for these discrepancies. The asynchronous-
concerted mechanism includes lengthening of both C-C and O-O bonds, along with simultaneous 
torsion about the O-C-C-O dihedral angle to approximately 44º to initiate O-O bond cleavage, 
serving as the rate limiting step for the reaction.35 The C-C bond shortly breaks thereafter, with 




























1.2.2 Activated decomposition of 1,2-dioxetanes and relatives 
It was found during the study of 1,2-dioxetanes, dioxetanones, and dioxetanediones, that  
decomposition was catalyzed by aromatic compounds.26,37,38 This phenomenon was investigated 
by Koo and Schuster in 1977.39 They uncovered that chemiluminescence intensity given off by 
diphenoyl peroxide was proportional to the concentration of added aromatic hydrocarbons, 
indicating that a bimolecular reaction was occurring to induce chemiluminescence. They 
proposed a mechanism, termed chemically initiated electron exchange luminescence (CIEEL), 
where the aromatic hydrocarbon serves as an activator in a bimolecular electron transfer reaction. 
The mechanism, given in Scheme 1-8 shows that an electron from the activator is donated into 
peroxide bond. The bond is then cleaved and a strongly reducing radical anion species is formed 
in solvent cage with the activator. An electron back transfer occurs, annihilating both radical 
species, and rendering the initial electron donor (activator) in the excited state and able to emit a 
photon through relaxation.  
 



















+ ArH* ArH + hν
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Chemiluminescence generation in the presence of activators through the bimolecular 
CIEEL mechanism provided a means to generate chemiluminescence emission at a much faster 
rate, and has been studied extensively with various aromatic compounds. Bioluminescent 
substrates such as D-luciferin, however, are unimolecular emitters with a 1,2-dioxetanone 
intermediate. Researchers thus expected that D-luciferin proceeds via a unimolecular activation 
CIEEL process.40 It was also known that bioluminescence emission wavelength and intensity 
from D-luciferin varied with pH. E.H. White and coworkers in 1966 synthesized analogs of 
luciferin to examine the role of the 6’-OH group on D-luciferin bioluminescence. They found 
that only 6’-OH and 6’-NH2 groups were capable of bioluminescence, and deprotonation of the 
6’-OH yielded a much brighter luminescent species when subjected to luciferase, suggesting that 
the increased electron density of the amino and phenolate groups served as particularly strong 
activators in the CIEEL mechanism.41 Inspired by this work, Schaap and coworkers synthesized 
a model compound of D-luciferin bearing a phenol covalently appended to a 1,2-dioxetane 
scaffold in 1982.42 The protonated dioxetane species exhibited a half-life of 17 years, and low 
singlet chemiexcitation efficiency. However, deprotonation of the phenol group to the phenolate 
exhibited an over 4x106-fold increase in decomposition kinetics, a sharp increase in singlet 
chemiexcitation efficiency, and showed similar flash luminescence properties to that firefly 
bioluminescence.  
In a series of three flagship papers, Schaap and coworkers reported chemical and 
enzymatic triggering of 1,2-dioxetanes using adamantylidene-substituted phenoxy-dioxetane 
chemiluminescent substrate. These papers had two-fold importance: 1. By protecting the 
phenolate of the dioxetane with selective trigger, one could cage the chemiluminescence 
substrate from reacting until it reacted with analytes of interest (commonly known as activity-
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based reactions in the probe world) 2. The newly synthesized chemiluminescent scaffold 
combined the excellent dioxetane-stabilizing properties of the adamantylidene group32 along 
with the flash luminescence capabilities derived from D-luciferin.42 This design strategy has 
proven to be extremely prolific, as almost all synthesized 1,2-dioxetane chemiluminescence 
agents can be derived from this core structure.  
 
1.3 1,2-Dioxetane Chemiluminescence Enhancement Strategies 
A clear trend in the development of chemiluminescence has been to create brighter 
chemiluminophores with red-shifted emission. Increasing the brightness ultimately increases the 
signal to noise response, providing lower detection limits of analytes relative to the concentration 
of the dioxetane. Red-shifted emission has two-fold importance. 1. The use of visible-light/ NIR-
light emission window greatly reduces risk of cellular damage by irradiation. 2. NIR light can 
pass through tissue to a much greater extent than UV and visible light, allowing for much higher 
depth penetration by compounds that possess NIR emission capabilities. Brighter, red-shifted 
chemiluminescence substrates have so far been achieved through multiple methods including 
encapsulation via luminescence enhancers, chemiluminescence self-amplification mechanisms, 
and direct scaffold modification, and creation of dioxetane-fluorophore conjugates. 
 
1.3.1 Self-amplification 
An interesting method to obtain chemiluminescence enhancement is through 
chemiluminescence self-amplification mechanisms. Gnaim and Shabat provided two such 
examples of auto-amplifying chemiluminescence substrates for fluoride43 (Scheme 1-9.) and 
H2O2.44 The general mechanism of these reactions follows that the chemiluminescence probe 
will react selectively with an analyte to generate luminescence emission while simultaneously 
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releasing the analyte it was reacted with to generate a chain reaction. Low concentrations of 
analyte are required for these systems, but the signal/noise is ultimately low. 
 




Methods of chemiluminescence encapsulation effectively enhance chemiluminescence by 
creating a hydrophobic environment for the chemiluminescence reaction to occur, thus reducing 
aqueous quenching effects. Sapphire IITM, Emerald IITM, and RubyTM are commercial polymeric 
enhancers developed by Applied Biosystems to increase sensitivity via encapsulation, while 
providing luminescence emission at 475 nm, 542 nm, and 620 nm, respectively. Both Emerald 
and Ruby enhancers contain fluorescent compounds that redshift the emission wavelength of the 
chemiluminophore through an energy transfer mechanism (Scheme 1-10). Other methods of 

























micelles, as well as luminescence enhancement via supramolecular complexation with b-
cyclodextrin.45b While these enhancement strategies are important findings, they are not ideal for 
cellular studies due to issues with cytotoxicity and low cell permeability.  
 
Scheme 1-10. Mechanism of luminescence enhancement through polymeric encapsulation. 
 
 
1.3.3 Fluorophore conjugation 
This method of chemiluminescence enhancement involves the direct conjugation of 
highly fluorescent compounds to the dioxetane structure, providing chemiluminescent emission 
through the appended fluorophore via resonance energy transfer. Schaap and Arkhavan-Tafti 
first adapted this methodology in a patent issued in 1997, where they conjugated a fluorescein or 
6-hydroxybenzothiazoate to the CL scaffold by tethering through the enol ether position.46 This 



































their aryl esterase-cleaved dioxetanes. This was later studied tby Hananya and others in 2016, 
showing up to 114-fold improvement in fCL through attaching fluorescein via a benzylamine 
linker directly bonded to the phenol of the CL scaffold, as well as NIR CL emission when a 
cyanine was appended to the structure instead.47 
 
1.3.4 Direct modification 
Perhaps the most important methods to increase brightness in chemiluminescence agents 
lie in direct modification of the chemiluminescent scaffold (Scheme 1-11). In the development of 
a viable in vivo chemiluminescence probe for hydrogen sulfide, Cao et. al. in 2015 studied the 
effect of halogen substitution on the dioxetane phenol substrate, finding that ortho-chlorination 
relative to the phenol had the greatest effect in lowering the pKa of the phenol relative to 
hydrogen and fluorine substitution at the same position, ultimately increasing brightness by 
increasing concentration of the phenolate-dioxetane (and therefore rate of CIEEL) at biological 
pH,48 This was later confirmed to be the case as well with acrylate-substituted dioxetanes.49 
 
Scheme 1-11. Advances in direct structural modification of 1,2-dioxetane compounds. 
 
 
Another major advancement in chemiluminescence technology came in 2017, where 




















scaffold, further decreasing the pKa of the phenol and generating much greater degree of 
electronic push-pull in the chemiluminophore p system.50 This red-shifted the wavelength of 
chemiluminescence emission to 530 nm, and increased the chemiluminescence quantum yield to 
up to 9.8% with acrylonitrile substitution, which is an approximate 3000-fold increase in 
quantum yield over the unsubstituted dioxetane. Styryl-substitution at the same position provided 
improvement in chemiexcitation efficiency, which the authors attribute to stabilization of the key 
diradical species generated during CIEEL.51 Other examples of scaffold modification include the 
production of NIR chemiluminescence emission from a dicyanomethylchromone (DCMC) 
substituted dioxetane by further increasing p conjugation within the chemiluminophore,52 as well 
as the development of a chemiluminescent coumarin-based scaffold with extremely high 
chemiluminescence quantum yield in aqueous media.53 
 
1.4 Activity-based sensing 
The field of activity-based sensing is based upon the design of chemoselective reactions to 
determine the concentration, reactivity, and activity of biomolecules in living systems.54 This is 
accomplished by exploiting inherent reactivity of these compounds to undergo selective 
transformations, which are then quantified by reporter compounds linked to the sensor. This 
process is often referred to a lock and key mechanism, where the lock is a caged reporter that 
will selectively react with a specific analyte, undergo chemical change, and ultimately unlock 
properties from the reporter that can be used to detect or quantify the analyte it reacted with. 
Because activity-based sensing is founded upon the detection of biomolecules, reporters must be 
biocompatible and exhibit ability to detect through tissue. Furthermore, the reaction should be 
selective with only one analyte to ensure accurate data. Finally, the reaction kinetics need to take 
place under reasonable time frames in physiological conditions to be considered true and 
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accurate. Therefore, tuning the reactivity, biocompatibility and reporting properties of the probe 
are paramount to the process of developing sophisticated ABS compounds. 
The history of activity-based sensing begins with Roger Tsien’s group in the 1980’s as they 
pioneered binding-based sensing through their study on a close relative of ethyl-
enediaminetetraacetic acid EDTA. They designed 1,2-bis(o-aminophenoxy)ethane-N,N,-N’,N’-
tetraacetic acid (BAPTA) which they could use to selectively bind Ca2+.55,56 They later attached a 
fluorophore to the chelator, realizing both fluorescence intensity-based57 and ratiometric 
detection58 of Ca2+, which they later adapted to chelators for MgII, MnII, and ZnII. This work was 
succeeded by the discovery of chemodosimeters by both Czarnik who devised reactive 
fluorescent sensors for heavy metals,59–61 and Nagano, who developed selective biosensors for 
nitric oxide.62–64  
Chang and coworkers set out to design fluorescence turn-on probes for other RSON species. 
By using a selective oxidation of boronate esters by H2O2, they established use of turn-on 
fluorescence probes with fluorescein65 and lanthanide-based fluorescers.66 Since these initial 
findings, the field of activity-based sensing has flourished, inspiring the development of new, 
selective reactions to study biomolecules and enzyme activity in living systems, as well as the 
development of sophisticated fluorescent,67 chemiluminescent, photoacoustic,68,69 and NMR-
based70,71 reporters to elicit their activity in biological settings. Furthermore, this area has 
expanded into the drug discovery sector with proteomics72 and activity-based protein profiling 
(ABPP).73 through the exploration of native reactive amino acid residues such as lysine, and 
cysteine, and methionine on proteins, Cravatt and others have developed selective probes to 
interrogate global protein activity and cellular signaling mechanisms. 
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1,2-dioxetanes have played a key role in the development and advancement of activity-based 
sensing.54 Since the discovery of protected phenoxy-dioxetanes, many different analyte selective 
triggers have been utilized for development of sensitive and selective detection of analytes and 
enzyme activity with 1,2 - dioxetane compounds, providing ultrasensitive methods to detect, and 
in some cases, quantify analytes of interest in in vitro and in vivo. Furthermore, the high depth 
penetration associated with these agents allows for photon detection through tissue in animal 
models.  
 
1.4.1 Chemiluminescence-based ABS detection of enzymes 
Applied Biosystems supplies chemiluminescence assay agents based on the phenoxy 1,2-
dioxetanes including substrates for alkaline phosphatase (Scheme 1-12A), b-glucaronidase 
(Scheme 1-12B), b-Glucosidase (Scheme 1-12B), Neuraminidase (Scheme 1-12D), and b-
galactosidase (Scheme 1-12E) with Galacton Star®. In 2010, Liu and Mason established the use 
of Galacton-star® for detection of the enzyme in tumor models, providing the first instance of in 
vivo analyte detection using 1,2-dioxetanes.74 This was further investigated by Eilon-Shaffer and 
coworkers using probe 2a (Scheme 1-12G), an acrylamide substituted dioxetane masked with a 
b-galactose group, and bearing a tumor-homing peptide to measure endogenous b-galactosidase 
activity in tumor bearing mice.49 Cao and coworkers established chemiluminescence-based 
detection of bacterial nitroreductase and CyP450 nitroreductase activity in live animals with 
HyCL-2 (Scheme 1-12I),75 improved upon by Sun et. al. (Scheme 1-12J) and Ryan et. al. 
(Scheme 1-12K) in separate publications in 2019.76,77 Roth-Konforti and others provided an 
ultrasensitive measurement of Cathepsin-B activity in cellulo using a chemiluminescent substrate 
bound to a self-immolative linker bearing the peptide responsive to cleavage by the cysteine 
protease (Scheme 1-12H).78,79 Das and collaborators established a chemiluminescence substrate 
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for carbapenemase detection, providing a detection limit with 10 µM CPCL of carbapenemase 
to 0.06 mU mL-1 in vitro (Scheme 1-12F).80 An interesting work provided fast and sensitive 
detection of Salmonella (Scheme 1-12M) and Listeria monocytogenes (Scheme 1-12L) with 
approximately 600-fold better detection limits than their fluorescent counterparts.81 Recently, An 
and collaborators devised a chemiluminescent probe for detection of g-glutamyl transpeptidase in 
both cells and animals (Scheme 1-12N).82 
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1.4.2 Chemiluminescence-based ABS detection of small molecules and reactive species 
Activity-based sensing using 1,2-dioxetane substrates has been particularly effective for 
studying reactive species in biological environments (Scheme 1-13). Particular attention has been 
put forth by the Lippert group to utilize chemiluminescence 1,2-dioxetanes to detect small 
molecules and reactive sulfur, oxygen, and nitrogen (RSON) species. Cao et. al. provided the 
first demonstration chemiluminescence detection of the H2S in live cells and animals with CHS-
3 (Scheme 1-13B) in 2015 utilizing an aryl azide trigger.48,83 This work continued in this area 
with the chemiluminescent probes for the detection of peroxynitrite with PNCL with utilizing a 
selective isatin trigger (Scheme 1-13E).84 Utilization of a phosphine trigger attached to an 
acrylonitrile substituted dioxetane with HNOCL-1 (Scheme 1-13D) provided the means to 
quantitatively measure HNO concentrations cells and in vitro, and could detect bolus injections 
of Angeli’s salt in live animals.85 Shabat and coworkers provided chemiluminescent substrates 







































































chemiluminescent substrates to detect H2O2 in cells and animals (Scheme 1-13C).44,86 Bruemmer 
et al. developed CPAF700 for sensitive NIR detection of formaldehyde using an aza-cope 
reaction mechanism.87 Furthermore, both green and red-emitting 1,2-dioxetanes for singlet 
oxygen detection have been developed (Scheme 1-13F,G).88-90 
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1.4.3 Chemiluminescence-based ABS detection of miscellaneous analytes 
A few works based on detection of analytes that fall outside the area of small molecules 
and enzymes. An et. al. developed the first instance of ratiometric imaging of pH using a 1,2-
dioxetane scaffold by utilizing an energy transfer mechanism initiate fluorescence in the pH 
sensitive fluorophore seminapthorhodafluor (Scheme 1-14A).91 Ryan and coworkers advanced 
this technology with a pH sensitive carbofluorescein moiety appended directly to the 1,2-
dioxetane through a piperazine linker, providing quantitative pH measurements in vitro and in 
live animals (Scheme 1-14B).92 Gnaim and coworkers established the use of a chemiluminescent 
substrate to monitor the release of monomethyl auristatin E through a self-immolative prodrug 
release mechanism in cells and mice grown with CT26-LacZ tumors (Scheme 1-14C).93 Huang 
et. al. designed a duplexed imaging agent of contrast induced acute kidney injury by attaching 
green emitting dioxetane responsive to superoxide to a NIR fluorescence emitter responsive to 
lysosomal damage through release of N-acetyl-b-D-glucosaminidase (Scheme 1-14D). Both the 
NIR fluorophore and chemiluminophore were attached together by a (2-hydroxypropyl)-b-
cyclodextrin (HPbCD) linker to promote renal clearance, allowing them to detect CIAKI in vivo 
before significant decline in kidney function occurred.94 
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1.5 Resonance Energy Transfer 
Resonance energy transfer is a physical process in which atoms or molecules can transfer 
energy between each other through a non-radiative dipole-dipole coupling mechanism. This 
process was first discovered by Cario and Franck in 1922,95 where excitation of a mercury and 
thallium mixture in the excitation range of mercury gave luminescence emission from thalium. 
This process was later explained by Theodor Förster,96 who made the key discovery that the 
efficiency of energy transfer is dependent upon two conditions: (1) spectral overlap of the donor 
and acceptor (2) distance between the donor and acceptor (Scheme 1-15). The equation for 
energy transfer efficiency (KET) is given in Equation 1. RO is the Förster radius, an empirically 
determined distance at which the energy transfer efficiency is 50%. tD is the fluorescence 
lifetime of the donor species, and dD-A is the distance between the donor and acceptor. The 
distance between the donor and acceptor dominates this phenomenon, because the efficiency is 
proportional to (1/dD-A)6. In practical terms, RET efficiency falls off very quickly the further the 








 Resonance energy transfer has particularly found uses in the field of biology to study 
processes that involve proximity. To this end, a vast array of biological and chemical 
luminophores have been developed to study biomolecular interactions.97-99 Some key research 
within this field is based on the use of Green Fluorescent Protein (GFP) and its multicolored 
mutant relatives.100 Furthermore, bioluminescence resonance energy transfer has also been 
established as an advantageous reporter in some cases over FRET-based detection due by 
attenuating photobleaching and autofluorescence effects, as well as unintentional excitation of 
both flurophores.101  
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Scheme 1-15. Plot of spectral overlap between FRET donor and acceptor. 
 
 
1.6 Research Objectives 
This research aims to utilize the chemiluminescence imaging modality to create low-cost 
preclinical methods for detection and quantification of analytes within the tumor 
microenvironment. Bearing this in mind, we developed a bright and selective 
chemiluminescence probe for hypoxia detection with HyCL-4-AM, which offers the unique 
ability to monitor native O2 dependent nitroreductase activity in cells and animals through 
monitoring its reaction kinetics. Furthermore, we developed Ratio-pHCL-1, a 
chemiluminescence resonance energy transfer sensor that can be used to quantify pH in vitro and 
in living systems that can reach a photon-flux through animal tissue of up to 1010 p/s, providing 
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KINETICS BASED MEASUREMENT OF HYPOXIA IN LIVING CELLS AND ANIMALS 





Cancer is defined as the uncontrolled proliferation of cells in organisms, and occurs due to 
genetic mutations that arise in affected cells.1 Normally, these mutations are recognized and 
eliminated by five major DNA damage repair pathways, including base excision repair, 
nucleotide excision repair, homologous recombination, and nonhomologous end joining.1 In the 
case that mutations persist beyond the repair of the cell, apoptosis can be induced to isolate 
uncontrolled expression. These regulation and repair mechanisms are often disrupted in 
malignant cells, allowing the potential for more stochastic DNA damage events within a cell 
before the DNA is repaired. It is estimated that 2–8 mutations need to occur in succession before 
uncontrolled cell division occurs, and also depends on cell type, cancer type, and age of the 
afflicted individual.2  
Development of the tumor microenvironment is paramount to its ability to proliferate. 
Mutated epithelial cells begin to secrete proteases that break down the extracellular matrix 
(ECM) in higher concentration than expressed protease inhibitors, thus allowing for breakdown 
and remodeling of the ECM and creating room for tumor growth.3 Cancer associated fibroblasts 
(CAF’s) also play an important role in tumorigenesis, providing essential growth factors for 
proliferation, as well as another source for ECM degrading proteases.4  
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 Unchecked cellular proliferation often leads to hypoxic tumors, where the oxygen 
demand within the tumor exceeds the oxygen supply. Hypoxia is self-propagating within the 
tumor, as uncontrolled expansion ultimately increases distance between vasculature and the cells 
that require oxygen, thus lowering the diffusion rate of O2 into those cells and creating an even 
more hypoxic environment. Chronic hypoxia within tumors leads to long-term cellular changes 
associated with increased tumorigenesis, including increased susceptibility to DNA damage 
coinciding with reduced efficacy of DNA repair mechanisms.5,6  
Changes in protein expression and regulation also occur in hypoxic environments. The 
HIF transcription pathway (responsible for expression of over 100 genes) is regulated in 
physoxic conditions through ubiquitination and proteosomal degradation of the HIF-a mediated 
by prolyl hydroxylase (PHD) and the Von Hippel Lindau (VHL) E3 ligase.7 Proteosomal 
degradation of HIF-1a is therefore inhibited in low O2, allowing for the dimerization of HIF-1b. 
This heterodimer is the active transcription factor that is responsible for the expression of a host 
of genes that promote tumor survival, including the upregulation proteins such of vascular 
epithelial growth factor (VEGF), inhibition of adhesion proteins, as well as upregulating glucose 
transporters and glycolytic proteins to shift cells into anaerobic energy production (the Warburg 
effect).8,9 Hypoxia is a critical component of tumor physiology, and viable scientific tools must 
be developed to understand hypoxia in both clinical and preclinical settings. 
Current implemented methods for hypoxia detection in clinical settings include oxygen 
electrodes,10 blood oxygen and tissue oxygen level dependent magnetic resonance imaging 
(BOLD and TOLD),11,12 and positron emission tomography/computed tomography (PET/CT). 
These methods are excellent for clinical use, but are either invasive in the case of electrodes or 
require expensive instrumentation and expertise in the case of MRI and PET. Preclinical methods 
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for hypoxia detection have thus gravitated toward less expensive and easy to implement optical 
imaging methods.13 Many optical, PET and immunohistochemical approaches utilize O2 
dependent nitroaromatic reduction to both monitor and treat hypoxia,14-17 and occurs through a 
series of 1 and 2 electron reductions mediated by cytochrome P450, 18 cytochrome c,19 xanthine 
oxidase, 20 and lipoamide dehydrogenase (Scheme 2-1).21 The first step in this reduction process 
forms the nitroaromatic radical anion (RNO2–•). Triplet oxygen, however, renders this step as a 
futile cycle by re-oxidizing the radical anion with concomitant formation of superoxide. 
Therefore, this reaction can only proceed in hypoxic conditions. This mechanism has been 
employed to develop sensitizers for radiation and chemotherapy, as well as compounds to aid in 
hypoxia imaging and detection.22 Fluorescent,13 photoacoustic,23 bioluminescent,24 and 
chemiluminescent25,26 imaging agents based on this approach have also been reported.  
 
Scheme 2-1. Mechanism of nitroaromatic reduction. 
 
 
It is, however, important to note that use of nitroaromatic groups and their redox 
byproducts present considerable hazards to human health, as they exhibit carcinogenic 
behavior.27 Most of their cytotoxicity revolves around generation of oxidative stress in cells. 
Redox cycling between the aforementioned nitroaromatic group and the nitroradical anion 
catalyzes the production of superoxide, a well-established carcinogen that oxidizes DNA, lipids, 
and proteins.28 Nitroaromatic compounds such as 2,4,6-trinitrotoluene,29 o-nitrotoluene,30 
nitrotyrosine,31 nitrobenzene,32 and others have been extensively linked in relation to oxidative 
stress and carcinogenesis. Redox cycling between nitroso and hydroxylamine species can also 




generate reactive oxygen species33 are also highly carcinogenic, and presence of nitroso-
compounds in the diet lead to significant increases in colorectal cancer.34 It has also been shown 
that aromatic hydroxylamine and amino compounds form covalent adducts with DNA, thus 
leading to mutagenesis through DNA damage.32 
Research thus far shows that nitroimidazole agents exhibit unacceptable toxicity for 
therapeutic use, but show clinical potential for hypoxia imaging at lower concentrations. There 
has been extensive research in using nitroimidazoles as oxygen mimetic radiosensitizers with the 
development and clinical testing of metronidazole, misonidazole, and etanidazole.35 
Metronidazole showed promise for both in vitro and clinical radiosensitization, but repeated 
doses of up to 2.5 g/m2 were not tolerated, as patients exhibited neuropathy 15-26 days post-
administration.36 Misonidazole and Etanidazole were developed as more polar amide-containing 
derivatives of metronidazole to decrease neural uptake,35 but were also unable to pass clinical 
trials for therapeutic use.37,38 Pimonidazole exhibited a similar fate through clinical trials,38 but 
has since been repurposed as a hypoxia imaging agent.39 A recent clinical study involving 
patients with prostate cancer showed effective tumor hypoxia staining in patients with one 500 
mg/m2 dose administered intravenously the day before their biopsy without significant side 
effects post-administration.40  
Chemiluminescence has proven to be advantageous for molecular imaging by providing 
bright luminescence output without the need for an external light source or genetic 
modification,41 ultimately increasing sensitivity and tissue imaging depth by drastically 
attenuating autofluorescence and light scattering effects.42,43 Indeed, recent advances in triggered 
spiroadamantane 1,2-dioxetane chemiluminescence technology have allowed for high quantum 
yields in aqueous systems,44,45 and have been applied for the detection of peroxynitrite,46 
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nitroxyl,47 formaldehyde,48 prodrug release,49 cathepsin B,50 NQO1,51 transition metals,52 and 
other analytes.  
Here, we use hypoxia mediated nitroaromatic reduction of a caged chemiluminophore  
Hypoxia ChemiLuminescence probe 3 (HyCL-3) and HyCL-4-AM (Scheme 1). While 
previously reported HyCL-225 and CL-NTR40 were demonstrated to be responsive to tissue 
oxygenation in vitro and in animal experiments, these probes were not studied in cellular milieu, 
and had limited animal imaging data. In this study, we evaluate HyCL-3 and HyCL-4-AM as 
chemiluminescent reporters for hypoxia in vitro, in cellulo, and in vivo. We demonstrate that 
incorporation of an acetoxymethyl (AM) ester dramatically increases probe performance 
compared to CL-NTR, and can be used as a tool to directly monitor in vivo oxygen dependent 
nitroreduction activity. 


















































2.2 Results and Discussion 
2.2.1 Design and synthesis of HyCL-3 and HyCL-4 AM 
In previous work, our lab has shown the efficacy of reaction-based hypoxia probes with 
HyCL-2.25 This features a chemiluminescent 1,2-dioxetane scaffold masked by a para-
nitrobenzyl group through an ether linkage. This para-nitrobenzyl group undergoes self-
immolative cleavage in response to enzymatic reduction from nitroreductase enzymes. The 
released phenolate-dioxetane species undergoes decomposition and concomitant luminescence 
emission via a chemically initiated electron exchange luminescence (CIEEL) mechanism. In 
continuation of our efforts to develop chemiluminescent probes for tumor hypoxia imaging, we 
sought methods to increase probe sensitivity for cellular measurements. We took a multi-faceted 
approach to this challenge and designed HyCL-3 and HyCL-4-AM, which we hypothesized 
would increase sensitivity through increased chemiluminescence quantum yields, as well as 
using an acetoxymethyl (AM) ester to improve cellular uptake (Scheme 1). A control compound 
HyCL-4-AM-Cont without the nitroaromatic trigger was also designed to control for effects 
unrelated to nitroaromatic group reduction.  
HyCL-3 was prepared by Mitsunobu coupling of acrylonitrile phenol 1 and para-
nitrobenzyl alcohol, followed by subsequent [2+2] cycloaddition with photogenerated singlet 
oxygen using Rose bengal as a photosensitizer (Scheme 2). Synthesis of HyCL-4-AM began 
with an SN2 reaction of phenol 2 and para-nitrobenzyl tosylate, followed by hydrolysis of the 
methyl ester to yield carboxylic acid 3. We then appended the acetoxymethyl ester through an 
SN2 reaction with bromomethyl acetate. Finally, we subjected this precursor to a [2+2] 
cycloaddition with singlet oxygen to achieve HyCL-4-AM. The control compound, HyCL-4-
AM-Cont was prepared using analogous procedures using benzyl bromide in place of para-
nitrobenzyl tosylate. 
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Scheme 2-3. Synthesis of HyCL-3, HyCL-4-AM, and HyCL-4-AM-Cont.  
 
 
2.2.2 HyCL-3,4-AM Response to Nitroreductase and NADH 
Upon synthesis of HyCL-3 and HyCL-4-AM, their responses towards bacterial 
nitroreductase and cofactor reduced nicotinamide adenosine dinucleotide (NADH) were 
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examined (Figure 2-1). Luminescence emission spectra for HyCL-3 and HyCL-4-AM were 
collected using a F-7000 Hitachi spectrophotometer by treating 10 µM HyCL-3 with 1 µg mL–1 
nitroreductase (NTR) and 0.2 mM NADH in 20 mM PBS buffer, revealing an emission peak 
centered at 525 nm (Figure 2-1A), whereas 10 µM HyCL-4-AM shows an emission maximum at 
516 nm when treated with 1 µg mL-1 NTR, 0.2 mM NADH, and 1 U mL-1 esterase to cleave the 
AM ester (Figure 2-1B). The dose dependence of the luminescence emission with regards to 
nitroreductase was evaluated from 0–1 µg mL–1 NTR for HyCL-3 and HyCL-4-AM using a 
luminescence plate reader (Figure 2-1C). While HyCL-4-AM showed a clear dose dependence 
under these conditions, the relative emission intensity for HyCL-3 was much lower and higher 
enzyme concentrations were required to observe a dose-dependence (Figure 2-2). The time-
course of the chemiluminescence emission of HyCL-4-AM reached a maximum at around 15 
minutes (Figure 2-1D). The reaction products of HyCL-3 and HyCL-4-AM were analyzed by 
GC/MS and a peak definitively assigned to 2-adamantanone (m/z = 150.1, M+•) as well as one 
tentatively assigned to (4-(hydroxyamino)phenyl)methanol (m/z = 138.8, M+•) were found for 




Figure 2-2. Response of HyCL-3. (A) Time-course and (B) integrated emission intensity of 
the chemiluminescence emission of 10 µM HyCL-3 alone (blue trace) or with 2.5, 5, 7.5, 10, 
and (red trace) 12.5 mg mL–1 NTR, and 0.4 mM NADH. All experiments were performed in 
20 mM PBS (pH 7.4) containing ≤ 1% DMSO. Values are the average of n = 3 technical 













































































































































































































































































r2 = 0.996 r2 = 0.998
A = 620.267
k1 = 0.0407 min–1
= 0.000679 s–1
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Figure 2-1. Response of HyCL-3 and HyCL-4-AM. Chemiluminescence emission spectra of 
(A) 10 µM HyCL-3 (blue trace) before and (red trace) after treatment with 1 µg mL–1 NTR and 
0.2 mM NADH and (B) 10 µM HyCL-4-AM (blue trace) before and (red trace) after treatment 
with 1 µg mL–1 NTR, 0.2 mM NADH, and 1 U mL–1 PLE. ( ) Integrated emission intensity of 
10 µM HyCL-4-AM (red trace) or HyCL-3 (blue trace) alone or with 200–1000 ng mL–1 NTR 
and 0.2 mM NADH. PLE (1 U mL–1) was added for HyCL-4-AM. (D) Time-course of the 
chemiluminescence emission of 10 µM HyCL-4-AM alone (blue trace) or with 200, 400, 600, 
800, and (red trace) 1000 ng mL–1 NTR, 0.2 mM NADH, and 1 U mL–1 PLE. All experiments 
were performed in 20 mM PBS (pH 7.4) containing ≤ 1% DMSO. Error bars are ± S.D. 
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Figure 2-4. Mass spectrum of the peak assigned to hydroxylamine for HyCL-3. Data 




Figure 2-5. Mass spectrum of the peak assigned to adamantanone for HyCL-4-AM. Inset is 
the NIST standard. 
 
 
Figure 2-6. Mass spectrum of the peak assigned to the hydroxylamine for HyCL-4-AM. 
 
2.2.3 HyCL-3,4-AM Response to rat liver microsomes, selectivity, and pH dependence 
We next studied the in vitro response to rat liver microsomes (RLM), a more relevant 
model to mammalian hypoxia due to the prevalence of cytochrome P450 reductases in the RLM 
(Figure 2-7). Solutions of 20 µM HyCL-3 with 50 µM cofactor reduced nicotinamide adenine 
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dinucleotide phosphate (NADPH) and 200 µg mL–1 RLM in 20 mM PBS (pH = 7.41) were 
incubated for 4 hours at 37 °C and compared against solutions of only 20 µM HyCL-3 in 20 mM 
PBS (pH = 7.4) as a negative control in both 1% and 20% O2. Under these conditions, HyCL-3 
showed a 37-fold increase in peak luminescence at 80 minutes versus the control, and a glow that 
persisted for more than 4 hours (Figure 2-7A). The local maximum seen at 80 minutes was not 
seen in the 20% oxygen condition. By comparison, the same experiment with 20 µM HyCL-4-
AM, which showed a more rapid onset of the peak intensity after 20 min, with a phenomenal 
60,000-fold increase in luminescence intensity versus the probe alone (Figure 2-7B).53 The 
reaction curve showed a similar small increase in luminescence intensity around 80 minutes for 
the 1% condition as compared to 20%. Knowing that HyCL-3 and HyCL-4-AM were sensitive 
to enzymatic reduction by RLM and NTR, we performed selectivity studies with other 
biologically relevant reductive species, including metal cations and nucleophilic thiols. The 
response of 20 µM HyCL-3 or HyCL-4-AM to RLM was monitored against analytes in PBS 
buffer (20 mM, pH = 7.4) by adding 200 µM CuI, 200 µM Cu(OTf)2, 200 µM Fe(OTf)2, 200 µM 
Fe(OTf)3, 200 µM Mn(OTf)2, 200 µM Co(OAc)2, 200 µM Ni(OTf)2, 200 µM Zn(OAc)2, 5 mM 
reduced glutathione (GSH), 1 mM L-cysteine, or 200 µM Na2S (Figure 2-7C,D). Both HyCL-3 
and HyCL-4-AM showed good selectivity and no significant increase in luminescence intensity 
towards any of the selected species over the blank control.  
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Figure 2-7. Selectivity of HyCL-3 ad HyCL-4-AM. (A) Response of 20 µM HyCL-3 in the 
presence of 200 µg mL–1 rat liver microsomes (RLM), 50 µM NADPH at 1% (red trace) and 
20% (black trace) O2. (B) Response of 20 µM HyCL-4-AM in the presence of 200 µg mL–1 rat 
liver microsomes (RLM), 50 µM NADPH at 1% (red trace) and 20% (black trace) O2. Response 
of (C) 20 µM HyCL-3 and (D) 20 µM HyCL-4-AM to the indicated analytes from 0 to (red 
bars) 50 min at 10-minute increments. All experiments were performed in 10 mM PBS (pH 7.4) 
containing ≤ 1% DMSO. Error bars are ± S.D. 
 
Finally, we examined the pH dependence of the acrylic acid dioxetane species 13, which 
is the pre-chemiluminescence product generated through nitroaromatic reduction and 
consumption of the compound’s AM ester (Figure 2-8). Responses from 2 µM acrylic acid 
dioxetane in 20 mM buffer ranging from pH 2.98-10.04 at 37 ºC were taken over 40 min. A clear 
dependence in chemiluminescence intensity maxima is seen over this pH range, as photon counts 
from pH 8.04-10.04 were maxed out in the first 3 measurements, and exhibited luminescence 
half-lives around t1/2 = 140 seconds. This indicates near full deprotonation of the dioxetane 
phenol above pH 8.0. Maximum luminescence intensity generated from the dioxetane is 
noticeably depreciated at pH 6.98 to 2.94x106 counts paired with an increase in luminescence 
half-life to approximately to t1/2 = 220 seconds. pH 5.98 shows an intensity maximum at 




























































































































































































































































not be measured at the experimental time scale. No appreciable luminescence is seen from 
acrylic acid dioxetanes from pH 2.98-5.02, indicating that deprotonation of dioxetane phenol at 
this pH range is minimal. These values are fairly consistent with the reported pKa values of the 
methyl acrylate benzoate ester (pKa = 6.14) generated after luminescence emission.49 However, it 
is likely that the generated acrylate methyl ester has a lower pKa due to increased electron-
withdrawing nature of the negatively charged oxygen as compared to the previously reported 
methyl ester species. Since 1,2-dioxetane agents are used as biological tools in the pH range of 
6.8 to 7.4, these results show there is a small pH dependences within this pH range. 
 
 
Figure 2-8. pH dependence of acrylate dioxetane phenol. Response to 2 µM acrylate 
dioxetane phenol in the presence of 20 mM carbonate, PBS, or Tris buffer (pH 2.98-10.04) 
containing 5% DMSO. 
 
2.2.4 HyCL-3, HyCL-4-AM biological studies 
Given that HyCL-4-AM exhibited higher sensitivity than HyCL-3, we decided to 
proceed with HyCL-4-AM as our primary agent for hypoxia detection in cellular models (see 
Figure 2-9 for HyCL-3 cellular data).We first tested the cellular toxicity of HyCL-4-AM using 
an MTT assay, which showed no significant reduction to cell growth at the tested concentrations 
(Figure 2-9). Next we tested whether HyCL-4-AM could distinguish hypoxic and normoxic 
conditions in A549 cells. Cells in 12-well plates were treated with 40 µM HyCL-4-AM or 40 








































of cytochrome P450 reductase that acts by phenylating the flavin ring through a radical 
mechanism, rendering it redox inactive) 54 and directly placed into a luminescence plate reader at 
37 °C with 5% CO2 and either 1%, 5%, or 20% O2 conditions for 20 hours. In all conditions, 
HyCL-4-AM showed an emission maximum after approximately one hour (Figure 2-10A,B). 
Interestingly, HyCL-4-AM exhibited a sharp decline from intensity maximum over 7 hours to 
near baseline values when incubated at 1% O2 (Figure 2-10A), whereas a slower decrease in 
chemiluminescence intensity over 16 and 19 hours was observed in cells that were monitored 
under 5% or 20% O2 atmosphere, respectively (Figure 2-10B). Comparison to the cellular 
response of the carboxylate HyCL-4 demonstrated the dramatic effect of the acetoxymethyl ester 
for efficient cellular operation (Figure 2-11). 
 
 
Figure 2-9. HyCL-3 Cellular Data. (A) A549 cells were incubated with 0–100 µM HyCL-3 
for 16 hours and then viability was evaluated using the MTT assay. Error bars are ± S.D. from 
n = 3 replicates. (B) Time-course of the chemiluminescence emission of A549 cells incubated 
with 40 µM HyCL-3 at (red trace) 1% O2 or (blue trace) 20% O2. (C) Luminescence intensity 
of 40 µM HyCL-3 at t = 30 min in 1% O2 and 20% O2 in A549 cells. Error bars are ± S.D. from 
n = 9 wells across 3 biological replicates. Statistical significance was assessed using a Student's 
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Figure 2-10. HyCL-4-AM MTT assay. A549 cells were incubated with 0–100 µM HyCL-3 
for 16 hours and then viability was evaluated using the MTT assay. Error bars are ± S.D. from 
n = 3 technical replicates. 
 
 
Figure 2-11. Measuring hypoxia in living A549 cells. (A)–(C) Time-course of the 
chemiluminescence emission of A549 cells incubated with 40 µM HyCL-4-AM at 1% O2, 5% 
O2 or 20% O2 in the presence or absence of DPI. (D) Chemiluminescence emission intensity at 
300 min of A549 cells incubated with 40 µM HyCL-4-AM at 1% O2, 5% O2, and 20% O2. (E) 
Measured rate constants for the cellular response of HyCL-4-AM. (F) Time-course of the 
chemiluminescence emission of A549 cells incubated with 40 µM HyCL-4-AM-Cont at 20% 
O2 in the presence or absence of DPI. All experiments were performed in F12K containing 
10% FBS and ≤ 1% DMSO. Error bars are ± S.D. Statistical significance was assessed using a 
two-tailed Student's t-test. *p<0.05 (n= 1-4 biological replicates) ******p<5x10-7 (n = 1–4 
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Figure 2-12. Comparison of the cellular response of HyCL-4-AM and HyCL-4. (A) Time-
course of the chemiluminescent emission of 40 µM HyCL-4-AM in the (red trace) presence 
and (blue trace) absence of A549 cells at 1% O2 and 37 ºC. (B) Time-course of the 
chemiluminescent emission of 40 µM HyCL-4 in the (red trace) presence and (blue trace) 
absence of A549 cells at 1% O2 and 37 ºC. Values are the average of n = 3 technical replicates, 
except for the red trace in Figure 2-12A, which are the average of n = 9 wells across three 
biological replicates. 
 
While HyCL-4-AM showed a clear response over four hours in the presence of A549 
cells, with no response from cell culture media in the absence of cells (Figure 2-11A), HyCL-4 
showed only a very bright background that rapidly decays with no clear difference in the 
presence or absence of cells (Figure 2-11B). Furthermore, treatment with 500 µM DPI at 1% O2 
slows the decay and yields a result indistinguishable from the response at 20% O2 (Figure 2-
10A,B), demonstrating that DPI has an effect similar to that of O2. Comparison of the cellular 
response of HyCL-4-AM at 1% versus 20% O2 showed a highly significant and reproducible 
reduction in luminescence emission under hypoxic conditions (Figure 2-10C,D). This, at first, 
appears contradictory to established literature on biological nitroaromatic reduction chemistry, 
but can be understood when considering the kinetics of chemiluminescence emission. The rate of 
chemiluminescence decomposition of the acrylic acid dioxetane phenol released by HyCL-4-
AM was measured to be 5.47 x 10–3 s–1 and completely decayed within 15 minutes at pH 7.4 
(Figure 2-12A), approximately ten times more rapidly than the acrylonitrile dioxetane phenol 
(Figure 2-12B). In cells, it takes more than 150 minutes for the signal decay, indicating that 
nitroaromatic group reduction is the rate-limiting step for producing chemiluminescence. 
 53 
 
Figure 2-13. Rate of chemiluminescence decomposition of dioxetane phenols at biological 
pH. (A) Time-course of the chemiluminescent emission of 0, 0.5, 1.0, 1.5, 2.0, 2.5, and (red 
trace) 3.0 µM acrylic acid phenol dioxetane in 20 mM PBS (pH = 7.4) and ≤ 1% DMSO. (B) 
Time-course of the chemiluminescent emission of 0, 0.5, 1.0, 1.5, 2.0, 2.5, and (red trace) 3.0 
µM acrylonitrile phenol dioxetane in 20 mM PBS (pH = 7.4) and ≤ 1% DMSO.  
 
2.2.5 HyCL-4-AM kinetic modeling in A549 cells 
We modeled the luminescence output from the probe in A549 cells as an X to Y to Z 
consecutive reaction (Figure 2-13) for . k1 represents cellular uptake and intracellular esterase 
activity, and k2 includes both nitroaromatic reduction and light emission through CIEEL. This is 
modeled by the rate equation (Figure 2-13B), where y is the relative emission intensity, k1 a rate 
of cell uptake and ester cleavage, k2 is the rate of nitroaromatic group reduction, A is a parameter 
proportional to the initial concentration of the probe, and B is a parameter to fit the background. 
Fitting the cellular data to this model (Figure 2-13C,D) shows that the rate constant k1 does not 
significantly change, but k2 significantly decreases from 2.82 x 10–4 M–1 s–1 at 1% O2 to 1.79 x 
10–5 M–1 s–1 at 20% O2 (Figure 2-13E), consistent with O2 inhibition of nitroreductase activity. 
This model demonstrates that HyCL-4-AM can provide a numerical measure of the inhibition of 
endogenous nitroreductase activity by O2 by tracking changes in k2. By comparison, 40 µM 
HyCL-4-AM-Cont in A549 cells showed only baseline luminescence emission over the same 
conditions and time span (Figure 2-13F), confirming the requirement of nitroreductase activity 
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Figure 2-14. Kinetic model. (A) Reactions used to model the chemiluminescence emission. 
(B) Rate equation for the chemiluminescence emission. y-value represents [HyCL-4] 
generated after k1. (C) Example fit of the chemiluminescence response of 40 µM HyCL-4-AM 
in A549 cells at 1% O2. (D) Example fit of the chemiluminescence response of 40 µM HyCL-
4-AM in A549 cells at 20% O2. See Appendix 2 for equation derivation and alternate fits. 
 
2.2.6 HyCL-4-AM in vivo imaging 
After demonstrating that HyCL-4-AM displayed an alteration in chemiluminescence 
kinetics dependent on O2 levels, we sought to investigate its behavior in animal models. We 
subcutaneously implanted the flanks of athymic nude mice with MDA-MB-231 breast cancer 
cells and allowed the tumors to grow to appropriate size for hypoxia testing. The mice were set 
to breathe 16% O2 with 2.5% isoflurane for 10 minutes and then treated with 30 µL of 120 µM 
HyCL-4-AM via intratumoral (IT) injection. These were compared with mice administered with 
the same amount of HyCL-4-AM via intramuscular (IM) injection. Images were acquired every 
minute for 100 minutes using an IVIS Spectrum. HyCL-4-AM showed strong luminescence 
through tissue that was dependent on O2 level the mouse was breathing (Figure 2-14). By 
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decay in hypoxic tumor tissue at 16% O2 was faster than in the well oxygenated muscle tissue 
(Figure 2-14A), consistent with the results of our cellular studies. 
 
 
Figure 2-15. Measuring oxygenation in healthy muscle tissue and tumor xenografts. (A)–(C) 
Time course of the chemiluminescence emission of 30 µL of 120 µM HyCL-4-AM in 20 mM 
PBS (pH 7.4) containing 2.4% DMSO in athymic nude mice after intramuscular (IM) injection 
into the flank, intratumoral injection while mice were breathing 16% O2 (IT, 16% O2), and 
intratumoral injection while mice were breathing 100% O2 (IT, 100%). (D) Photon flux and (E) 
chemiluminescence images of athymic nude mice 60 minutes after IM injection, IT injection while 
mouse breathed 16% O2, and after IT injection while mouse breathed 100% O2. Error bars are ± 
S.E. from n = 3–6 mice. Statistical significance was assessed using a two-tailed Student's t-test. 
*p<0.05. 
 
It has been shown that hyperoxic treatment of tumors can be used to both characterize 
and resensitize tumors to support aerobic metabolism.12,55 When mice were set to breath 100% 































































































injection, showing that hyperoxic treatment can re-oxygenate tumors and this tumor response can 
be monitored using HyCL-4-AM (Figure 2-14B). Comparison between IT injections with mice 
breathing 16% O2 versus 100% O2 showed that, on average, signal decayed more rapidly when 
mice breathe 16% O2 (Figure 2-14C). It was observed, however, some tumors responded 
differently to hyperoxic treatment, indicating potential for HyCL-4-AM to differentiate between 
tumors that respond to hyperoxic treatment from those that don't. Representative images from 
mice 60 minutes after injection showed differentiation between hypoxic and well oxygenated 
tissues (Figure 2-14E). Overall, these results show that HyCL-4-AM can effectively distinguish 
hypoxic tumors from healthy tissue in vivo. 
 
2.4 Conclusions 
In conclusion, we have synthesized HyCL-3 and HyCL-4-AM as chemiluminescent 
indicators of hypoxia in cellular and animal models. Both probes provide a luminescence 
response to nitroreduction by bacterial nitroreductase or RLM with added cofactors. Due to 
increased sensitivity, HyCL-4-AM was further tested in cells, where it exhibited luminescence 
emission kinetics that were highly dependent on oxygen concentrations within the cell. 
Furthermore, robust animal studies demonstrated the ability of HyCL-4-AM to measure and 
image hypoxia in tumor xenograft models. The observed inhibition of reductase activity in 
oxygenated tissue is consistent with the response expected from one-electron mammalian 
reductase enzymes and is unlikely to be due to oxygen-independent bacterial nitroreductase 
activity. In comparison to the recently published CL-NTR,25 the inclusion of the AM ester 
moiety provides a drastic increase in sensitivity and response due to increased cell uptake. This 
opens up the possibility of high throughput cell experiments that have thus far not been reported 
for previous chemiluminescent probes HyCL-225 and CL-NTR.40 HyCL-4-AM provides a 
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maximum photon flux of more than 1 x 107 photons s–1 in tumor xenografts, which is ca. 1000-
fold greater mole for mole than previously reported chemiluminescent hypoxia probes.25,40 This 
kinetics-based approach to monitoring cellular hypoxia is a significant advance in 
chemiluminescence detection technology since the reaction kinetics are less dependent on tumor 
size and depth of injection, which can vary greatly between experiments, and could explain 
potential differences in results from less sensitive probes. This study establishes that HyCL-4-
AM is a highly reproducible tool to investigate hypoxia in cells and has efficacy in monitoring 
tumor oxygenation in animal models. More generally, we showed that installation of an AM ester 
provides a versatile strategy for using 1,2-dioxetane probes in cellular systems. 
 
2.4 Experimental section 
2.4.1 General synthetic methods and materials 
All reactions were performed in dried glassware under an atmosphere of dry N2. Silica 
gel P60 (SiliCycle) was used for column chromatography and SiliCycle 60 F254 silica gel 
(precoated sheets, 0.25 mm thick) was used for analytical thin layer chromatography. Plates were 
visualized by fluorescence quenching under UV light or by staining with iodine. Other reagents 
were purchased from Sigma-Aldrich (St. Louis, MO), Alfa Aesar (Ward Hill, MA), EMD 
Millipore (Billerica, MA), Oakwood Chemical (West Columbia, SC), and Cayman Chemical 
(Ann Arbor, MI) and used without further purification. 1H NMR for compounds 13, 14, 15, 3, 
16, HyCL-4-AM, 17, 4, 18, HyCL-4 and HyCL-4-AM-Cont and 13C NMR for compounds 13, 
15, 3, 16, 4, and 8 were collected on a Bruker 400 MHz spectrometer in the Department of 
Chemistry at Southern Methodist University. 1H NMR for compound HyCL-3 and 13C NMR for 
compounds 14, HyCL-3, HyCL-4-AM, 17, HyCL-4 and HyCL-4-AM-Cont were measured on 
a JEOL 500 MHz spectrometer in the Department of Chemistry at Southern Methodist 
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University. All 1H and 13C NMR spectra for characterization of new compounds and monitoring 
reactions were collected in CDCl3 (Cambridge Isotope Laboratories, Cambridge, MA). All 
chemical shifts are reported in the standard notation of parts per million using the peak of 
residual proton signals of the deuterated solvent as an internal reference. Coupling constant units 
are in Hertz (Hz) Splitting patterns are indicated as follows: br, broad; s, singlet; d, doublet; t, 
triplet; q, quartet; m, multiplet; dd, doublet of doublets; dt, doublet of triplets. High resolution 
mass spectroscopy was performed on a Shimadzu IT-TOF (ESI source) at the Shimadzu Center 
for Advanced Analytical Chemistry at the University of Texas, Arlington, and low-resolution 
mass spectrometry was performed on an Advion ExpressionL CMS (ESI source) at Southern 
Methodist University.  
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2-chloro-1-(dimethoxymethyl)-3-methoxy-benzene (6). 2-chloro-3-methoxybenzaldehyde 5 
(10 g, 59 mmol, 1.0 equiv) was dissolved in 100 mL anhydrous methanol in a round bottom flask 
under a nitrogen atmosphere at room temperature. p-toluenesulfonic acid (1115 mg, 6.475 mmol, 
0.1 equiv) and trimethyl orthoformate (6.41 mL, 58.6 mmol, 1.0 equiv) were then added. The 
reaction was stirred at room temperature for 24 hr. Upon completion, the crude mixture was 
poured into a separatory funnel and washed with saturated NaHCO3 and brine mixture. The 
organic layer was extracted with 3 x 50 mL EtOAc. The combined organic layers were collected 
and dried over Na2SO4, filtered, and concentrated under reduced pressure to give 6 as a colorless 
oil without further purification. 1H NMR (500 MHz, CDCl3) d 7.25 (m, 2H), 6.93 (m, 1H), 5.65 
(s, 1H), 3.90 (s, 3H), 3.38 (s, 6H). 
 
 
Diethyl ((2-chloro-3-methoxyphenyl)(methoxy)methyl)phosphonate (7). Acetal 6 (19 g, 88 
mmol, 1.0 equiv) was dissolved in 100 mL anhydrous DCM in a dry round bottom flask under 
N2 atmosphere and cooled to 0 ºC. Boron trifluoride diethyl etherate (11.4 mL, 90.9 mmol, 1.0 
equiv) was added dropwise and allowed to stir for 10 min. Then, triethyl phosphite (15.6 mL, 
90.9 mmol, 1.03) equiv was also added dropwise and stirred for 10 min. The reaction was then 
heated to 45 ºC and refluxed for 1.5 hr and monitored by TLC. Upon completion, the reaction 










combined organic layer was dried with Na2SO4, filtered, and concentrated under reduced 
pressure. Purification by column chromatography (50% EtOAc/ hexanes) yielded 7 as a beige 
oil. 1H NMR (400 MHz, CDCl3) d 7.32 (m, 2H), 6.94 (m, 1H), 5.23 (d, 1H, J = 16.0 Hz), 4.17–





Phosphonate 7 (4.33 g, 13.4 mmol, 1.0 equiv) was dissolved in 50 mL anhydrous THF in an 
oven-dried round bottom flask under N2 atmosphere at –78 ºC. 2.6 M n-BuLi (6.2 mL 16. mmol, 
1.2 equiv), was added dropwise over 10 min and allowed to stir for 20 min. Then, 2-
adamantanone (2420 mg, 16.12 mmol, 1.2 equiv) dissolved in 15 mL anhydrous THF was added 
dropwise and allowed to stir for 5 min. Then, the reaction was taken out of the –78 ºC bath and 
allowed to stir for 2 hr. The temperature was raised to 90 ºC and the reaction was refluxed for 1 
hr. Upon completion as determined by TLC, the reaction was transferred to a separatory funnel 
and quenched with sat. NH4Cl. The organic layer was extracted with 3 x 30 mL EtOAc, dried 
with Na2SO4, and concentrated under reduced pressure. Column chromatography (5% EtOAc/ 
hexanes) yielded 8 (3.56 g, 11.2 mmol, 83%) as an amber oil. 1H NMR (400 MHz, CDCl3) d 








3-(((1r,3r,5R,7S)-adamantan-2-ylidene)(methoxy)methyl)-2-chlorophenol (9).30 Ether 8 (4.5 
g, 14 mmol, 1.0 equiv) was dissolved in 50 mL anhydrous DMF in an oven-dried round bottom 
flask under N2 atmosphere. Sodium ethanethiolate (1430 mg, 17.00 mmol, 1.2 equiv) and 
Cs2CO3 (5540 mg, 17.00 mmol, 1.2 equiv) were added to the solution. The reaction was heated 
to 90 ºC and stirred for 12 hr. Upon completion as determined by TLC, the crude reaction was 
washed with sat. NH4Cl and brine, and extracted with 3 x 30 mL EtOAc. The organic layer was 
dried with Na2SO4, filtered, and concentrated under reduced pressure. Column chromatography 
(10% EtOAc/ hexanes) yielded compound 9 (3.68 g, 12.06 mmol, 85%) as an off-white solid. 1H 
NMR (500 MHz, CDCl3) d 7.05 (t, 1H, J = 7.5 Hz), 6.92 (d, 1H, J = 6.0 Hz), 6.73 (d, 1H, J = 6.0 




Compound 91 (3677 mg, 12.06 mmol, 1.0 equiv) was dissolved in 50 mL anhydrous toluene 
under N2 atmosphere at 0 ºC. N-Iodosuccinimide (2714 mg, 12.06 mmol, 1.0 equiv) was then 
added in 1 portion. The reaction was stirred for 1 hr. Upon completion of the reaction as 
determined by TLC, the reaction was transferred into a separatory funnel and washed with brine. 
A few crystals of sodium thiosulfate pentahydrate were added and the separatory funnel was 











from pink to colorless. The organic layer was then extracted with 3 x 30 mL EtOAc, dried with 
Na2SO4, and concentrated under reduced pressure. Washing the crude residue with hexanes 
yielded compound 10 (1.68 mg, 3.9 mmol, 30%) as a white solid. 1H NMR (400 MHz, CDCl3) d 
7.64 (d, 1H, J = 8.0 Hz), 6.65 (d, 1H, J = 8.0 Hz), 6.16 (s, 1H), 3.33 (s, 3H), 3.28 (s, 1H), 1.63–




hydroxyphenyl)acrylonitrile (1).1 Iodophenol 101 (500 mg, 1.16 mmol, 1.0 equiv) was 
dissolved in 3 mL anhydrous MeCN under N2 atmosphere in a 10 mL microwave flask. 
Acrylonitrile (0.22 mL, 3.5 mmol, 3.0 equiv), anhydrous Et3N (0.24 mL, 1.7 mmol, 1.5 equiv), 
and Pd(OAc)2 (13.0 mg, 0.058 mmol, 0.05 equiv) were added to the solution. The reaction was 
capped and microwaved at 120 ºC for 70 min. Upon completion, the reaction was transferred to a 
separatory funnel and washed with NH4Cl and brine mixture. The organic layer was extracted 
with 3 x 30 mL EtOAc, dried with Na2SO4, filtered, and concentrated under reduced pressure. 
Column chromatography (100 % DCM) yielded compound 1 (201 mg, 0.56 mmol, 48%) as a 
yellow solid. 1H NMR (400 MHz, CDCl3) d 7.61 (d, 1H, J = 16.8 Hz), 7.29 (d, 1H, J = 8.0 Hz), 











Compound (11).1 Compound 11 (112 mg, 0.341 mmol, 1 equiv) and Rose bengal (18.1 mg, 
0.0186 mmol, 0.0545 equiv) added to a 2-neck round bottom flask and dissolved in 5 mL THF. 
Oxygen was bubbled through the reaction mixture, while irradiating with a 120 W light bulb 
(Home Depot, Dallas, TX) at 0 °C. After 2 hr of reaction, TLC showed no starting material left 
and the mixture was then concentrated under vacuum at 0 ºC. The residue was purified by 
column chromatography (5% EtOAc/ hexanes) to deliver compound 10 (74.8 mg, 0.129 mmol, 
41%) as a white solid. 1H NMR (400 MHz, CDCl3) d 7.72 (d, 1H, J = 8.0 Hz), 7.60 (d, 1H, J = 
16.8 Hz), 6.44 (d, 1H, J = 8.0 Hz), 6.23 (d, 1H, J = 16.8 Hz), 3.24 (s, 3H), 3.04 (s, 1H), 1.22–




hydroxyphenyl)acrylic acid (2).1 In an oven-dried round bottom flask, iodophenol 101 (431 mg, 
1.00 mmol, 1.0 equiv) was dissolved in 5 mL anhydrous MeCN under N2 atmosphere. Methyl 
acrylate (0.26 mL, 3.0 mmol, 3.0 equiv), Et3N (0.20 mL, 1.5 mmol, 1.5 equiv), Pd(OAc)2 (11 mg 
0.05 mmol, 0.05 equiv), and tri(o-tolyl) phosphine (3 mg, 0.01 mmol, 0.01 equiv) were added 
into the solution. The reaction was heated to 120 ºC and refluxed for 2 hr. Upon completion of 













washed with NH4Cl. The organic layer was extracted with 3 x 30 mL EtOAc, dried with Na2SO4, 
filtered, and concentrated under reduced pressure. Purification by column chromatography (15% 
EtOAc/ hexanes) yielded compound 2 (215 mg, 0.55 mmol, 55%) as a yellow solid. 1H NMR 
(400 MHz, CDCl3) d 7.98 (d, 1H, J = 16.0 Hz), 7.41 (d, 1H, J = 8.0 Hz), 6.90 (d, 1H, J = 8.0 
Hz), 6.67 (d, 1H, J = 16.0 Hz), 6.22 (s, 1H), 3.84 (s, 3H), 3.33 (s, 3H), 3.29 (s, 1H), 1.63–2.20 




hydroxyphenyl)acrylic acid (12).1 Acrylic methyl ester phenol 21 (0.668 mmol, 260 mg 1 
equiv) was dissolved in 5.0 mL THF in a dry round bottom flask flushed with nitrogen. 5 mL of 
1.0 M LiOH in H2O was added to the solution. The reaction was then heated to 80 ºC and stirred 
under reflux for 4 hr. Upon completion of the reaction as determined by TLC, the crude was 
washed with 1 M HCl and extracted with 3 x 30 mL EtOAc. The organic layer was collected, 
dried with Na2SO4, and evaporated under reduced pressure, yielding compound 12 (257 mg, 
0.668 mmol, quantitative) without further purification. 1H NMR (400 MHz, CDCl3) d 8.00 (d, 
2H, J = 16.1 Hz), 7.49 (d, 2H, J = 8.0 Hz), 6.83 (d, 2H, J = 8.0 Hz), 6.59 (d, 2H, J = 16.1 Hz), 











4'-yl)phenyl)acrylic acid (13). Enol ether 121 (20 mg, 0.053 mmol, 1 equiv) and methylene blue 
(5.0 mg, 0.015 equiv, 0.028 equiv) were added into a dry flask and dissolved in 5 mL THF. 
Oxygen was bubbled through the reaction mixture, while irradiating with a 120 W light bulb 
(Home Depot, Dallas, TX) at 0 °C. After 1.5 hr of reaction, TLC showed no starting material left 
and the mixture was then concentrated under vacuum at 0 ºC. The residue was purified by 
column chromatography (50% EtOAc/ hexanes) to deliver 13 (19.5 mg, 97%) as a white solid. 
1H NMR (400 MHz, CDCl3) d 8.06 (d, 1H, J = 16.4 Hz), 7.72 (d, 1H, J = 8.0 Hz), 7.58 (d, 1H, J 
= 8.0 Hz), 6.70 (d, 1H, J = 16.4 Hz), 6.65 (br s, 1H), 3.26 (s, 3H), 3.04 (s, 1H), 1.27-2.26 (m, 
12H); 13C NMR (100 MHz, CDCl3) 171.80, 151.04, 140.73, 134.25, 127.16, 124.76, 123.49, 
120.37, 96.32, 49.72, 39.28, 36.51, 34.07, 33.45, 32.82, 32.16, 31.56, 26.12, 25.78; LRMS data 




nitrobenzyl)oxy)phenyl)acrylonitrile (14). Acrylonitrile phenol 142 (85 mg, 0.22 mmol, 1.0 
equiv), triphenyl phosphite (69 mg, 0.26 mmol, 1.2 equiv) and 4-nitrobenzyl alcohol (33 mg, 













reaction contents were dissolved in 3.0 mL THF, and the reaction was cooled to 0 °C. Diethyl 
azodicarboxylate (41 µL, 0.26 mmol, 1.2 equiv) was added dropwise to the solution, and stirred 
for 1 hr. The crude mixture was combined with 30 mL brine solution, and mixture was washed 
with 2 x 20 mL EtOAc. The combined organic layers were collected and dried over Na2SO4, 
filtered, and concentrated under reduced pressure. Purification by column chromatography (10% 
EtOAc/Hexanes) yielded 14 (99 mg, 92%) as a pale yellow solid. 1H NMR (400 MHz, CDCl3) d 
8.31 (d, 2H, J = 8.8 Hz), 7.69 (d, 2H, J = 8.8 Hz), 7.60 (d, 1H, J = 16.8 Hz), 7.41 (d, 1H, J = 8.0 
Hz), 7.16 (d, 1H, J = 8.0 Hz), 6.98 (d, 1H J =16.8 Hz), 5.13 (d, 2H, J = 6.8 Hz), 3.32 (s, 3H), 
3.30 (s, 1H), 1.61–2.08 (m, 12H); 13C NMR (125 MHz, CDCl3) d 153.07, 148.03, 144.38, 
143.05, 139.69, 139.07, 133.62, 129.87, 128.53, 128.38, 124.01, 117.91, 99.12, 77.86, 76.86, 
57.69, 38.74, 37.02, 33.10, 29.84, 28.36, 28.19; HRMS calcd for C28H27ClN2O4 [M-H]- 




((4-nitrobenzyl)oxy)phenyl)acrylonitrile (HyCL-3). Enol ether 14 (40 mg, 0.081 mmol, 1.0 
equiv) and Rose bengal (8.5 mg, 0.0087 mmol, 0.11 equiv) were added into a dry flask and 
dissolved in 5 mL THF. Oxygen was bubbled through the reaction mixture, while irradiating 
with a 120 W light bulb (Home Depot, Dallas, TX) at 0 °C. After 3.5 h of reaction, TLC showed 
no starting material left. The mixture was then concentrated under vacuum at 0 ºC and the 








(56.4 mg, 87%) as a white solid. 1H NMR (500 MHz, CDCl3) d 8.30 (d, 2H, J = 6.25 Hz), 7.99 
(d, 1H, J = 7.45 Hz), 7.67 (d, 2H, J = 6.25 Hz), 7.57 (d, 1H, J = 17.2 Hz), 7.25 (d, 1H, J = 7.45 
Hz), 6.02 (d, 1H, J =17.2 Hz), 5.02 (s, 2H), 3.22 (s, 3H), 3.02 (s,1H) 1.71–2.28 (m, 12H); 13C 
NMR (125 MHz, CDCl3) d 153.53, 148.11, 143.86, 142.69, 136.79, 130.33, 129.77, 128.36, 
127.93, 124.91, 124.07, 117.55, 111.59, 100.59, 96.44, 72.14, 49.87, 36.58, 33.73, 32.23, 31.61, 




nitrobenzyl)oxy)phenyl)acrylate (15). Methyl acrylate phenol 21 (215 mg, 0.55 mmol, 1.0 
equiv) was dissolved in 5.0 mL anhydrous acetone in a dry round bottom flask flushed with 
nitrogen. p-Nitrobenzyl tosylate (253 mg, 0.825 mmol, 1.5 equiv) and K2CO3 were added in 2 
separate portions. The reaction was stirred at room temperature for 12 hr, at which time TLC 
inspection showed complete consumption of starting material 2. The crude mixture was 
combined with 30 mL brine solution, and mixture was washed with 2 x 20 mL EtOAc. The 
combined organic layers were collected and dried over Na2SO4, filtered, and concentrated under 
reduced pressure. Purification by column chromatography (10% EtOAc/ hexanes) yielded 15 
(228 mg, 92%) as an off-white solid. 1H NMR (400 MHz, CDCl3) d 8.28 (d, 2H, J = 8.8 Hz), 
7.90 (d, 1H, J = 16.0 Hz), 7.70 (d, 2H, J = 8.8 Hz), 7.48 (d, 1H, J = 8.0 Hz), 7.13 (d, 1H, J = 8.0 
Hz), 6.47 (d, 1H, J = 16.0 Hz), 5.11 (d, 2H, J = 5.2 Hz), 3.81 (s, 3H), 3.35 (s, 3H), 3.30 (s, 1H), 








128.26, 132.87, 129.42, 128.63, 128.28, 125.26, 123.76, 123.38, 74.40, 57.36, 51.88, 39.17, 
39.02, 38.67, 36.99, 32.95, 29.71, 28.31, 28.16; HRMS calcd for C29H30ClNO6 [M+Na]+ 




nitrobenzyl)oxy)phenyl)acrylic acid (3). Acrylate phenol 15 (228 mg, 0.49 mmol, 1.0 equiv) 
was dissolved in 5 mL THF in a 20 mL round bottom flask. 5 mL of 1 M LiOH was then added 
to the mixture. The reaction was placed under an inert atmosphere, heated to 80 ºC, and refluxed 
for 2 hr. Upon completion, the reaction was transferred into a separatory funnel. The organic 
layer was washed with 1 M HCl and extracted with 2 x 20 mL EtOAc. The combined organic 
layers were collected and dried over Na2SO4, filtered, and concentrated under reduced pressure. 
Purification by column chromatography (50% EtOAc/ hexanes) yielded 3 (142 mg, 57%) as a 
yellow solid. 1H NMR (400 MHz, CDCl3) d 8.27 (d, 2H, J = 8.4 Hz), 7.99 (d, 1H, J = 16.0 Hz), 
7.70 (d, 2H, J = 8.4 Hz), 7.52 (d, 1H, J = 8.0 Hz), 7.15 (d, 1H, J = 8.0 Hz), 6.47 (d, 1H, J = 16.0 
Hz), 5.14 (d, 2H, J = 5.2 Hz), 3.36 (s, 3H), 3.30 (s, 1H), 1.73–2.19 (m, 12H); 13C NMR (100 
MHz, CDCl3) d 171.65, 153.60, 147.89, 143.26, 140.44, 139.20, 138.88, 133.16, 129.63, 129.11, 
128.72, 128.33, 125.43, 123.83, 119.85, 74.61, 57.41, 39.20, 39.05, 38.67, 38.58, 37.00 33.01, 










((4-nitrobenzyl)oxy)phenyl)acrylic acid (HyCL-4). Compound 3 (13 mg, 0.048 mmol, 1.0 
equiv) and methylene blue (5.0 mg, 0.015 mmol, 0.31 equiv) were added into a dry flask and 
dissolved in 5 mL THF. Oxygen was bubbled through the reaction mixture, while irradiating 
with a 120 W light bulb (Home Depot, Dallas, TX) at 0 °C. After 2 h of reaction, TLC showed 
no starting material left and the mixture was then concentrated under vacuum. The residue was 
purified by column chromatography (15% EtOAc/hexanes) to deliver HyCL-4 as a white solid 
(2.6 mg, 20 %). 1H NMR (400 MHz, CDCl3) d 8.29 (d, 2H, J = 8.8 Hz), 8.00 (d, 1H, J = 8.0 Hz), 
7.96 (d, 1H, J = 16.4 Hz), 7.66 (d, 2H, J = 8.0 Hz), 5.07 (s, 2H), 3.25 (s, 3H), 3.05 (s, 1H), 1.67–
2.11 (m, 12H); 13C NMR (125 MHz, CDCl3) d 170.42, 154.10, 148.06, 142.96, 139.92, 136.04, 
131.08, 129.62, 128.82, 125.71, 124.01, 121.02, 111.70, 96.45, 74.04, 49.86, 36.62, 33.70, 32.27, 




((4-nitrobenzyl)oxy)phenyl)acrylate (16). Acrylate 3 (98 mg, 0.19 mmol, 1.0 equiv) was 

















flask flushed with nitrogen. Anhydrous DIPEA (0.12 mL, 0.69 mmol, 3.6 equiv) was added and 
allowed to mix for 2 min. Bromomethyl acetate (0.08 mL, 0.79 mmol, 4.1 equiv) was then added 
dropwise. The reaction was stirred for 24 hr at RT, upon which the starting material was fully 
consumed as determined by TLC. The crude reaction was then diluted with 4 mL EtOAc and 
transferred into a separatory funnel. The organic layer was washed with 1 M HCl and extracted 
with 2 x 20 mL EtOAc. The combined organic layers were collected and dried over Na2SO4, 
filtered, and concentrated under reduced pressure. Purification by column chromatography (10–
30% EtOAc/ hexanes gradient) yielded 16 (33 mg, 30%) as a pale yellow solid. 1H NMR (400 
MHz, CDCl3) d 8.29 (d, 2H, J = 8.8 Hz), 7.98 (d, 1H, J = 16.0 Hz), 7.69 (d, 2H, J = 8.8 Hz), 7.49 
(d, 1H, J = 8.0 Hz), 7.14 (d, 1H, J = 8.0 Hz), 6.47 ( d, 1H, J = 16.0 Hz), 5.87 (s, 2H), 5.12 (d, 
2H, J = 5.6 Hz), 3.36 (s, 3H), 3.30 (s, 1H), 2.16 (s, 3H), 1.62–2.14 (m, 12H); 13C NMR (100 
MHz, CDCl3) d 169.73, 165.05, 153.53, 147.94, 143.13, 140.13, 139.21, 138.99, 133.16, 129.65, 
129.03, 128.79, 128.33, 125.26, 123.86, 119.16, 57.44, 39.20, 39.20, 39.05, 38.69, 38.59, 37.00, 
33.00, 31.59, 29.76, 28.32, 28.16, 22.66, 20.75, 14.13; HRMS calcd for C31H32ClNO8 [M-H]- 




[1,2]dioxetan]-4'-yl)-2-((4-nitrobenzyl)oxy)phenyl)acrylate (HyCL-4-AM). Enol ether 16 (22 
mg, 0.038 mmol, 1.0 equiv) and Rose bengal (9.8 mg, 0.0087 mmol, 0.107 equiv) were added 









while irradiating with a 120 W light bulb (Home Depot, Dallas, TX) at 0 °C. After 3.5 h of 
reaction, TLC showed no starting material left and the mixture was then concentrated under 
vacuum. The residue was purified by column chromatography (10% EtOAc/ hexanes) to deliver 
HyCL-4-AM as a pale-yellow solid (20 mg, 85%). 1H NMR (400 MHz, CDCl3) d 8.30 (d, 2H, 
8.8 Hz), 7.99 (d, 1H, J = 8.4 Hz), 7.97 (d, 1H, J = 16.0 Hz), 7.71 (d, 1H, J = 8.4 Hz), 7.69, (d, 
2H, J = 8.8 Hz) 6.53 (d, 1H, J = 16.0 Hz), 5.87 (s, 2H), 5.05 (s, 2H), 3.25 (s, 3H), 3.05 (s, 1H), 
2.16 (s, 3H), 1.60–2.14 (m, 12H); 13C NMR (125 MHz, CDCl3) d 169.76, 164.84, 148.11, 
142.82, 139.60, 129.60, 128.92, 125.55, 124.01, 120.57, 111.68, 96.42, 49.84, 36.62, 33.71, 




chlorophenyl)acrylate (17). Acrylate phenol 2 (90 mg, 0.231 mmol 1.0 equiv) was dissolved in 
anhydrous acetone and transferred into a dry round bottom flask flushed with nitrogen. K2CO3 
(64 mg, 0.46 mmol, 2.0 equiv) was added in one portion and stirred for 2 min. Then, benzyl 
bromide (0.04 mL, 0.34 mmol, 1.2 equiv) was added in one portion and the reaction was 
monitored for 3 hr. Additional benzyl bromide (0.03 mL, 0.25 mmol, 1.0 equiv) was added to 
drive the reaction to completion. The reaction was stirred for 16 hr, then transferred into a 
separatory funnel. The reaction was then washed with brine and extracted with 3 x 15 mL 
EtOAc. The combined organic layers were collected and dried over Na2SO4, filtered, and 







hexanes) yielded 6 (97 mg, 88%) as a pale-yellow solid. 1H NMR (400 MHz, CDCl3) d 7.94 (d, 
1H, J = 16.0 Hz), 7.53 (m, 2H), 7.45 (d, 2H, J = 8.0 Hz), 7.39–7.44 (m, 3H), 6.45 (d, 1H, J = 
16.0 Hz), 5.03 (d, 2H, J = 5.6 Hz), 3.83 (s, 3H), 3.35 (s, 3H), 3.30 (s,1H), 1.72–2.10 (m, 12H); 
13C NMR (125 MHz, CDCl3) d 167.08, 153.66, 139.50, 138.94, 132.51, 129.76, 128.89, 128.63, 
127.86, 125.11, 119.96, 57.35, 51.88, 38.73, 37.14, 33.01, 29.79, 28.44, 28.28; LRMS for 




nitrobenzyl)oxy)phenyl)acrylic acid (4). Methyl acrylate 17 (90 mg, 0.19 mmol, 1.0 equiv) was 
dissolved in 5 mL THF in a 20 mL round bottom flask. 5 mL of 1 M LiOH was then added to the 
mixture. The reaction was placed under an inert atmosphere, heated to 80 ºC and refluxed for 6 
hr. Upon completion, the reaction was transferred into a separatory funnel. The organic layer was 
washed with 1 M HCl and extracted with 2 x 20 mL EtOAc. The combined organic layers were 
collected and dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification 
by column chromatography (50% EtOAc/ hexanes) yielded 4 (77 mg, 86%) as a pale-yellow 
solid. 1H NMR (400 MHz, CDCl3) d 8.05 (d, 1H, J = 16.0 Hz), 7.51 (m, 3H) 7.38–7.49 (m, 3H), 
5.06 (d, 2H, J = 5.6 Hz), 3.37 (s, 3H), 3.32 (s, 1H), 1.73–2.21 (m, 12H); 13C NMR (100 MHz, 
CDCl3) d 171.92, 153.92, 140.98, 139.36, 138.62, 135.83, 132.59, 129.96, 129.43, 128.93, 
128.64, 128.62, 127.85, 125.23, 119.32,57.29, 39.22, 39.06, 38.65, 37.07, 32.97, 30.94, 29.74, 









(benzyloxy)-3-chlorophenyl)acrylate (18). Acrylic acid 4 (72 mg, 0.15 mmol, 1.0 equiv) was 
dissolved in 1 mL anhydrous DMF and quantitatively transferred into a dry 10 mL round bottom 
flask flushed with nitrogen. Anhydrous DIPEA (0.096 mL, 0.55 mmol, 3.6 equiv) was added and 
allowed to mix for 2 min. Bromomethyl acetate (0.08 mL, 0.79 mmol, 4.1 equiv) was then added 
dropwise. The reaction was stirred for 24 hr at RT, upon which the starting material was 
consumed as determined by TLC. The crude reaction was then diluted with 4 mL EtOAc and 
transferred into a separatory funnel. The organic layer was washed with saturated NH4Cl and 
extracted with 2 x 20 mL EtOAc. The combined organic layers were collected and dried over 
Na2SO4, filtered, and concentrated under reduced pressure. Purification by column 
chromatography (10–30% EtOAc/ hexanes gradient) yielded 6 (33 mg, 71%) as a pale-yellow 
solid. 1H NMR (400 MHz, CDCl3) d 8.02 (d, 1H, J = 16.4 Hz), 7.37–7.51 (m, 6H), 7.10 (d, 1H, J 
= 8.0 Hz), 6.44 (d, 1H, J = 16.4 Hz), 5.90 (s, 2H), 5.03 (d, 2H, J = 5.6 Hz), 3.53 (s, 3H), 3.31 (s, 
1H), 1.68–2.19 (m, 15H); 13C NMR (100 MHz, CDCl3) d 169.72, 165.18, 153.92, 140.76, 
139.37, 138.71, 135.79, 132.57, 129.96, 129.35, 128.94, 128.63, 128.61, 127.84, 125.08, 118.59, 
57.30, 39.21, 39.05, 38.64, 37.06, 32.96, 30.94, 29.73, 28.36, 28.21, 20.80; HRMS calcd for 










[1,2]dioxetan]-4'-yl)-2-((4-nitrobenzyl)oxy)phenyl)acrylate (HyCL-4-AM-Control). Enol 
ether 18 (29 mg, 0.081 mmol, 1.0 equiv) and Rose bengal (7.9 mg, 0.0081 mmol, 0.1 equiv) 
were added into a dry flask and dissolved in 5 mL THF. Oxygen was bubbled through the 
reaction mixture, while irradiating with a 120 W light bulb (Home Depot, Dallas, TX) at 0 °C. 
After 3.5 h of reaction, TLC showed no starting material left and the mixture was then 
concentrated under vacuum. The residue was purified by column chromatography (20% EtOAc/ 
hexanes) to deliver HyCL-4-AM-Cont as a pale-yellow solid (25 mg, 82%). 1H NMR (400 
MHz, CDCl3) 7.99 (d, 1H, J = 16.0 Hz), 7.94 (d, 1H, J = 8.0 Hz), 7.58 (d, 1H, J = 8.0 Hz), 7.48 
(m, 2H), 7.38–7.44 (m, 3H), 6.48 (d, 1H, J = 16.0 Hz), 5.90 (s, 2H), 4.97 (s, 2H), 3.25 (s, 3H), 
3.05 (s, 1H), 1.75–2.36 (m, 15H); 13C NMR (125 MHz, CDCl3) d 169.77, 164.98, 154.42, 
140.22, 135.77, 135.53, 131.33, 129.08, 128.88, 128.79, 125.34, 119.94, 111.81, 86.46, 49.84, 
33.68, 32.30, 33.68, 32.30, 31.65, 29.80, 26.24, 25.89, 20.87, 14.22; HRMS calcd for 
C31H33ClO8 [M+Na]+ 591.1756, found 591.1702. 
 
 
p- Nitrobenzyl tosylate (19).56 In a 100 mL round bottom flask under nitrogen atmosphere, p-













11.88 mmol, 1.0 equiv) were dissolved in 25 mL THF. In a separate 50 mL roundbottom flask, 
NaOH (713 mg, 17.82 mmol, 1.5 equiv was dissolved in 25 mL H2O and poured into the flask. 
The reaction was stirred at rt for 3 hr. Upon completion as determined by TLC, the reaction was 
transferred into a separatory funnel and washed with sat. NH4Cl, brine and EtOAc. The organic 
layer was then extracted with 3 x 50 mL EtOAc. The combined organic layer was dried with 
Na2SO4, filtered, and concentrated under reduced pressure. Product was recrystallized in hot 
EtOH to give p-nitrobenzyl tosylate (3655 mg, 91%) as a burnt orange solid. 1H NMR (400 
MHz, CDCl3) d 6.89–6.94 (m, 2H), 3.95 (s, 3H), 3.34 (s, 3H), 3.30 (s, 1H), 1.34–2.20 (m, 12H). 
 
2.4.2 Chemiluminescence response of HyCL-3 to NTR and NADH 
Dose dependent responses to NTR and NADH for HyCL-3 were acquired using a Hitachi F-
7000 Fluorescence Spectrophotometer (Hitachi, Tokyo, Japan) using the luminescence detection 
module and setting luminescence emission at 525 nm. 10 μM HyCL-3 was treated with 400 µM 
NADH and 0, 2.5, 5, 7.5, 10, and 12.5 µg mL-1 NTR. Scans were started immediately after 
addition of all agents, and luminescence was measured over 30 min. The integrated emission 
intensity was measured on a Cytation 5 BioTek plate reader via luminescence detection mode at 
37 ºC using a gain set to 135. Measurements were taken every 20 minutes over 4 hours. Reported 
values are the average of 3 technical replicates. 
 
2.4.3 Chemiluminescence response of HyCL-3 and HyCL-4-AM to NTR and NADH and 
rat liver microsomes (RLM) 
 
Chemiluminescent emission wavelength spectra were acquired using a Hitachi F-7000 
fluorescence spectrophotometer via the luminescence detection module and scanning 
luminescence emission from 400–700 nm in response to NTR and NADH. Final concentrations 
of 200 µM NADH, 1 µg mL-1 nitroreductase from Escherichia coli (NTR, Sigma-Aldrich 
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N9284-1MG) in DI-H2O, and 10 µM HyCL-3 or HyCL-4-AM were added to a solution of 20 
mM PBS buffered to pH 7.41. A final concentration of 1 U mL-1 pig liver esterase (PLE) was 
also added for HyCL-4-AM reads. Scans were acquired using the wavelength scan module 10 
min after addition of the probe to the solution. Dose dependent responses to NTR and NADH for 
HyCL-3 and HyCL-4-AM from 0–1000 ng mL-1 NTR were acquired using a Cytation 5 BioTek 
plate reader via the luminescence detection mode, end point read type. The temperature was set 
at 37 °C under ambient atmosphere. The gain was set at 135 and the read height was set at 4.5 
mm. In a 96 well plate, 10 µM HyCL-3 or HyCL-4-AM in 20 mM PBS buffered to pH 7.4, 
containing ≤ 1% DMSO were treated 0–1000 ng mL-1 NTR and 200 µM NADH. A final 
concentration of 1 U mL-1 PLE was used for HyCL-4-AM reads. Luminescence emission was 
measured for 4 hours. Rat liver microsome experiments were conducted in a 96 well plate using 
final concentrations of 200 µg mL–1 RLM, 50 µM NADPH, and 20 µM HyCL-3 or HyCL-4-
AM in 20 mM PBS (pH 7.4). The plate was then placed into a Cytation 5 BioTek plate reader. 
The luminescence was recorded using the luminescence detection mode, end point read type, and 
setting gain to 135 and temperature to 37 ºC for 4 hr. Control experiments with probe alone were 
performed in a separate plate to avoid increased background due to light leakage. Reported 
values are the average of 3 technical replicates. 
 
2.4.4 GC/MS determination of HyCL-3 and HyCL-4-AM products 
In a 20 mL vial, 1.5 mg of HyCL-3 or HyCL-4-AM was dissolved in 10 mL acetone. Then, 9.9 
mL of 100 µM NADPH were added to the vial and 100 µL of 20 mg mL-1 RLM were added for 
a final concentration of 122 µM HyCL-4-AM or 144 µM HyCL-3, 50 µM NADPH and 200 µg 
mL-1 RLM. The reaction was capped and allowed to stir for 12 hr. Upon completion, the reaction 
was transferred to a separatory funnel and washed with sat. NH4Cl. The organic layer was 
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extracted with 3 x 10 mL EtOAc. The organic layer was then dried with Na2SO4, filtered, and 
concentrated under reduced pressure, reconstituted with 1.5 mL DCM, and transferred into a 2 
mL GC/MS vial. GC/MS was conducted immediately using a 6850 Series GC/MS (Agilent 
Technologies, Santa Clara, CA). Mass spectra were averaged across the major peaks in the 
chromatogram and molecular ions for m/z = 150.1 (Figure S1) and m/z = 138.8 (Figure S2) were 
found. The spectrum of 2-adamantanone was matched against the NIST standard, which can be 
found via web at: 
https://webbook.nist.gov/cgi/cbook.cgi?ID=C700583&Units=CAL&Mask=200#MassSpec, 
accessed September 26, 2018. 
 
2.4.5 Selectivity studies.  
Selectivity for HyCL-3 was measured by monitoring the time-dependent full-spectrum 
chemiluminescence emission using a Cytation 5 BioTek plate reader (Winooski, VT) by using 
the luminescence detection method, endpoint read type, and setting gain to 135 and temperature 
to 37 ºC. All assays were performed in 20 mM PBS buffered to pH 7.4. All analytes were tested 
with a final concentration of 200 µM for all metal species, 5 mM for GSH, 1 mM for cysteine, 
and 200 µM for Na2S. Values are the average of 3 technical replicates. 
Cu2+ (200 µM): 1 µL of 50 mM Cu(OTf)2 in DI H2O was added to a solution of 245 µL 20 mM 
PBS (pH 7.43) buffer and 1 µL of 5 mM HyCL-3 or HyCL-4-AM (20 µM final concentration) 
in DMSO. 
Fe2+ (200 µM): 1 µL of 50 mM Fe(OTf)2 in DI H2O was added to a solution of 245 µL 20 mM 
PBS (pH 7.43) buffer and 1 µL of 5 mM HyCL-3 or HyCL-4-AM (20 µM final concentration) 
in DMSO. 
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Fe3+ (200 µM): 1 µL of 50 mM Fe(OTf)3 in DI H2O was added to a solution of 245 µL 20 mM 
PBS (pH 7.43) buffer and 1 µL of 5 mM HyCL-3 or HyCL-4-AM (20 µM final concentration) 
in DMSO. 
Mn2+ (200 µM): 1 µL of 50 mM Mn(OTf)2 in DI H2O was added to a solution of 245 µL 20 mM 
PBS (pH 7.43) buffer and 1 µL of 5 mM HyCL-3 or HyCL-4-AM (20 µM final concentration) 
in DMSO. 
Co2+ (200 µM): 1 µL of 50 mM Co(OAc)2 in DI H2O was added to a solution of 245 µL 20 mM 
PBS (pH 7.43) buffer and 1 µL of 5 mM HyCL-3 or HyCL-4-AM (20 µM final concentration) 
in DMSO. 
Ni2+ (200 µM): 1 µL of 50 mM Ni(OTf)2 in DI H2O was added to a solution of 245 µL 20 mM 
PBS (pH 7.43) buffer and 1 µL of 5 mM HyCL-3 or HyCL-4-AM (20 µM final concentration) 
in DMSO. 
Zn2+ (200 µM): 1 µL of 50 mM Zn(OAc)2 in DI H2O was added to a solution of 245 µL 20 mM 
PBS (pH 7.43) buffer and 1 µL of 5 mM HyCL-3 or HyCL-4-AM (20 µM final concentration) 
in DMSO. 
GSH (5 mM): 10 µL of 125 mM GSH in 0.01 M NaOH was added to a solution of 236 µL 20 
mM PBS (pH 7.43) buffer and 1 µL of 5 mM HyCL-3 or HyCL-4-AM (20 µM final 
concentration) in DMSO. 
Cysteine (1 mM): 1 µL of 250 mM cysteine in 0.01 M NaOH was added to a solution of 245 µL 
20 mM PBS (pH 7.43) buffer and 1 µL of 5 mM HyCL-3 or HyCL-4-AM (20 µM final 
concentration) in DMSO. 
Na2S (200 µM): 1 uL of 50 mM Na2S in 0.01 M NaOH was added to a solution of 245 µL 20 
mM PBS (pH 7.43) buffer and 1 µL of 5 mM HyCL-3 or HyCL-4-AM (20 µM final 
concentration) in DMSO. 
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2.4.6 Biological studies 
Cell culture. Human lung adenocarcinoma epithelial cells (A549) cells were purchased from 
ATCC and cultured in Ham’s F-12K (Kaighn’s) Medium supplemented with 10% Fetal Bovine 
Serum (FBS) and 1% antibiotics (penicillin/streptomycin, 100 U/mL). Cells were maintained in a 
humidified incubator at 37 °C with 5% CO2. One or two days before the experiment, cells were 
passaged and plated on Costar® 12-well plates by adding 150K–200K of cells per well, filling 
each well up to 1 mL of media. Chemiluminescence responses were measured using a Cytation 5 
BioTek plate reader (Winooski, VT).  
 
Cellular Hypoxia Studies. Chemiluminescence responses were measured using a Cytation 5 
BioTek plate reader. Before imaging, the medium was removed upon 90%–95% confluency and 
the cells were washed with 1 mL PBS. Each well was filled with 996 µL F-12K media. Then, 4 
µL of 10 mM HyCL-4-AM or HyCL-3 in DMSO (40 µM final concentration) was added to 
each well and immediately placed into a Cytation 5 BioTek plate reader. The luminescence was 
recorded using the luminescence detection mode, end point read type. The temperature was set at 
37 °C, O2 level was set to 0.5%–1% or 20%, and CO2 was set at 5%. Each experiment consisted 
of three technical replicates for each condition, and each experiment was repeated with three or 
four biological replicates on separate days. The reported chemiluminescence intensity values are 
the average of a total of nine to twelve wells across three or four biological replicates. 
 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Human lung 
adenocarcinoma epithelial cells (A549) were purchased from ATCC and were seeded in a 96-
well plate to a total volume of 120 µL/ well. The plate was maintained at 37 °C with 5% CO2 for 
12 h. Then the medium was removed upon reaching 70%–80% confluency and the cells were 
washed with PBS. The cells were then incubated for 18 h after adding HyCL-3 or HyCL-4-AM 
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at 0, 0.1, 1, 10, and 100 µM respectively in 125 µL completed F12K media. 10 µL of the MTT 
reagent (Cayman Chemical, Ann Arbor, MI) was then added to each well, and mixed gently. 
After 4 h incubation, 100 µL of crystal dissolving solution was added to each well to dissolve the 
formazan crystals. Absorbance was measured at 570 nm in a Cytation 5 BioTek plate reader and 
cell viability was expressed as a percent of the control. 
 
Hypoxia detection in A549 cells. Human lung adenocarcinoma epithelial cells (A549) were 
seeded in a 12-well plate to a total volume of 1 mL per well. Before imaging, the media was 
removed upon 70%–80% confluency and the cells were washed with 1 mL PBS. Each well was 
filled with 996 µL F-12K media. Then, 4 µL of 10 mM HyCL-3 in DMSO (40 µM final 
concentration) was added to each well and immediately placed into a Cytation 5 BioTek plate 
reader. Then, the luminescence was recorded using the luminescence detection mode, end point 
read type. The temperature was set at 37 °C, O2 level was set to 1% or 20%, and CO2 was set at 
5%. Each experiment consisted of three technical replicates for each condition, and each 
experiment was repeated with three biological replicates on three separate days. The reported 
integrated chemiluminescence intensity values are the average of a total of nine wells across 
three biological replicates. Control experiments with HyCL-4-AM and HyCL-4 were performed 
in F12K media in the absence of cells and reported values are the average of three technical 
replicates. 
 
2.4.7 Kinetic modeling. 
Measurement of chemiluminescent decomposition of acrylonitrile and acrylic acid dioxetane 
phenols. The chemiluminescence decomposition rate of the acrylonitrile and acrylic acid 
dioxetane phenols were obtained using a Cytation 5 BioTek plate reader (Winooski, VT) by 
using the luminescence detection method, endpoint read type, and setting gain to 135 and 
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temperature to 25–28 ºC. 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0 µM 11 or 13 were dissolved in 20 mM 
PBS buffered to pH 7.4 and placed immediately into the plate reader for measurement. The 
procedure was timed from the initial addition of probe into solution until the first read to account 
for time differences for kinetic modeling.  
 
Kinetic fits for the cellular response of HyCL-4-AM. A549 cells were incubated with 40 µM 
HyCL-4-AM and the chemiluminescence response was immediately measure in a Cytation 5 
BioTek plate reader using the luminescence detection mode at 37 ºC, gain set to 135, and either 
0.5–1% O2 or 20% O2. The average of 3 technical replicates in a single plate were fit to the rate 
equation given in Figure 2-14B, based on the reactions given in Figure 2-14A using Mathematica 
11.0.0.0 for Mac OS X. The values reported in the manuscript, Figure E are the average values of 
fits from three or four biological replicates. Example fits are given in Figure 2-14C,D. 
 
2.4.8 Animal Imaging 
Hypoxia imaging in living mice. The UT Southwestern Institutional Animal Care and Use 
Committee approved these investigations under Animal Protocol Number (APN #2017-102329). 
Tumor xenografts were established by subcutaneous injection of MDA-MB-231 cells into the 
flanks of athymic nude mice. Mice were placed on a breathing regimen of 16% or 100% O2 for 
10 minutes, then anesthetized and maintained using inhalation of 2.5% isoflurane, while 
breathing 16% or 100% O2. The anesthetized mice were administered intratumoral (IT) or 
intramuscular (IM) injections of 30 µL of 120 µM HyCL-4AM (20 mM PBS buffer containing 
2.4% DMSO). Images were acquired every 60 seconds using a Caliper Xenogen IVIS 
Spectrum® (PerkinElmer, Santa Clara, CA) with auto exposure, medium binning, f-stop set to 1, 
blocked excitation, open emission, FOV set to C, and height set to 1.5. Reported values are the 
average photon flux from three to six mice.
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RATIOMETRIC pH IMAGING USING A 1,2-DIOXETANE CHEMILUMINESCENCE 





Regulation of physiological pH is an important factor for maintaining homeostasis. 
Whole body pH is regulated through numerous methods, including renal control of bicarbonate 
storage,1 ammonia excretion,2,3 CO2 respiration,4 and excretion of non-volatile acids obtained 
from the diet.5 These processes are controlled at a subcellular level through active transport by 
H+-ATPase, and passive transport by Na+/HCO3- coporters,5,6 and Cl-/ HCO3- and Na+/H+ 
antiporters.7 Deviations in pH homeostasis can have major implications on cellular and whole 
body function and can be both a cause and effect of disease states. For example, untreated type 1 
diabetes can result in ketoacidosis (a lowering of blood pH from overproduction of ketone bodies 
in β-oxidation of fatty acids) due to insulin deficiency.8 Diseases associated with chronic 
inflammation display decreased pH levels, and are positively correlated with increased cancer 
risk.9 Extracellular pH is also altered in malignant tumors, as cancer cells generate excess lactate 
due to increased rates of glycolysis, even in the presence of sufficient O2 needed for aerobic 
oxidation.10 Because of their highly heterogenous microenvironments, tumors often display “hot 
spots” of increased acidity.11 The ability to accurately quantify pH in a pre-clinical and clinical 
setting is critical to understand its impact on human health. 
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Current clinically relevant methods to measure pH include magnetic resonance imaging 
(MRI) techniques such as intra and extracellular 31P MRI,12 chemical exchange saturation 
transfer (CEST) MRI,13-15 and other infused reporter molecules, notably 19F-based agents, which 
can provide a large chemical shift range, but often suffer from poor signal to noise.16 These 
methods, however, can be time consuming and often require extensive training and expertise. 
Preclinical techniques for pH detection offer a more cost-effective approach to study pH in a 
laboratory setting. Insertion of pH microelectrodes have been used for preclinical measurement 
of pH in tumors,17,18 but is invasive and may disturb tumor physiology. Optical imaging using 
luminescent pH reporters has been extensively developed in recent years,19-23 however, these 
compounds can be challenging to apply in vivo due to changes in luminescence intensity through 
tissue, hampering the ability to acquire accurate measurements. Ratiometric imaging agents 
circumvent this issue by providing an internal reference, and this technology has been utilized in 
GFP,24 luciferase,25 quantum dot,26,27 and nanoparticle-based28-30 agents for pH. However, no 
small molecule 1,2-dioxetane ratiometric chemiluminescence agents for pH imaging have been 
made for in vivo application. 
Chemiluminescence is light generation through an exothermic chemical reaction and is 
achieved through the breaking of chemical bonds. Specifically, 1,2-dioxetane compounds have 
garnered interest in this area due to their innate ability for triggered chemiluminescence emission 
via chemically initiated electron exchange luminescence (CIEEL).31,32 This technology has been 
employed for imaging analytes by protecting the chemiluminophore with an analyte selective 
trigger.33 Upon deprotection of the dioxetane by the analyte, it will undergo CIEEL and 
luminesce. This strategy has been employed for detection of various analytes including 
hypoxia,34-36 hydrogen sulfide,37 peroxynitrite,38 nitroxyl,39 cathepsin B,40 b-galactosidase,41,42 
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formaldehyde,43 and others.44-52 Chemiluminescence provides many advantages compared to 
other optical methods in vivo by providing its own light source, thus attenuating autofluorescence 
and light scattering effects.53 Chemiluminescent probes have also been shown to achieve much 
higher fold turn-on than comparable fluorophores.39 Furthermore, they do not require expression 
of an enzyme for use, making them valuable standalone optical imaging tools as opposed to 
bioluminescence methods for monitoring pH.25 
A major need for both chemiluminescence and fluorescence in vivo imaging is the 
development of luminophores with high quantum yields and redshifted emission. Fluorophore 
development has flourished in this area, particularly with modifications to BODIPY,54-57 
xanthene,58-63 and cyanine64-66 cores. However, red-shifting emission of 1,2-dioxetane 
chemiluminescent compounds has been difficult. Arguably the largest breakthrough in this area 
in recent years was the development of acryl-substituted phenoxy dioxetanes that greatly 
increased quantum yield and shifted emission to near 530 nm.67 A dicyanomethylchromone-
substituted scaffold has also been reported, providing the first 1,2-dioxetane to emit in the near-
infrared (NIR) region,68 and has been successfully implemented in the detection of 
formaldehyde43 and b-galactosidase.42 One strategy to obtain bathochromic emission is by 
pairing donor and acceptor luminophores through resonance energy transfer mechanisms. 
Fluorescence resonance energy transfer (FRET) pairs have been rigorously vetted, and are often 
used to detect macromolecular interactions in biochemical applications.69 FRET also allows for 
fluorophores to be paired to dyes with sensing capabilities, thus providing ratiometric detection 
of analytes with the FRET pair.70-73 It is currently known that 1,2-dioxetanes exhibit energy 
transfer capabilities,50,74,75 but to our knowledge, no single-molecule 1,2-dioxetane ratiometric 
chemiluminescent probes for imaging pH have been developed. Here, we report the first single 
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molecule ratiometric chemiluminescence resonance energy transfer (CRET) sensor for pH 
imaging in living systems. 
 
3.2 Results 
3.2.1 Design and synthesis of Ratio-pHCL-1 
In previous work, we demonstrated ratiometric quantification of pH in vitro using the 
light emission from 1,2-dioxetane chemiluminophores.75 These studies, however, required the 
addition of the pH sensitive dye seminaptharhodafluor (SNARF) coupled with the addition of a 
chemiluminescence enhancer solution and were not viable for in vivo application. We sought a 
molecule with increased chemiluminescence quantum yields, red-shifted emission, and a pH 
sensitive fluorophore directly conjugated to the dioxetane scaffold for increased energy transfer 
efficiency and ease of use. Inspired by previously reported pH-sensitive carbofluoresceins with 
fluorescence emissions near 580 nm that interconvert between an open, fluorescent form at high 
pH and a colorless, non-fluorescent closed form under acidic conditions,58 we postulated that 
conjugation of this fluorophore to the dioxetane scaffold could provide a ratiometric measure of 
pH (Scheme 3-1.). 
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Synthesis of Ratio-pHCL-1 began with the with synthesis of tert-butyl-dimethylsilyl 
ether (TBS)-protected anthrone 20 from reported literature procedures (Scheme 3-2).58 Due to 
difficulties in conjugation of the top segment of the fluorophore to 20 using reported Grignard 
metathesis to form the carbofluorescein unit, we decided to explore alternative methods. It has 
been shown that iodo compounds react faster than their bromo counterparts during lithium 
halogen exchange,76 so we proceeded to synthesize 2-iodo-tert-butyl-isophthalate 21 from 
commercially available 2-aminoisophthalic acid (Scheme 3-3).77 TBS-protected carbofluorescein 
22 was successfully formed in 35% yield by premixing 20 and 21, purging the mixture three 
times under vacuum, addition of dry THF, then addition of 1 equivalent of n-BuLi at 0 °C. This 
protocol proved to be general, and could be used for preparing other xanthene scaffolds, 
including silicon rhodamines (Scheme 3-3). We postulate that the faster rate of lithium-iodine 
exchange compared to nucleophilic addition of n-BuLi to the anthrone enables the use of n-BuLi 
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Scheme 3-2. Synthesis of Ratio-pHCL-1. 
 
 




Compound 22 was further modified in order to conjugate it to the chemiluminescent 















































































































































trifluoroacetic acid (TFA). The xanthene phenols were protected with acetic anhydride to obtain 
24, but it was noticed that a less polar spot as shown by thin layer chromatography (TLC) also 
formed during the reaction, which was presumed to be the mixed anhydride product. This spot 
disappeared by subjecting the crude mixture to one equivalent of triethylamine and five 
equivalents of pyridine in a 1:1 THF/H2O mixture to produce 24 in a 64% yield. We then 
appended tert-butyl piperazine-1-carboxylate to 24 and subsequently deprotected the tert-
butyloxy carbamate with TFA to obtain amine 26.  
The final steps were to conjugate the chemiluminescent scaffold and carbofluorescein 
together, deprotect to form the free phenol precursor, and form the dioxetane compound. We 
decided to also use an acetate protection strategy to form compound 27 from literature reported 
compound 12 in 64% yield (Scheme 3-3). This was advantageous to preparation of the final 
probe because all three acetates could be deprotected in a single step. We proceeded to conjugate 
26 and 27 together via 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU) coupling to form triacetate 28, which was subsequently 
deprotected with 1 M LiOH to form precursor 29 in quantitative yield. 29 underwent a light 
mediated [2+2] cycloaddition with singlet oxygen generated with methylene blue as a 
photosensitizer to obtain Ratio-pHCL-1 in 90% yield.  
 
3.2.2 Ratio-pHCL-1 in vitro characterization  
Upon synthesis of Ratio-pHCL-1, we proceeded to characterize its properties in vitro. 
We verified the absorbance spectrum of 100 µM Ratio-pHCL-1 (100 mM PBS, pH 7.45, 5% 
DMSO) against the chemiluminescence emission spectrum of the reported methyl acrylate 
dioxetane (20 µM, 100 mM PBS, pH 7.45, 5% DMSO) (Figure 3-1). 67 The emission wavelength 
of the methyl acrylate dioxetane centered at 530 nm coincides with an absorbance maximum of 
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Ratio-pHCL-1 at 544 nm, indicating strong spectral overlap between the chemiluminescence 
emission profile of the dioxetane donor and absorption of the carbofluorescein acceptor. We 
measured the chemiluminescence emission of 20 µM Ratio-pHCL-1 (100 mM PBS or Tris, pH 
6.81–8.42, 5% DMSO). Analysis of the emission spectra over this pH range revealed one peak 
centered at 580 nm attributed to luminescence from the carbofluorescein scaffold, and a shoulder 
around 530 nm corresponding to CIEEL from the chemiluminescent scaffold (Figure 3-2A). As 
the pH of the system is increased, emission at both peaks increases due to increased 
concentration of phenolate over phenol, however, luminescence intensity from the 
carbofluorescein increases in this system to a greater extent than the luminescence from the 
chemiluminophore; analysis shows a 24-fold change in the ratio of emission intensities at 580 
nm over 530 nm from pH 6.81–8.42 (Figure 3-2B), demonstrating that the emission spectra of 
the Ratio-pHCL-1 is pH dependent. We then measured decomposition kinetics of 1.0 µM Ratio-
pHCL-1 (100 mM PBS, pH 7.45, 5% DMSO, 37 °C). Figure 3-3 shows an observed peak 
emission at the initial time point followed by a steady decline to baseline values over 50 minutes.  
 
 
Figure 3-1. (black trace) Absorbance of 100 µM Ratio-pHCL-1 (100 mM PBS, pH 7.45, 5% 
DMSO) and (red trace) chemiluminescence emission spectra of 20 µM methyl acrylate 


































Figure 3-2. The pH dependent (A) chemiluminescence emission spectra of 20 µM Ratio-
pHCL-1 and 5% DMSO in 100 mM PBS buffer from pH 6.81–7.63 and (B) ratio of 
chemiluminescence emission intensities at 580 nm and 530 nm of 20 µM Ratio-pHCL-1 and 
5% DMSO in aqueous buffer (pH = 6.81–8.44). All measurements were taken in 100 mM PBS 
or 100 mM Tris, and measurements were taken 20 s after mixing. Error bars are ± SD from n = 
3 independent experiments. 
 
 
Figure 3-3. Kinetic emission plot of 1.0 µM Ratio-pHCL-1 in 100 mM PBS, pH 7.44, 5% 
DMSO, 37 ºC. 
 
We subjected Ratio-pHCL-1 to variables to confirm its ratiometric response is 
independent of testing conditions. We first examined changes in emission spectra as compared 
with concentration of Ratio-pHCL-1 (Figure 3-4). We tested 10, 20, and 40 µM Ratio-pHCL-1 
(100 mM PBS, pH 6.81-8.02, 5% DMSO). Ratio-pHCL-1 shows a dose dependent increase in 
emission intensity as concentration increases, however, both peaks increase proportionally 
(Figure 3-4B). Analysis of the ratio of emission intensities at 580 nm and 530 nm plotted versus 
the concentration of Ratio-pHCL-1 reveals that the signal remains relatively consistent despite 
changes in its concentration (Figure 3-4B), only showing a slight downward trend with 































































concentrations (100 mM PBS, pH 6.81–8.02, 1–10% DMSO). Ratio-pHCL-1 showed a dose 
dependent increase in overall emission intensity with increasing DMSO concentration, likely due 
to increases in chemiluminescence quantum yield (Figure 3-5A). However, changes in DMSO 
concentration did not greatly change the ratio of emission intensities at 580 and 530 nm, albeit 
showing a slight upward trend in chemiluminescence emission at pH 7.45 (Figure 3-5B).  
 
 
Figure 3-4. The dependence of chemiluminescence emission on the concentration of Ratio-
pHCL-1. (A) Emission spectra at pH 7.45 and (B) ratio of the chemiluminescence emission 
intensity at 580 nm and 530 nm of 10, 20, and 40 µM Ratio-pHCL-1 in PBS buffer at pH 6.81 
(white trace), 7.45 (gray trace), and 8.02 (black trace) containing 5% DMSO. All 




Figure 3-5. The dependence of chemiluminescence emission on the concentration of DMSO. 
(A) Emission spectra at pH 7.45 with 1, 5, or 10% DMSO and (B) ratio of the 
chemiluminescence emission intensity at 580 nm and 530 nm of 20 µM Ratio-pHCL-1 in 
PBS buffer at pH 6.81 (white trace), 7.45 (gray trace), and 8.02 (black trace) containing 1, 5 or 


















































































We then measured 20 µM Ratio-pHCL-1 (100 mM PBS, pH 6.81–8.02) from 0–30 min 
with 10 min intervals to test probe stability over time. Figure 3-6A reveals that the overall 
chemiluminescence intensity decreases over time, as was expected from free phenol dioxetane 
kinetics. Plotting the ratio of emission intensities at 580 nm over 530 nm does reveal changes in 
emission intensities over time, with a slight upward trend at pH 7.45 and a more pronounced 
downward trend at pH 8.02 over a 30-minute period (Figure 3-6B), likely due to more rapid 
decomposition kinetics at this pH. These variations indicate that care should be taken when using 
Ratio-pHCL-1 at higher pH values. Imaging experiments should be performed quickly after 
injection to ensure equal comparisons, especially when measuring higher pH values.  
 
 
Figure 3-6. Time dependent (A) emission spectrum at pH 7.45 and (B) ratio of the 
chemiluminescence emission intensities at 580 nm and 530 nm of 20 µM Ratio-pHCL-1 in 100 
mM PBS at pH 6.81 (white trace), 7.45 (gray trace), and 8.02 (black trace) containing 5% DMSO. 
All measurements were taken 20 s after mixing. Error bars are ± SD from n = 3 independent 
experiments. 
 
Next, we examined the behavior of Ratio-pHCL-1 in biological systems. Cellular uptake 
of 20 µM Ratio-pHCL-1 in A549 cells was examined over an 80 min period (Figure 3-7), and 
changes in fluorescence were monitored using a fluorescence microscope. After washing the 
cells, increased intracellular fluorescence could be seen from the acrylamide and 
carbofluorescein motifs by using GFP and RFP filter sets, respectively. These results show that 









































measure cell viability of Ratio-pHCL-1 (Figure 3-8) using a 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. Cells maintained at least 67% viability when exposed 
to 1–250 µM Ratio-pHCL-1. 
 
 
Figure 3-7. (A-B) Fluorescence microscopy images using a GFP filter set of A549 cells with 
(A) no probe and (B) 20 µM Ratio-pHCL-1 incubated in cells for 80 min, followed by wash 
step. (C-D) Fluorescence microscopy images using an RFP filter set of A549 cells with (A) no 
probe and (B) 20 µM Ratio-pHCL-1 incubated in cells for 80 min, followed by wash step.  
 
 
Figure 3-8. Ratio-pHCL-1 MTT assay. A549 cells were incubated with 0–250 µM Ratio-
pHCL-1 for 16 hours and then viability was evaluated using the MTT assay. Error bars are ± 
S.D. from n = 3 technical replicates. 
 
3.2.3 In vitro ratiometric pH imaging 
Upon completion of the in vitro spectrophotometry experiments and cellular studies, we 
confirmed the feasibility of quantitative pH imaging using Ratio-pHCL-1 in an IVIS Spectrum. 





















and took sequential images using 580 and 540 nm bandpass filters and 0.5 second exposure time. 
Four independent experiments were completed, and each buffered solution was measured with 
three technical replicates per experiment. A solution of 20 µM Ratio-pHCL-1 was too bright and 
saturated the images at this setting, so the concentration was lowered to 1.0 µM. Images of the 
plate taken with average radiance heat maps set to 109 photons sec-1 cm-2 sr-1and 108 photons sec-
1 cm-2 sr-1 for the 540 nm filter (Figure 3-9A, 3-9B, respectively) show that average radiance 
increases with pH on both filter settings. Plotting the flux (photons /s) at 580 nm over flux at 540 
nm for each well shows an increase in the ratio between the two wavelengths over increase in 
pH, and the generated curve trends well with our previous in vitro calibration. The imaging data, 
as shown in Figure 3-9, were used to determine the observed pKa of the response. It was found 
that a modified Henderson-Hasselbalch equation with the inclusion of a Hill coefficient78 was 
needed to fit the data. The observed pKa of the response was determined to be 7.70 ± 0.03 with a 
Hill coefficient of 2.21±0.32 (S.D., n = 12) indicating cooperativity between multiple 
protonation sites. We then confirmed that a ratiometric chemiluminescence response could be 
measured through a tissue surrogate by placing a 2.8 mm thick slice of bologna (Kroger, Dallas, 
TX) atop a 96 well plate loaded with 20 µM Ratio-pHCL-1 in buffered solutions (100 mM PBS 
or Tris, pH 6.81-8.42, 5% DMSO) and took sequential 580 nm and 540 nm filtered images with 




Figure 3-9. Chemiluminescence intensity images of the pH dependent emission of 1 µM Ratio-
pHCL-1 in 100 mM PBS or Tris (pH 6.81–8.42) containing 5% DMSO using (A) 580 nm 
bandpass filter or (B) 540 nm bandpass filter in an IVIS Spectrum. Rows represent technical 
repeats. (C) Ratio of total flux (p/s) at 580 nm and 540 nm. n = 12 technical replicates across 4 
independent experiments, error bars are ± SD. 
 
 
3.2.4 Ratiometric pH imaging in mouse models 
Finally, we investigated the response of Ratio-pHCL-1 in animal models. First, we did a 
proof-of-principle experiment in recently sacrificed C57BL6 mice, which were given 950 µL 
intraperitoneal (IP) injections of 1.0 M PBS (pH 5.99-7.99), then subsequently given 50 µL IP 
injections of 400 µM Ratio-pHCL-1 to achieve a theoretical final concentration of 20 µM 
Ratio-pHCL-1 with 5% DMSO in the injection volume, and imaged with a 580 nm and 540 nm 
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Figure 3-10. Chemiluminescence intensity images of the pH dependent emission of 20 µM Ratio-
pHCL-1 in 100 mM PBS or Tris (pH 6.81–8.42) containing 5% DMSO using (A) 580 nm 
bandpass filter or (B) 540 nm bandpass filter in an IVIS Spectrum with bologna slice (2.8 mm 
thickness) covering 96 well plate. Rows represent technical repeats (C) Ratio of total flux (p/s) at 
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filter. With radiance heat maps of both 580 and 540 nm images set to 109 p sec–1 cm–2 sr–1 
(Figure 3-11A, B), there is a clear increase in flux from the 580 nm image from pH 6.0-8.0, with 
a less pronounced increase in the 540 nm image over the same pH range. Plotting total flux at 
580 nm over flux at 540 nm shows an increase in the ratio of total flux from each filter set with 
increasing pH (Figure 3-11C), demonstrating that Ratio-pHCL-1 can discern changes in pH in 
the peritoneal cavity of mice. Confident with these results, we moved to in vivo measurement of 
pH in the peritoneal cavity of mice. Live male BALB-C mice aged 4.5 months were given 475 
µL injections of 20 µM Ratio-pHCL-1 (1.0 M PBS, pH 5.99–7.99, 5% DMSO), and 
immediately imaged with a 580 nm and 540 nm filter. With radiance heat maps set to 108 p sec–1 
cm–2 sr–1 for both images, there are pronounced increases in overall intensity through each filter 
sets across the pH gradient, and discernable changes in flux output in each mouse from the 580 
nm filter over the 540 nm filter images (Figure 3-12A,B). Indeed, the flux ratio between these 
filter sets increases with increasing pH (Figure 3-12C). This result was consistent across three 
independent experiments, demonstrating the robustness of using Ratio-pHCL-1 for in vivo 








Figure 3-11. Chemiluminescence images of the pH dependent emission of 20 µM Ratio-
pHCL-1 in 1.0 M PBS (pH 5.99-7.99) containing 5% DMSO injected into the peritoneal cavity 
of sacrificed C57BL6 mice using a (A) 580 nm bandpass filter or (B) 540 nm bandpass filter in 
an IVIS Spectrum. (C) Ratio of total flux (p/s) at 580 nm and 540 nm. n = 3 biological 
replicates for each pH tested, error bars are ± SD. 
 
 
Figure 3-12. Chemiluminescence images of the pH dependent emission of 475 µL of 20 µM 
Ratio-pHCL-1 (1.0 M PBS, pH 5.99-7.99, 5% DMSO) injected into the peritoneal cavity of 
male BALB-C mice aged to 4.5 months using a (A) 580 nm bandpass filter or (B) 540 nm 
bandpass filter in an IVIS Spectrum. (C) Ratio of total flux (p/s) at 580 nm and 540 nm. n = 3 
biological replicates for each pH tested, error bars are ± SD. Statistical significance was 
assessed using a two-tailed Student’s t test. **p < 0.005 (n = 3 biological replicates). 
 
3.3 Discussion 
 While Ratio-pHCL-1 clearly shows a pH dependent flux ratio when measured in vitro 
and in animal models, the question arises as to why the ratiometric signal differs from 
experiment to experiment. When comparing the in vitro ratiometric output in Figure 3-9 to the in 

















































































approximately 13-fold over the experimental pH range, whereas flux ratio measurements through 
bologna are much higher. Figure 3-10 shows approximately 98-fold change in flux ratio over the 
same pH range. It is likely that this change is largely due to high absorption of the 540 nm 
emission by hemoglobin present in the bologna slices, as both oxygenated and deoxygenated 
hemoglobin exhibit high extinction coefficients in this region of the visible spectrum.79 This can 
be corroborated with differences in flux seen from the contribution from the 540 nm images 
(Figures 3-9B, 3-10B). However, when comparing the pH dependent flux ratios of Ratio-pHCL-
1 in animal models (Figure 3-11, 12) to in vitro (Figure 3-9) there is an overall decrease in the 
flux ratio, making the analysis more complex. These results likely exhibit contribution from 
multiple factors. First, increased spectral coloring through absorbance in the 580 nm region may 
arise from a higher contribution of oxygenated hemoglobin vs deoxygenated hemoglobin, which 
exhibits a local maximum in its extinction coefficient near 580 nm.79 Second, we believe that a 
decreased contribution from the carbofluorescein unit may arise to solvatochromism, where a 
change in the solvent (i.e., biological milieu) may cause changes in the pKa of the dye. 
Solvatochromism has been shown in fluoresceins,80 and it is possible that the related structure of 
the carbofluorescein exhibits similar properties. It is also seen that there are small differences 
between the flux ratio in the sacrificed animal imaging experiment (Figure 3-11) which exhibited 
a 5-fold change in flux ratio from pH 6-8 as compared to the live animal imaging (Figure 3-12), 
which exhibited an approximate 4-fold change over the same pH range. Differences may arise 
from a higher proportion of deoxygenated hemoglobin vs. oxygenated hemoglobin in the 
sacrificed mice as compared to live mice. A higher proportion of spectral coloring may be 
exhibited in the sacrificed mice due to an increase in melanin content in their skin as compared 
to white mice used in the in vivo studies. 
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3.4 Conclusion 
In summary, we have developed the first single molecule 1,2-dioxetane ratiometric 
chemiluminescence probe for quantitative imaging of pH in animal tissue. This was synthetically 
achieved by attaching a pH sensitive carbofluorescein to the chemiluminescent acrylamide 
dioxetane scaffold via a piperazine linker. Ratio-pHCL-1 generates light through CIEEL 
decomposition, and concomitant pH dependent emission from the appended fluorophore through 
a CRET mechanism. Ratio-pHCL-1 is highly accurate in vitro, providing measurement of pH in 
biological ranges. Its ratiometric output is stable to confounding variables, and provides a similar 
response when collected through optical imaging methods. A pH dependent ratiometric emission 
is also reported in the peritoneal cavity of sacrificed mice, and we plan to conduct in vivo 
quantification of pH in live mouse models in future experiments. We report flux outputs of more 
than 1010 p/s from 20 µM Ratio-pHCL-1 through biological tissue, which exceeds the photon 
flux of most reported chemiluminescence agents. This increase in brightness is achieved through 
use of an unmasked phenoxy dioxetane that provides instantaneous decomposition and light 
output. This shows a clear advantage to chemiluminescence detection using unmasked 
dioxetanes – they have the potential for much higher sensitivity in biological settings. This 
methodology can be applied to highly sensitive quantitation of other analytes, and has provided 
the foundation for in vivo ratiometric imaging with 1,2-dioxetanes. 
 
3.4 Experimental Procedure 
3.4.1 General synthetic methods and materials  
All reactions were performed in dried glassware under an atmosphere of dry N2. Silica 
gel P60 (SiliCycle) was used for column chromatography and SiliCycle 60 F254 silica gel 
(precoated sheets, 0.25 mm thick) was used for analytical thin layer chromatography. Plates were 
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visualized by fluorescence quenching under UV light. Other reagents were purchased from 
Sigma-Aldrich (St. Louis, MO), Alfa Aesar (Ward Hill, MA), EMD Millipore (Billerica, MA), 
Oakwood Chemical (West Columbia, SC), and Cayman Chemical (Ann Arbor, MI) and used 
without further purification. 1H NMR for compounds and 13C NMR for compounds were 
collected on a Bruker 400 MHz or a JEOL 500 MHz spectrometer in the Department of 
Chemistry at Southern Methodist University. 1H and 13C NMR spectra for characterization of 
new compounds and monitoring reactions were collected in CDCl3, acetone-d6, methanol-d4, or 
DMSO-d6 (Cambridge Isotope Laboratories, Cambridge, MA). All chemical shifts are reported 
in the standard notation of parts per million using the peak of residual proton signals of the 
deuterated solvent as an internal reference. Coupling constant units are in Hertz (Hz) Splitting 
patterns are indicated as follows: br, broad; s, singlet; d, doublet; t, triplet; q, quartet; m, 
multiplet; dd, doublet of doublets; dt, doublet of triplets. High resolution mass spectroscopy was 
performed on a Shimadzu IT-TOF (ESI source) at the Shimadzu Center for Advanced Analytical 
Chemistry at the University of Texas, Arlington, and low-resolution mass spectrometry was 




5-iodoisophthalic acid (31).81 In a 1L roundbottom flask equipped with a stir bar, 2-
aminoisophthalic acid (50.0 mmol, 9.06 g, 1.0 equiv) was suspended in 300 mL 5.8 M HCl at 0 
ºC under N2 atmosphere. Sodium nitrite (125 mmol, 8.63 g, 2.5 equiv) was dissolved in 100 mL 






(300 mmol, 45 g, 6.0 equiv) was dissolved. The contents of the 1L flask were then added to the 
sodium iodide solution, upon which the reaction smoked and turned black. The reaction was 
stirred for another 18 hr. The reaction was then quenched with sodium bisulfite, and 450 mL 
DCM was added to the mixture. The solution was then filtered with filter paper, and the resulting 
brown solid was left to dry overnight, yielding 2-iodoterepthalic acid (48.94 mmol 14.29 g, 




di-tert-butyl 5-iodoisophthalate (21).81 in a 100 mL roundbottom flask equipped with a stir bar 
under N2 atmosphere, 2-iodoterephthalic acid (7.23 mmol, 2111 mg, 1.0 equiv) and DMAP (1.44 
mmol, 176 mg, 0.2 equiv) were dissolved in 2 mL DMF and 20 mL toluene. Di-tert-butyl 
dicarbonate (21.69 mmol, 4734 mg, 3.0 equiv) was added. The reaction was heated to 80 ºC and 
stirred for 30 min. 1 equiv Boc anhydride was added to drive the reaction to completion and 
stirred for 30 more min. Upon completion, the reaction was allowed to cool to RT, washed with 
sat. NH4Cl, extracted with 3x 30 mL EtOAc, dried with Na2SO4, and concentrated under reduced 
pressure. Column chromatography in 5% EtOAc/Hexanes yielded compound 2 (5.35 mmol, 
74%) as a yellow oil. 1H NMR (400 MHz, CDCl3) d 8.52 (d, 1H, J = 1.2 Hz), 7.97 (dd, 1H, J1 = 










spiro[anthracene-9,1'-isobenzofuran]-5'-carboxylate (22).58 In a 25 mL oven-dried 
roundbottom flask equipped with a stir bar, compound 20 (0.46 mmol, 220 mg, 1.0 equiv) and 
compound 21 (1.6 mmol, 647 mg, 3.5 equiv) were added, and purged 3x with N2. 6 mL 
anhydrous THF was then added, and the reaction contents were cooled to 0 ºC. 2.6 M n-BuLi 
(1.76 mmol, 0.68 mL, 3.85 equiv) was added dropwise, over which period the reaction changed 
from light yellow to deep purple in color. The reaction was stirred 10 min, then allowed to warm 
to RT and stirred for 2 hr. The reaction was then quenched with 5 mL H2O, washed with 
brine/1M HCl, extracted 2x with 20 mL EtOAc, dried with Na2SO4, filtered, and concentrated 
under reduced pressure. Column chromatography (3-5% EtOAc/Hexanes) yielded compound 3 
(0.231 mmol, 109 mg, 35%) as a white solid. 1H NMR (400 MHz, CDCl3) d 8.17 (dd, 1H, J = 
8.0 Hz, J = 1.2 Hz), 8.04 (d, 1H, J = 8.0 Hz), 7.64 (s, 1H), 7.10 (s, 2H), 6.62 (d, 4H, J = 1.2 Hz), 













tert-butyl 3-iodo-4-methylbenzoate (33). 3-Iodo-4-methylbenzoic acid (32) (7.63 mmol, 2.00 g, 
1.0 equiv), di-tert-butyl dicarbonate (19.0 mmol, 4.10 g, 2.5 equiv), and DMAP (1.53 mmol, 186 
mg, 0.2 equiv) were combined in a roundbottom flask and dissolved in 20 mL anhydrous THF. 
The reaction was heated to 60 °C and stirred under reflux for 20 hours. After cooling the reaction 
to RT, the solvent was evaporated off under reduced pressure and the residue was dissolved in 
Et2O, which was then washed with sat. aq. NaHCO3 (x3), H2O, and brine. The organic layer was 
dried over Na2SO4 and concentrated. Purification via column chromatography with 10% 
EtOAc/Hexanes yielded the product as a golden oil (6.82 mmol, 2.17 g, 89%). 1H NMR 
(500 MHz, CDCl3) d 8.36 (d, J = 1.7 Hz, 1H), 7.81 (dd, J = 1.7, 8.0 Hz, 1H), 7.22 (d, J = 8.0 Hz, 
1H), 2.42 (s, 3H), 1.55 (s, 9H); 13C NMR (125 MHz, CDCl3) d 164.23, 146.18, 139.90, 131.25, 













silicon anthrone 3471 (1.23 mmol, 0.400 g, 1.0 equiv), prepared according to literature procedure, 
were added to an oven dried flask, which was evacuated and flushed with nitrogen. Dry THF (25 
mL) was added to the flask and the reaction was stirred until starting materials dissolved. The 
reaction was then cooled to 0 °C, and 1.5M n-BuLi in hexanes (5.25 mmol, 3.5 mL, 4.2 equiv) 
was added dropwise, and a color change from yellow to orange was observed. The reaction was 
stirred for an additional 3 hours, allowing the temperature to rise to RT. TLC in 15% 
EtOAc/Hexanes indicated disappearance of the anthrone starting material and formation of a 
deep blue colored product. 1M HCl was then added to quench the reaction, resulting is an intense 
blue solution of pH = 1. Saturated aqueous NaHCO3 was added to neutralize the reaction, which 
was then extracted with DCM. The blue organic layer was washed with brine, dried over Na2SO4 
and concentrated to a blue solid. This crude tert-butyl ester product was dissolved in DCM (15 
mL) and trifluoroacetic acid (3 mL) was added. The reaction was stirred at RT for 3.5 hours, 
while monitoring product formation via mass spectroscopy. The volatiles were then evaporated 
under reduced pressure. The product was isolated using column chromatography with 10% 
MeOH/DCM to obtain S6 as a blue solid (0.851 mmol, 0.377 g, 69%). 1H NMR (500 MHz, 
CD3OD) d 8.10 (dd, J = 2.3, 8.0 Hz, 1H), 7.72 (d, J = 1.7 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.37 
(d, J = 2.3 Hz, 2H), 7.02 (d, J = 9.7 Hz, 2H), 6.77 (dd, J = 2.9, 9.7 Hz, 2H), 3.34 (s, 12H), 2.10 (s, 
3H), 0.62 (s, 3H), 0.60 (s, 3H); 13C NMR (125 MHz, CD3OD) d 169.05, 168.86, 155.78, 149.51, 







carboxylic acid (23).58 In a 20-dram vial equipped with a stir bar, Compound 22 (0.278 mmol, 
191 mg) was dissolved in 10 mL DCM. 2 mL TFA was added, and the reaction was stirred at RT 
under N2 atmosphere for 6 hr. Upon completion of the reaction as determined by TLC, the 
reaction was evaporated onto silica gel. Column chromatography (5% MeOH/DCM, 1% AcOH) 
afforded compound 23 (0.189 mmol, 76 mg, 68%) as a red-orange solid. 1H NMR (400 MHz, 
Acetone-D6) d 8.29 (d, 1H, J = 8.0 Hz), 8.10 (d, 1H, J = 8.0 Hz), 7.67 (s, 1H), 7.22 (d, 2H, J = 
2.4 Hz), 6.71 (dd, 2H, J = 8.8 Hz, J = 2.4 Hz), 6.65 (d, 2H, J = 8.8 Hz); 13C NMR (100 MHz, 
Acetone-D6) d 171.8, 169.0, 158.1, 155.7, 147.1, 130.5, 129.8, 129.3, 125.0, 124.7, 122.3, 114.9, 














carboxylic acid (24).58 Compound 23 (0.189 mmol, 76.0 mg, 1.0 equiv) was dissolved in 2 mL 
Ac2O in a 20 mL roundbottom flask equipped with a stir bar. Pyridine (0.98 mmol, 76. µL, 5.0 
equiv) was added. The reaction was heated to 80 ºC and stirred for 1 hr until TLC showed 
disappearance of starting material, and appearance of two spots, indicating a mixture of the 
generated mixed anhydride and free acid. The crude mixture was washed in 1 M HCl, extracted 
with 2x 10 mL DCM, dried with Na2SO4, and concentrated under reduced pressure. The crude 
was then dissolved in 10 mL 1:1 THF H2O mixture. Pyridine (0.98 mmol, 76. µL, 5.0 equiv) and 
Et3N (0.19 mmol, 30. µL, 1.0 equiv) was added. The reaction was heated to 80 ºC and stirred for 
1 hr, at which point TLC showed disappearance of the mixed anhydride. Column 
chromatography in 50% EtOAc/Hexanes and 1% AcOH yielded 24 (0.12 mmol, 59 mg, 64%) as 
a white foam. 1H NMR (400 MHz, CDCl3) d 8.30 (d, 1H, J = 8.0 Hz), 8.12 (d, 1H, J = 8.0 Hz), 
7.75 (s, 1H) 7.40 (d, 1H, J = 1.6 Hz), 7.40 (s, 1H), 6.92 (dd, 2H, J = 8.8 Hz, J = 2.4 Hz), 6.76 (d, 
1H, J = 8.8 Hz), 2.33 (s, 6H), 1.87 (s, 3H), 1.77(s, 3H); 13C NMR (100 MHz, CDCl3) d 169.4, 
169.2, 169.2, 154.7, 141.5, 146.7, 135.8, 131.3, 130.1, 129.1, 128.1, 125.7, 125.6, 120.7, 119.5, 












spiro[anthracene-9,1'-isobenzofuran]-3,6-diyl diacetate (25). In a 25 mL roundbottom flask 
equipped with a stir bar under N2 atmosphere, Compound 24 (0.119 mmol, 58 mg, 1.0 equiv) 
was dissolved in 8 mL DCM. The reaction was cooled to 0 ºC. DIPEA (0.16 mmol, 27 µL, 1.3 
equiv) and N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl) uronium hexafluorophosphate 
(HBTU) (0.14 mmol, 54 mg, 1.2 equiv) were then added and stirred for 10 min, upon which the 
HBTU activated ester was visible by TLC. tert-Butyl piperazine-1-carboxylate (0.14 mmol, 27 
mg, 1.2 equiv) was then added, and the reaction was allowed to stir overnight. Upon completion, 
the reaction was washed in brine/NH4Cl, extracted with 2x 20 mL DCM, dried with Na2SO4, 
filtered, and concentrated under reduced pressure. Column chromatography (50-75% 
EtOAc/Hexanes) yielded Compound 25 (0.10 mmol, 66 mg, 85%) as a white foam. 1H NMR 
(500 MHz, CDCl3) d 8.01 (d, 1H, J = 8.0 Hz), 7.56 (d, 1H, J = 8.0 Hz), 7.33 (s, 2H), 7.02 (s, 
1H), 6.86 (d, 2H, J = 4.0 Hz), 6.73 (d, 2H, J = 4.0 Hz), 3.18–3.76 (m, 8H), 2.25 (s, 6H), 1.79 (s, 
3H), 1.78 (s, 3H), 1.38 (s, 9H); 13C NMR (125 MHz, CDCl3) d 169.11, 168.5, 155.1, 154.4, 
151.6, 146.7, 142.0, 129.1, 128.2, 122.7, 120.8, 119.6, 85.5, 80.5, 69.3, 53.9, 38.6, 35.0, 32.6, 












isobenzofuran]-3,6-diyl diacetate (26). in a 20 mL vial, compound 25 was dissolved in 5 mL 
DCM. 1 mL TFA was added under N2 atmosphere at RT and stirred for 2 hr. Upon completion as 
monitored by TLC, 5 mL toluene was added, and the reaction contents were evaporated. The 
crude product was triturated 2x with 5 mL MeOH to obtain compound 26 (0.098 mmol, 54 mg, 
98%) as a tan foam. 1H NMR (400 MHz, CDCl3) d 8.04 (d, 1H, J = 7.2 Hz), 7.59 (d, 1H, J = 7.2 
Hz), 7.38 (d, 2H, J = 1.6 Hz), 7.073 (s, 1H), 6.90 (dd, 2H, J = 8.8 Hz, J = 1.6 Hz), 6.76 (d, 2H, J 
= 8.8 Hz), 3.42-3.96 (m, 4H), 3.13 (bs, 4H), 2.29 (s, 6H), 1.84 (s, 3H) 1.75 (s, 3H); 13C NMR 
(100 MHz, CDCl3) d 169.5, 169.3, 168.6, 155.5, 151.6, 146.5, 140.3, 128.9, 128.3, 127.7, 127.4, 
126.1, 122.8, 120.9, 119.7, 85.6, 43.3, 38.4, 34.7, 33.1, 21.1; HRMS calcd for C32H30N2O7 















chlorophenyl)acrylic acid (27). Compound 1272 (0.368 mmol, 138 mg, 1.0 equiv) was dissolved 
in 5 mL acetic anhydride in a 20 mL roundbottom flask equipped with a stir bar. Pyridine (1.84 
mmol, 0.148 mL, 5.0 equiv) was added. The reaction was heated to 80 ºC and stirred for 30 min 
until TLC showed disappearance of starting material, and appearance of two spots, indicating a 
mixture of the generated acrylic anhydride and free acid. The crude mixture was washed in 1 M 
HCl, extracted with 2x 10 mL DCM, dried with Na2SO4, and concentrated under reduced 
pressure. The crude was then dissolved in 10 mL 1:1 THF H2O mixture. Pyridine (1.84 mmol, 
0.148 mL, 5.0 equiv) and Et3N (0.37 mmol, 51 µL, 1.0 equiv). was added. The reaction was 
heated to 80 ºC and stirred for 20 min, at which point TLC showed disappearance of the mixed 
anhydride. Column chromatography in 50% EtOAc/Hexanes and 1% AcOH yielded 27 (116 mg, 
76%) as a yellow foam. 1H NMR (400 MHz, CDCl3) d 10.58 (bs, 1H), 7.74 (d, 1H, J = 16.0 Hz), 
7.57 (d, 1H, J = 8.0 Hz), 7.24 (d, 1H, J = 8.0 Hz), 6.49 (d, 1H, J = 16.0 Hz), 3.34 (s, 3H), 3.30 (s, 
1H), 2.47 (s, 3H) 1.61–2.13 (m, 12H); 13C NMR (100 MHz, CDCl3) d 171.4, 168.1, 146.4, 
139.5, 138.9, 138.3, 133.3, 129.5, 129.1, 128.5, 125.1, 120.6, 60.5, 57.4, 39.2, 39.0, 38.6, 37.0, 













spiro[anthracene-9,1'-isobenzofuran]-3,6-diyl diacetate (28). In a 25 mL roundbottom flask 
equipped with a stir bar under N2 atmosphere, Compound 27 (0.055 mmol, 23 mg, 1.0 equiv) 
was dissolved in 2 mL DCM. The reaction was cooled to 0 ºC. DIPEA (0.072 mmol, 13 µL, 1.3 
equiv) and HBTU (0.14 mmol, 54 mg, 1.2 equiv) were then added and stirred for 10 min, upon 
which the HBTU activated ester was visible by TLC. Compound 26 (0.055 mmol, 30 mg, 1.0 
equiv) was then added, and the reaction was allowed to stir overnight. Upon completion, the 
reaction was washed in brine/NH4Cl, extracted with 2x 20 mL DCM, dried with Na2SO4, 
filtered, and concentrated under reduced pressure. Column chromatography (75-100% 
EtOAc/Hexanes) yielded Compound 28 (0.10 mmol, 8 mg, 85%) as a white solid. 1H NMR (400 
MHz, CDCl3) d 8.10 (d, 1H, J = 7.6 Hz) 7.65 (m, 2H), 7.53 (d, 1H, 8.0 Hz), 7.38 (s, 1H), 7.18 (d, 
1H, J = 8.0 Hz), 6.79-6.94 (m, 6H), 4.52-4.85 (m, 6H) 3.25-3.36 (m, 6H), 2.41 (s, 3H), 2.31 (s, 
6H), 1.61-2.16 (m, 12H); 13C NMR (100 MHz, CDCl3) d 169.1, 168.5, 168.2, 164.9, 151.5, 
146.1, 141.5, 139.0, 137.5, 136.4, 133.0, 129.3, 129.0, 128.6, 128.1, 126.1, 124.5, 120.8, 119.6, 
60.4, 57.3, 56.0, 39.22, 38.5, 37.0, 34.9, 32.9, 29.7, 28.3, 28.1, 21.2, 21.1, 20.6, 14.2; HRMS 














spiro[anthracene-9,1'-isobenzofuran]-3'-one (29). In a 20-dram vial, compound 28 (0.021 
mmol, 20 mg) was dissolved in 2 mL THF, and 2 mL 10 M LiOH was added under N2 
atmosphere at RT. The reaction was stirred for 2.5 hr. upon completion as determined by TLC, 
the reaction was washed in brine, and 30 mL 1M HCL was then added. The organic layer was 
extracted with 2x 10 mL EtOAc, then 2x 10 mL DCM, dried with Na2SO4, filtered, and 
concentrated under reduced pressure, yielding 29 (18 mg, 0.021 mmol, quantitative) as a red 
solid without further purification. 1H NMR (400 MHz, Acetone-d6) d 8.06 (d, 1H, J = 7.6 Hz), 
7.96 (d, 1H, J = 15.6 Hz), 7.21(m, 1H), 6.86 (d, 4H, J = 8.0 Hz), 6.72 (d, 1H, J = 2.0 Hz) 6.70 (d, 
2H, J = 2.0 Hz), 6.63 (d, 1H, J = 8.8 Hz), 3.50-3.92 (m, 6H), 3.28 (s, 6H), 2.65-3.15 (m, 12H); 
13C NMR (100 MHz, CDCl3) d 171.2, 169.0, 168.1, 165.1, 158.2, 155.5, 151.4, 147.4, 140.3, 
136.5, 136.2, 130.3, 129.2, 128.2, 125.7, 125.2, 125.0, 124.0, 123.1, 122.8, 122.5, 119.8, 118.9, 
114.8, 112.7, 86.6, 56.1, 38.7, 38.5, 38.1, 37.9, 36.8, 34,6, 32.9, 19.6; HRMS calcd for 















3'H,10H-spiro[anthracene-9,1'-isobenzofuran]-3'-one (Ratio-pHCL-1). In a 2-neck 
roundbottom flask, compound 29 (0.021 mmol), was dissolved in 2 mL THF at 0 ºC. 2 mg 
methylene blue was added. The reaction was irradiated under yellow light for 1 hr and monitored 
by LRMS. Upon completion, the crude was evaporated onto silica gel and loaded for column 
chromatography in 5% MeOH/DCM, yielding Ratio-pHCL-1 (16 mg, 90%) as a white solid. 1H 
NMR (400 MHz, Acetone-d6) d 8.06 (d, 1H, J = 8.0 Hz), 7.94 (d, 1H, J = 16.0 Hz), 7.76 (dd, 
1H, J = 8.0 Hz, J = 1.2 Hz), 5.64 (d, 1H, J = 7.6 Hz), 7.35 (bs, 1H), 7.20 (m, 4H) 6.70 (dd, 2H, J 
= 8.8 Hz, J = 2.4 Hz), 3.50-4.00 (m, 4H), 3.19, (s, 3H), 2.96 (s, 1H), 2.75 (s, 4H), 2.062 (s, 3H), 
2.71 (s, 3H);13C NMR (100 MHz, Acetone-d6) d 168.9, 168.1, 164.8, 158.1, 155.5, 152.6, 150.5, 
147.3, 142.7, 140.5, 136.5, 136.9, 133.2, 129.3, 128.2, 127.5, 125.8, 125.0, 123.9, 122.8, 122.5, 
120.2, 114.7, 112.6, 112.0, 111.5, 95.5, 86.5, 67.17, 48.8, 38.1, 37.8, 36.3, 34.6, 33.5, 32.4, 31.9, 















3.4.2 Ratio-pHCL-1 in vitro characterization  
Calibration of Ratio-pHCL-1. Chemiluminescent emission spectra were acquired using a Hitachi 
F-7000 fluorescence spectrophotometer via the luminescence detection module and scanning 
luminescence emission from 400-900 nm in response to exposure of Ratio-pHCL-1 to pH 
buffered solutions. Ratio-pHCL-1 in DMSO was added to a solution of 100 mM Tris, PBS or 
carbonate buffers ranging from pH 6.81–10.02. For concentration dependence, 10, 20, and 40 
µM Ratio-pHCL-1 in 5% DMSO were subjected to 100 mM PBS buffered to pH 6.81, 7.45, and 
8.02. For time dependence, 20 µM Ratio-pHCL-1 in 5% DMSO was subjected to 100 mM PBS 
buffered to pH 6.81, 7.45, and 8.02, and the chemiluminescence emission spectra was measured 
at t = 0, 10, 20 and 30 min. For DMSO dependence, 20 µM Ratio-pHCL-1 in a final 
concentration of 1, 5, or 10% DMSO was subjected to 100 mM PBS buffered to pH 6.81, 7.45, 
or 8.02. Each experiment was independently conducted 3 times, and analysis of each experiment 
was conducted by dividing emission intensity values at 580 nm over emission intensity values at 
530 nm from the emission plot. 
 
Ratio-pHCL-1 kinetics. Kinetics data were acquired using a Biotek Cytation 5® plate reader 
using the luminescence detection mode, end point read type. The temperature was set at 37 °C 
under ambient atmosphere. The gain was set at 135 and the read height was set at 4.5 mm. In a 
96-well plate, 1.0 µL of 0.25 mM Ratio-pHCL-1 was added to wells containing a solution of 
237.5 µL 100 mM PBS (pH = 7.45) and 11.5 µL DMSO to create a final concentration of 1.0 
µM, 5% DMSO. The plate was then immediately placed into the plate reader and allowed to stir 




3.4.3 Cell culture and biological studies.  
Human lung adenocarcinoma epithelial cells (A549) cells were purchased from ATCC and 
cultured in Ham’s F-12K (Kaighn’s) Medium supplemented with 10% Fetal Bovine Serum 
(FBS) and 1% antibiotics (penicillin/streptomycin, 100 U/mL). Cells were maintained in a 
humidified incubator at 37 °C with 5% CO2. One or two days before the experiment, cells were 
passaged and plated on Costar® 12-well plates by adding 150K–200K of cells per well, filling 
each well up to 1 mL of media.  
 
Ratio-pHCL-1 cell penetration A549 cells were seeded in a 12 well plate , and maintained at 37 
ºC with 5% CO2, and monitored until the plate reached 80% confluency. The cells were then 
washed with 1x PBS, and 996 µL complete F12k was added. Next, 4.0 µL of 5 mM Ratio-
pHCL-1 in DMSO was added to obtain a final concentration of 20 µM Ratio-pHCL-1 
incubated for t = 80 min. Upon completion of incubation, cells were washed twice with 1x PBS 
and reconstituted with 1000 µL incomplete F12K, or were given no wash,  and the plate was 
imaged with an EVOS microscope, and images were taken using GFP and RFP filters with the 
20x objective. Images taken with the GFP filter were uniformly processed using Image J with 
contrast changed to min = 18, max = 112, and RFP images were uniformly processed using 
Image J with contrast changed to min = 66, max = 135. 
 
3.4.4 Ratiometric pH imaging  
Chemiluminescent images were acquired with an IVIS Spectrum (Caliper, Waltham, MA) using 
the “Luminescent” and “Photograph” mode. For in vitro 96 well plate measurements, the 
exposure time was set as 0.5 seconds, binning was set to medium, F/stop was set as 4, FOV was 
set as C (12.9 cm), Excitation was blocked, and the sequence was set for the emission mode, and 
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images were acquired sequentially first using a 580 nm bandpass filter, then a 540 nm bandpass 
filter. A final concentration of 1 µM Ratio-pHCL-1 was added in a snake-like fashion (left to 
right across pH gradient, then down one row, right to left across pH gradient, etc.) to 100 mM 
buffer ranging from pH 6.81-8.42. Image analysis was carried out by setting individual ROI’s to 
each well for both 580 and 540 nm filter images. The ROI’s were then measured, which gave a 
total flux (p/s) for each ROI, the flux value at 580 nm was divided by the flux at 540 nm for each 
well.  
 
In vitro pH measurement through tissue surrogate. For measurements through tissue surrogate 
(bologna, Kroger, Dallas, TX), the exposure time was set as 10.0 seconds, binning was set to 
medium, F/stop was set to 1, FOV was set to C (12.9 cm), Excitation was blocked, and the 
sequence was set for the emission mode. Images were acquired sequentially first using a 580 nm 
bandpass filter, then a 540 nm bandpass filter. A final concentration of 20 µM Ratio-pHCL-1 
was added in a snake-like fashion (left to right across pH gradient, then down one row, right to 
left across pH gradient, etc.) to 100 mM buffer ranging from pH 6.81-8.42. Then, 1 slice of 
bologna measuring 2.8 mm thickness (Oscar Meyer) was placed on top of the 96-well plate, and 
luminescence was measured through the meat sample. All images were analyzed using Living 
Image software. Image analysis was carried out by setting individual ROI’s to each well for both 
580 and 540 nm filter images. The ROI’s were then measured, which gave a total flux (p/s) for 
each ROI, the flux value at 580 nm was divided by the flux at 540 nm for each well.  
Sacrificed mouse imaging. A solution of 950 µL of 1.0 M PBS (pH 5.99-7.99) was injected into 
the peritoneal cavity of recently sacrificed CL6B57 mice aged 6-12 weeks old, then 50 µL of 
400 µM Ratio-pHCL-1 in DMSO was injected shortly after to achieve an approximate final 
concentration of 20 µM Ratio-pHCL-1 with 5% DMSO. The mice were imaged immediately 
 122 
after injection of the probe with a 580 nm and 540 nm filter with capture settings set to 
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 Light and chemistry have a uniquely intertwined relationship, where light can be used to 
enact and enable control of chemical phenomena.1 Photoswitches are one such class of molecules 
that can be precisely manipulated by light.2 Light interacts with photoswitch structures by 
inducing reversible photochemical isomerization or bond formation/cleavage to metastable 
intermediates.3 Rhodopsin is one such naturally occurring photoswitch that enables vision in 
animals4 and photosynthesis for some archaea.5 Furthermore, synthetically devised 
photoswitches such as azobenzenes and stilbenes have been implemented for controlling both 
structure and expression of biomacromolecules.6-8 Spiropyrans are another type of photoswitch 
that has unique properties as compared to others in its class.9 The spiropyran converts from a 
relatively non-polar, non-fluorescent spiropyran (SP) form to an open merocyanine (MC) 
chromophore, coinciding with a large shift in the molecule’s polarity in zwitterionic form. While 
the MC chromophore shows higher absorbance than the closed SP form, it exhibits moderate 
fluorescence in polar solvents and is virtually non-fluorescent in water. However, encapsulation10 
or incorporation into polymers,11-13 nanodots,14 and thin films15 has granted major improvements 
in fluorescence efficiency. Spiropyrans have been largely implemented for dynamic fluorescence 
due to increased fluorescence quantum yield that arises from conformational restraint and 
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minimization of solvent-based quenching, as well as innate thermochromic,16 acidochromic,17 
solvatochromic,18 electrochromic,19 and mechanochromic12,20,21 properties. 
Light can also initiate irreversible photochemical processes. Photolabile protecting 
groups (PPGs) are an established method to cage compound activity through covalent attachment 
of a photolabile group, allowing for buildup of the substrate in regions of interest and high 
spatiotemporal control for the release of a substrate through photochemical bond cleavage. 
Development of photoremovable groups has been of particular interest over the last half century, 
and its study has garnered a diverse array of new PPGs exhibiting a wide range of uncaging 
mechanisms, uncaging wavelengths, and functional group compatibility. Some PPGs include 
phenacyl,22-24 nitroaryl,25-29 coumarinyl,30,31 BODIPY,32-37 and cyanine38 derivatives. Of this 
class, ortho-nitrobenzyl protecting groups exhibit uncaging capability in both the UV and NIR 
regions through single and two photon28,29 mechanisms, respectively, and have been 
implemented in a wide range of applications, including natural product synthesis,39,40 caged 
ATP,41 RNA,42 DNA,42 and peptide43 synthesis, prodrug release,44-46 and others. 
Activity-based sensing (ABS) relies on the use of caged luminophores that are uncaged 
based on selective cleavage of protecting groups to obtain a readout.47 Common ABS detection 
techniques use optical readouts including absorption, NMR, optoacoustic, 48-50  fluorescence,51-53 
and chemiluminescence-based agents.54 Chemiluminescence provides many advantages to other 
optical reporters, including high turn-on and increased depth penetration, while obviating the 
need for external excitation.55 Specifically, 1,2-dioxetanes have been established as critical 
chemiluminescence-based ABS reporter substrates, as they provide a facile and functional means 
of caging luminescent emission through protection of the dioxetane phenol with a reactive 
handle. Subsequent interaction with the analyte of interest will uncage the dioxetane phenol, 
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initiating an electron exchange luminescence (CIEEL) process to generate photonic emission.56-
60 This strategy has been used for activity-based detection and quantification of various 
substrates.61-71 
A key challenge for in vivo chemiluminescence imaging is attaining good spatiotemporal 
control of the luminescent signal for localization and maximizing total luminescent output. 
Utilization of photocaged chemiluminescent compounds can ultimately circumvent this issue by 
localizing chemiluminescence signal to the point of illumination. Herein, we report the use of 
both irreversible and reversible photoinitiated uncaging of 1,2-dioxetane chemiluminophores as a 
fundamental step towards this goal. We synthesized ortho-nitrobenzyl protected dioxetanes 
UVC-454 and UVA-454 that can be irradiated by UVC (254 nm) and UVA (365 nm) light, 
respectively to emit luminescence at 454 nm. We also report the first chemiluminescent 
spiropyran compound Spiro-CL that undergoes reversible opening to its MC form under UV 
light, and exhibits chemiluminescence in DMSO (Scheme 4-1). 
 









































4.2.1 Synthesis and in vitro response of UVC-454 and UVA-454 
Both UVC-454 and UVA-454 were synthesized from literature reported precursor , 5-
(((1r, 3r, 5R, 7S)-adamantan-2-ylidene) (methoxy) methyl)-2-chlorophenol 71,73 through 
Mitsunobu couplings with 2-nitrobenzyl alcohol (UVC-454) and 4,5-dimethoxy-2-nitrobenzyl 
alcohol (UVA-454) to make ethers 36 and 37, followed by a [2+2] cycloaddition with 1O2 via 
sensitization with Rose bengal to make the final photocaged dioxetane compounds (Scheme 4-2).  
 
Scheme 4-2. Synthesis of UVC-454 and UVA-454. 
 
 
Upon synthesis of the photocaged compounds, we proceeded to test their photoactivation 
capabilities (Figure 4-1). Solutions of 10 mM concentrations of UVC-454 or UVA-454 in DMSO 
were irradiated with 254, 365, and 488 nm light for 180 minutes, and aliquots were transferred 
into 20 mM PBS pH 7.4 buffer containing 10% Emerald II® enhancer solution to give a final 
concentration of 50 µM. Figure 4-1A and 4-1C show the luminescence emission response of 
UVC-454 and UVA-454 to uncaging with UVC and UVA light, respectively. Both give off bright 
luminescence, with emission peaks centered at 454 nm from the chemiluminescent scaffold, and 
540 nm through energy transfer to Emerald II®. UVC-454 gives an overall brighter response than 








R1 = H, R2 = H, 48 %
R1 = OMe, R2 = OMe,  64%
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UVC-454 (R1, R2 = H)
 UVA-454 (R1, R2 = OMe)
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significant uncaging response at its respective uncaging wavelength of 342 nm over 180 min as 
compared to 254 nm and 488 nm. Utilizing 254 nm light over 365 nm light with UVC-454 did 
not show a statistically significant response, however the uncaging response was statistically 
significant as compared to photoinitiated cleavage using 488 nm light.  
 
 
Figure 4-1. Photoactivation of UVC-454 and UVA-454 in DMSO with 254 nm, 365 nm, 
and 488 nm irradiation (A) Plot of relative emission intensities of 50 µM UVC-454 in PBS 
7.4 buffer and 10% Emerald II® irradiated with 254 nm for 0–180 min. Inlay denotes emission 
intensity at 545 nm over 180 min. (B) Integrated emission intensities at 545 nm of 50 µM 
UVC-454 in PBS 7.4 buffer and 10% Emerald II irradiated with 254 nm (red), 365 nm (black), 
and 488 nm (gray) light over 180 min. (C) Plot of relative emission intensities of 50 µM UVA-
454 in PBS 7.4 buffer and 10% Emerald II® irradiated with 365 nm for 0–180 min. Inlay 
denotes emission intensity at 545 nm over 180 min. (D) Integrated emission intensities at 545 
nm of 50 µM UVC-454 in PBS 7.4 buffer and 10% Emerald II irradiated with 254 nm (red), 
365 nm (black), and 488 nm (gray) light over 180 min. Error bars are ± SD. Statistical 
significance was assessed using a two-tailed Student’s t test. *p < 0.05 (n =3 technical 
replicates), **p<0.005 (n = 3 technical replicates), ***p <0.0005 (n = 3 technical replicates), 
****p < 0.00005 (n = 3 technical replicates). 
 
We also controlled for uncaging due to thermolysis with UVC-454 (Figure 4-2). The 
agent showed a small but steady luminescence output due to heating of the sample. We also 
tested the uncaging response UVC-454 directly in aqueous media (Figure 4-3), where 100 µM to 







































































































 in 20 mM PBS pH 7.4 buffer containing 10% Emerald II® solution were prepared and 
irradiated with 254 nm light for 180 min. Relatively low luminescence output was seen from 
both the 100 µM and 500 µM concentrations over the 180 min time period, but could be readily 
seen at the 750 µM and 1 mM concentrations. 
 
 
Figure 4-2. UVC-454 thermolysis. plot of relative emission intensities of 50 µM UVC-454 in 
PBS 7.4 buffer and 10 % Emerald II®. 10 mM UVC-454 in DMSO was irradiated at 254 nm in 




Figure 4-3. UVC-454 photoactivation in water. Plot of relative emission intensities 
measured 545 nm of 1 mM (red), 750 µM (black), 500 µM (dark gray), and 100 µM (light 
gray) UVC-454 in 20 mM PBS pH 7.4 buffer and 10% Emerald II® irradiated at 254 nm in 
aqueous solution over 180 min. Measurements were taken in 30 min intervals.  
 
4.2.2 Synthesis and in vitro response of Spiro-CL 
Spiropyrans are synthesized through condensation of indoline compounds to 
salicylaldehydes. Due to the structural similarities between the spiropyrans and reported 
chemiluminescent salicylaldehyde precursor,65 we decided to explore the possibility of 













































portion of the spiropyran. We first synthesized aldehyde 38 via a palladium catalyzed 
formylation method74 in 85% yield (Scheme 4-3). We then appended 1,3,3-trimethyl-2-
methyleneindoline to this structure through condensation to form the spiropyran precursor 39 in 
30% yield. Finally, the enol ether underwent a [2+2] cycloaddition with 1O2 generated by 
photosensitizer methylene blue under white light to generate Spiro-CL in 35% yield. 
 
Scheme 4-3. Synthesis of Spiro-CL. 
 
 
Upon synthesis of Spiro-CL, we began to examine its photoswitching capabilities. We 
first monitored changes in its absorbance to examine the effect of UV light irradiation on the 
sample. A 100 µM sample of Spiro-CL was irradiated for 20 min with a 254 nm light source and 
absorbance was measured every two minutes during that time period (Figure 4-4). The 
absorbance spectra show clear increases in absorbance with the growth of a peak from 0 minutes 
to 20 minutes centered at 418 nm, indicating changes in the absorbance profile of the compound 
upon UV radiation. After the 20-minute UV irradiation period, the solution was irradiated for 10 
minutes with a white light source and absorbance was monitored every two minutes. Absorbance 
at 418 nm decreased down to a steady state of around 0.06 absorbance units for the sample. 
We then monitored changes in the fluorescence and chemiluminescence profiles of Spiro-CL 
due to UV light exposure (Figure 4-5). A 10 µM solution of Spiro-CL in EtOH was subjected to 
fluorescence excitation and emission measurements before and after irradiation with UV light 
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peaks centered at 290 nm and 350 nm, respectively. After 20 minutes of irradiation with the UV 
source, the excitation profile of the spiropyran broadens, with excitation maxima located at 260, 
350, and 450 nm. Fluorescence emission spectra after irradiation red-shifted to a peak centered 
around 540 nm. Finally, we tested the ability of the compound to exhibit chemiluminescence due 
to UV light-mediated opening of the luminophore (Figure 4-5B). We subjected 10 µM Spiro-CL 
in DMSO to irradiation with a 254 nm light source and monitored chemiluminescence emission 
from the sample for 16 minutes. After 16 minutes, a small peak centered at 510 nm arose, 
indicating that the ring opening process mediated by UV irradiation enabled luminescence 
emission from the open MC form. 
 
 
Figure 4-4. UV monitoring of Spiro-CL photoswitching. (A) Absorbance of 100 µM Spiro-
CL in EtOH upon irradiation with 254 nm light from t = 0–20 min. (B) Absorbance at 418 nm 
of 100 µM Spiro-CL in EtOH in response to 254 nm irradiation from t = 0–20 min and white 
light irradiation from t = 22–30 min. 
 
 
Figure 4-5. Fluorescence and chemiluminescence monitoring of Spiro-CL 
photoswitching. (A) Fluorescence excitation and emission spectra before (red traces) and after 
(blue traces) 254 nm irradiation. (B) Chemiluminescence emission spectra of 10 µM Spiro-CL 










































































In conclusion, we synthesized and conducted in vitro characterization of photoactivatable 
chemiluminescence agents UVC-454, UVA-454, and Spiro-CL. UVC-454 and UVA-454 
undergo irreversible uncaging processes to emit light, and Spiro-CL acts under a reversible 
photoswitching mechanism governed by UV light irradiation to generate its chemiluminescent 
merocyanine form. Photoactivated chemiluminescence provides an attractive target for targeted 
imaging agents. We envision that 1,2-dioxetane probes outfitted with targeting capability such as 
homing peptides75 or antibodies promote the use of in vivo tail vein injections that localize and 
build up in areas of interest. Uncaging of the chemiluminophore system using directed light 
excitation provides extremely high spatiotemporal control over imaging agent activity. With the 
production of new chemiluminescence scaffolds that emit in green76 and red77 regions, along 
with a myriad of PPGs that have uncaging abilities across the spectrum, a wide variety of 
photocaged chemiluminescence agents could be devised with catered uncaging and emission 
wavelengths. This technology could be applied for formal energy upconversion applications78 by 
use of PPGs that are uncaged in the NIR to far red regions to formally generate anti-Stokes 
emission from the photocaged chemiluminescent systems. 
To our knowledge, Spiro-CL represents the first example of photoswitch – enabled 
chemiluminescence. While most 1,2-dioxetanes exhibit turn-on luminescence by caging the 1,2-
dioxetane species with an activity-based reactive handle, this unique strategy enables the 
chemiluminophore to be self-caged, and uncaging the chemiluminescent photoswitch species 
allows for emission at longer wavelength than the initial input. While Spiro-CL represents a 
novel chemiluminescent scaffold modality with a unique photoswitching mechanism to initiate 
luminescence, due to the low chemiluminescence emission seen from Spiro-CL, we believe that 
further improvement on the photoswitching and chemiluminescence emission properties of this 
 139 
compound need to be explored, potentially including aforementioned encapsulation or 
incorporation into polymers.  
 
4.4 Experimental Procedure 
4.4.1 General synthetic materials and methods  
All reactions were performed in dried glassware under an atmosphere of dry N2. Silica gel 
P60 (SiliCycle) was used for column chromatography and SiliCycle 60 F254 silica gel 
(precoated sheets, 0.25 mm thick) was used for analytical thin layer chromatography. Plates were 
visualized by fluorescence quenching under UV light. Other reagents were purchased from 
Sigma-Aldrich (St. Louis, MO), Alfa Aesar (Ward Hill, MA), EMD Millipore (Billerica, MA), 
Oakwood Chemical (West Columbia, SC), Beantown Chemical (Hudson, NH), and Cayman 
Chemical (Ann Arbor, MI) and used without further purification. 1H NMR for compounds and 
13C NMR for compounds were collected on a Bruker 400 MHz or a JEOL 500 MHz 
spectrometer in the Department of Chemistry at Southern Methodist University. 1H and 13C 
NMR spectra for characterization of new compounds and monitoring reactions were collected in 
CDCl3 (Cambridge Isotope Laboratories, Cambridge, MA). All chemical shifts are reported in 
the standard notation of parts per million using the peak of residual proton signals of the 
deuterated solvent as an internal reference. Coupling constant units are in Hertz (Hz). Splitting 
patterns are indicated as follows: br, broad; s, singlet; d, doublet; t, triplet; q, quartet; m, 
multiplet; dd, doublet of doublets; dt, doublet of triplets. Low resolution mass spectrometry was 






(36). To an oven-dried 50 mL roundbottom flask, 5-(((1r, 3r, 5R, 7S)-adamantan-2-ylidene) 
(methoxy) methyl)-2-chlorophenol72 (441 mg, 1.45 mmol, 1.0 equiv) and 24 mL anhydrous THF 
were added and cooled to 0 °C. Diethyl azodicarboxylate (0.54 mL, 3.5 mmol, 2.4 equiv) was 
added. Triphenyl phosphine (663 mg, 1.74 mmol, 1.2 equiv) was dissolved in 3 mL anhydrous 
THF was added dropwise over 5 min. The reaction was stirred for 2 hr until completion as 
determined by TLC. The crude contents were washed with saturated NH4Cl, extracted with 3 x 
25 mL EtOAc, dried with Na2SO4, filtered, and concentrated under vacuum. Column 
chromatography (1% EtOAc/Hexanes) yielded 36 (310 mg, 0.70 mmol, 48%). 1H NMR d 8.23 
(d, 1H, J = 7.6 Hz), 8.09 (d, 1H, J = 7.6 Hz) 7.74 (t, 1H, J = 7.6 Hz), 7.52 (t, 1H, J = 7.6 Hz), 
7.39 (d, 1H, J = 8.0 Hz), 6.98 (s, 1H), 6.93 (m, 1H), 5.59 (s, 2H), 3.30 (s, 3H), 2.25 (s, 1H), 
1.76-1.99 (m, 11H). 13C NMR (100 MHz, CDCl3) d 153.2, 142.4, 135.5, 134.3, 133.6, 132.9, 
130.0, 128.4, 128.4, 125.1, 123.1, 121.9, 114.5, 67.5, 39.1, 39.0, 37.1, 32.4, 30.3, 28.2. LRMS 














nitrobenzyl)oxy)phenyl)(methoxy)methylene)adamantane (37). To an oven-dried 50 mL 
roundbottom flask, 5-(((1r, 3r, 5R, 7S)-adamantan-2-ylidene) (methoxy) methyl)-2-
chlorophenol72 (158 mg, 0.518 mmol, 1.0 equiv) and 5 mL anhydrous THF were added and 
cooled to 0 °C. Diethyl azodicarboxylate (0.09 mL, 0.6 mmol, 1.2 equiv) was added. Triphenyl 
phosphine (164 mg, 0.624 mmol, 1.2 equiv) dissolved in 1 mL anhydrous THF was added 
dropwise over 5 min. The reaction was stirred for 2 hr until completion as determined by TLC. 
The crude contents were washed with saturated NH4Cl, extracted with 3 x 25 mL EtOAc, dried 
with Na2SO4, filtered, and concentrated under vacuum. Column chromatography (1-5% 
EtOAc/Hexanes) yielded 37 (170 mg, 0.34 mmol, 64%). 1H NMR (400 MHz, CDCl3) d 7.82 (s, 
1H), 7.71 (s, 1H), 7.40 (d, 1H, J = 8.0 Hz), 7.06 (d, 1H, J = 1.2 Hz), 6.93 (dd, 1H, J1 = 8.0 Hz, J2 
= 1.2 Hz), 5.57 (s, 2H), 4.04 (s, 3H), 4.00 (s, 3H), 3.32 (s, 3H), 3.26 (s, 1H), 2.62 (s, 1H) 
1.79-2.00 (m, 11H). 13C NMR (100 MHz, CDCl3) d 154.1, 153.2, 147.8, 142.4, 138.7, 135.7, 
133.0, 129.8, 129.2, 123.1, 121.7, 114.6, 109.5, 107.9, 67.6, 56.5, 56.4, 39.1, 39.0, 37.1, 32.4, 





[1,2]dioxetane] (UVC-454). In a 2-neck roundbottom flask, Compound 36 (50 mg, 0.12 mmol) 
was dissolved in 3 mL THF. Rose bengal (8 mg, 0.0082 mmol) was added. Upon cooling to 







for 1 hr. Upon completion as determined by TLC, the crude was evaporated onto silica and 
loaded for column chromatography in 5% EtOAc/Hexanes, yielding UVC-454 (4.4 mg, 0.008 
mmol, 35%) as a mixture of diastereomers 1H NMR (500 MHz, CDCl3) d 8.12 (d, 1H, J = 1.1 
Hz), 7.92 (d, 1H, J = 1.1 Hz), 7.63 (m, 2H) 7.40–7.45 (m, 4H), 5.54 (s, 2H), 3.12 (s, 3H), 2.93 (s, 
1H), 1.71–1.91 (m, 12H).13C NMR (125 MHz, CDCl3) d 146.8, 135.0, 134.1, 133.0, 130.3, 





methoxyspiro[adamantane-2,3'-[1,2]dioxetane] (UVA-454). In a 2-neck roundbottom flask, 
Compound 37 (45 mg, 0.09 mmol) was dissolved in 3 mL THF. Rose bengal (12 mg, 0.012 
mmol) was added. Upon cooling to 0 °C, O2 was bubbled into the solution the solution and the 
flask was irradiated under white light for 3 hr. Upon completion as determined by TLC, the 
crude was evaporated onto silica and loaded for column chromatography in 5% EtOAc/Hexanes, 
yielding UVA-454 (30 mg, 0.056 mmol, 63%). 1H NMR (500 MHz, CDCl3) d 7.73 (s, 1H), 7.52 
(s, 1H), 7.40 (s, 1H), 7.19 (m, 2H), 3.93 (s, 3H), 3.91 (s, 3H), 3.15 (s, 3H), 2.93 (s, 1H), 1.61–














(38).65 In an oven-dried 3 mL pressure flask, 3-(((1r,3r,5R,7S)-adamantan-2-
ylidene)(methoxy)methyl)-2-chloro-6-iodophenol64 (600. mg, 1.39 mmol, 1 equiv), N-
formylsaccharine (441 mg, 2.09 mmol, 1.5 equiv), Na2CO3 (221 mg, 2.09 mmol, 1.5 equiv), 
Pd(OAc)2 (9.4 mg, 0.042 mmol, 0.03 equiv), and 1,4-bis(diphenylphosphino)butane (26 mg, 
0.062 mmol, 0.045 equiv) were added, and purged 3x with N2. 4 mL of anhydrous DMF was 
added, followed by anhydrous triethylsilane (0.29 mL, 1.8 mmol, 1.3 equiv). The reaction was 
capped and pre-stirred for 10 min, then brought up to 80 °C and stirred for 16 hr. The reaction 
was taken off heat and allowed to cool to RT, washed with saturated NH4Cl, extracted with 3 x 
25 mL EtOAc, dried with Na2SO4, filtered, and concentrated under vacuum. Column 
chromatography (10% EtOAc/Hexanes) yielded 38 (250 mg, 0.76 mmol, 75%) as a yellow solid. 
H1 NMR (500 MHz, CDCl3) d 11.63 (s, 1H), 9.90 (s, 1H), 7.48 (d, 1H, J = 7.4 Hz), 6.97 (d, 1H, 





trimethylspiro[chromene-2,2'-indoline] (39). In a 2-neck roundbottom flask, Compound 38 (32 








equiv) were dissolved in 4 mL pure EtOH under nitrogen atmosphere. The reaction was heated to 
90 °C and refluxed for 5 hr. Upon completion as determined by TLC and ESI-MS, the reaction 
was washed in brine, extracted with 3 x 10 mL EtOAc, and concentrated under vacuum. Column 
chromatography (2% EtOAc/hexanes) yielded 39 (14 mg, 0.029 mmol, 30%). 1H NMR (400 
MHz, CDCl3) d 7.17 (t, 1H, J = 7.2 Hz), 7.08 (d, 1H, J = 7.2 Hz), 6.95 (d, 1H, J = 7.6 Hz), 6.85 
(m, 2H), 6.75 (d, 1H, J = 8.0 Hz), 6.55 (d, 1H, J = 7.6 Hz), 5.76 (d, 1H, J = 10.0 Hz), 3.15-3.32 
(m, 6H), 2.77 (d, 3H, J = 7.2 Hz), 2.20 (s, 6H), 1.21-1.89 (m, 12H). 13C NMR (100 MHz, 
CDCl3) d 136.6, 135.8, 131.1, 128.7, 127.5, 123.9, 122.9, 121.4, 121.1, 120.7, 119.6, 119.2, 
106.8, 56.9, 52.0, 51.8, 39.2, 39.1, 38.6, 37.2, 34.7, 32.9, 30.9, 29.7, 29.6, 29.0, 28.5, 28.3, 26.9, 





trimethylspiro[chromene-2,2'-indoline] (Spiro-CL). In a 2-neck roundbottom flask, 
Compound 39 (12.1 mg, 0.024 mmol) was dissolved in DCM. Methylene blue (3.5 mg, 0.011 
mmol) was added. Upon cooling to 0 °C, O2 was bubbled into the solution the solution and the 
flask was irradiated under yellow light for 1 hr. Upon completion as determined by ESI-MS, the 
crude was evaporated onto silica and loaded for column chromatography in 2% EtOAc/Hexanes, 
yielding Spiro-CL (4.4 mg, 0.008 mmol, 35%) as a mixture of diastereomers 1H NMR (400 
MHz, CDCl3) d 7.58 (d, 1H, J = 7.6 Hz), 7.18 (t, 1H, J = 7.6 Hz), 7.07 (m, 2H), 6.87 (m, 2H), 







(s, 1H), 2.69-2.81 (d, 3H), 2.28 (d, 1H), 2.03 (d, 1H) 1.84 (m, 2H), 1.71 (m, 2H), 1.63 (s, 6H) 
1.3–1.8 (m, 4H). 13C NMR (100 MHz, CDCl3) d 150.7, 150.5, 148.1, 147.7, 136.5, 136.3, 132.7, 
128.5, 127.6, 124.1, 122.7, 121.7, 121.4, 121.4, 121.2, 119.4, 119.3, 118.9, 122.1, 106.9, 106.8, 
106.1, 105.4, 96.3, 42.4, 51.8, 49.7, 49.6, 36.7, 33.7, 33.5, 32.3, 32.2, 31.6, 31.4, 29.7, 29.1, 28.7, 
26.2, 25.9, 25.8, 25.5, 20.2, 20.0, 14.1. 
 
4.4.2 In Vitro characterization of UVC-454 and UVA-454 
UVC-454 and UVA-454 irradiation in DMSO. Samples of UVC-454 and UVA-454 were 
dissolved to a concentration of 10 mM in DMSO in a 20-dram vial. The vial contents were 
irradiated by placing the vial directly in front of a Hitachi F-7000 fluorescence 
spectrophotometer Xe lamp source with 20 nm slit widths, and irradiated with 254, 365, and 488 
nm light. A portion of the irradiated sample was then transferred into a cuvette containing 20 mM 
PBS pH 7.4 buffer with 10% Emerald II® to make a final concentration of 50 µM UVC-454 or 
UVA-454. Luminescence was measured using a Hitachi F-7000 fluorescence spectrophotometer 
from 0–180 min, and readings were taken every 20 min 
 
In vitro chemiluminescence response of UVC-454 to irradiation in aqueous media. Samples of 
UVC-454 and UVA-454 were dissolved to give 100 mM solutions in DMSO. Aliquots of UVC-
454 and UVA-454 were then transferred into a cuvette containing 20 mM PBS pH 7.4 buffer 
containing 10% Emerald II® solution to give a final concentration of 100–1000 µM UVC-454 
and 5% DMSO. The solution was irradiated by placing the cuvette in the cuvette holder of a 
Hitachi F-7000 fluorescence spectrophotometer Xe lamp source with 20 nm slit widths, and 
irradiated for 180 min. Chemiluminescence readings were taken every 20 min. 
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4.4.3 In Vitro characterization of Spiro-CL 
Monitoring Spiro-CL photoswitching using absorption spectroscopy. Absorbance spectra of 
Spiro-CL were collected using a Beckman Colter DU 800 spectrophotometer scanning from 
200–800 nm, wavelength interval of 1.0 nm, and scan speed of 1200 nm/min. For solutions in 
EtOH, 100 µM Spiro-CL were dissolved in 200 proof EtOH and added to a cuvette. An initial 
absorbance read at t = 0 was taken, then the cuvette was taken out of the spectrophotometer and 
irradiated with 254 nm light from a Spectroline® ENF-240C UV lamp for 2 min. This process 
was repeated until t = 20 min. Then, the solution was irradiated with white light using a 120 W 
lamp (Home Depot, Dallas, TX) for 2 min, and an absorbance read was taken, and this process 
was repeated until t = 30 min. For solutions in DMSO, 10 µM Spiro-CL was dissolved in 
DMSO and added to a cuvette. The cuvette was then irradiated with 254 nm light from a 
Spectroline® ENF-240C UV lamp for 2 min, and repeated for 20 min. 
 
Monitoring fluorescence of Spiro-CL before and after UV irradiation. Fluorescence 
measurements were taken using a Hitachi F-7000 fluorescence spectrophotometer via the 
fluorescence detection mode. Fluorescence excitation and emission spectra were acquired with a 
slit widths of 5.0 nm. 10 µM Spiro-CL was dissolved in 200 proof EtOH, and fluorescence 
excitation and emission spectra were taken before irradiation of the sample with UV light. For 
the t = 0 fluorescence excitation read, the emission wavelength was set to 330 nm, and the 
excitation range was scanned from 200–320 nm. For the t = 0 fluorescence emission read, the 
excitation wavelength was set to 269 nm, and emission range was set from 279–600 nm. Then, 
the sample was taken out of the fluorometer and irradiated with 254 nm light from a Spectroline® 
ENF-240C UV lamp for 20 min. After irradiation, fluorescence excitation and emission reads 
were retaken. For the t = 20 min fluorescence excitation read, the emission wavelength was set to 
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525 nm, and the excitation range was scanned from 200–515 nm. For the t = 20 min fluorescence 
emission read, the excitation wavelength was set to 410 nm, and emission range was set from 
420–600 nm. 
 
Chemiluminescence of Spiro-CL. Chemiluminescence measurements were taken using a Hitachi 
F-7000 fluorescence spectrophotometer via the fluorescence detection mode. Fluorescence 
excitation and emission spectra were conducted with slit widths of 20 nm. solutions of 10 µM 
Spiro-CL were dissolved in 200 proof EtOH or pure DMSO and transferred into a cuvette. 
Then, the solutions were irradiated for t = 16 min using the 254 nm light source from a 
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5.1 Future hypoxia quantification strategies 
HyCL-4-AM served as a highly sensitive chemiluminescence agent that utilized activity-
based nitroaromatic reduction to quantify enzyme activity within the native reductive 
environment in tumors. Its advancements are numerous as compared to previous hypoxia 
detection probes, however, to truly quantify hypoxia, it is more viable to directly measure 
oxygen content within cells and tissues rather than use enzymatic activity as a proxy for the same 
measurement. To accomplish this task, we plan to employ a ratiometric quantification strategy 
similar to that of Ratio-pHCL-1. We will append an oxygen sensitive iridium-based 
phosphorescence complex whose excitation overlaps with the emission wavelength of the 
chemiluminescent scaffold.1–4 The phosphorescence emission of the iridium complex is 
quenched in the presence of oxygen through triplet quenching. When exposed to an aqueous 
environment, the chemiluminescent scaffold will undergo CIEEL to generate chemiluminescence 
emission at 530 nm. Some of the energy from CIEEL can undergo resonance energy transfer into 
the iridium complex, which can then emit oxygen-dependent phosphorescence emission 
wavelength based on the degree of oxygen quenching exhibited on the iridium complex. By 
taking the ratio of emissions between the donor and acceptor, oxygen content can be quantified 
in a ratiometric manner. Examples of some target compounds being researched by my coworker 
Husain Kagalwala is shown in Scheme 5-1. 
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Scheme 5-1. Designs of 1,2-dioxetane ratiometric hypoxia sensors. 
 
 
 This strategy provides many advantages to the currently implemented activity-based 
nitroreduction method. First, it has the potential to quantify oxygen through ratiometric analysis, 
which is often a more accurate measurement for in vivo studies because ratiometric sensors are 






































dioxetane phenol, which we have previously shown with Ratio-pHCL-1 greatly increases the 
brightness of the probe.5 It may also allow for NIR hypoxia detection through NIR 
phosphorescence emission from the iridium phosphor. Granted we are successful in the 
development of a ratiometric oxygen sensor, we will provide a great advancement for 
chemiluminescence quantification of hypoxia in cells and animals. 
 
5.2 Future studies based on Ratio-pHCL-1 
 Ratio-pHCL-1 implemented many novel strategies to ultimately quantify pH in vitro and 
in animal models, and we are very excited by the accurate pH dependent response and sheer 
brightness of the sensor. While Ratio-pHCL-1 gave highly accurate outputs in vitro, it is unclear 
whether the sensor quantified pH in our animal studies, because we did not truly know the pH of 
the peritoneal fluid after injection of the buffer. Peritoneal fluid normally exhibits a pH buffered 
to the range of 7.6-8.0,6 and while we used highly concentrated (1.0 M) buffer to change the 
intraperitoneal pH as close as possible to the pH of the injected buffer, it may have been buffered 
toward the physiological pH by the peritoneal fluid. This could be examined in future studies by 
obtaining a secondary pH measurement of the peritoneal cavity using pH microelectrodes before 
and after injection of the buffer solution, and would give us a more accurate calibration of Ratio-
pHCL-1 in animal tissue. 
 Further studies may also be relevant to test with Ratio-pHCL-1 in the future. The focus 
of this thesis is to develop imaging agents to study the tumor microenvironment. Unfortunately, 
due to the current COVID-19 pandemic, we were unable to proceed with further animal testing 
with Ratio-pHCL-1 in animal tumor models. One possible experiment that could see success 
using Ratio-pHCL-1 in tumors is to conduct injections of Ratio-pHCL-1 into tumor mouse 
models, and through detection of its pH dependent luminescence output in various regions of the 
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tumor using an IVIS spectrum, we could detect heterogenous pH expression throughout the 
tumor microenvironment. This would ultimately show regions in the tumor that are more acidic, 
and therefore more reductive and less responsive to chemo and radiotherapy.  
 One major drawback of Ratio-pHCL-1 was that its response pKa of 7.7 was too high to 
be seen as a truly viable agent for biological pH studies. The agent would be more impactful if 
the response pKa were to be reduced to a range between 6.8-7.4. This could be readily achieved 
through synthetic modification of the carbofluorescein unit. It has been previously shown that 
fluorine substitution on the carbofluorescein’s xanthene core lowers the pKa of the fluorophore 
from 7.5 (no fluorine substitution) to 6.75 (difluoro substitution).7 I postulate that a mono-
fluorinated carbofluorescein would exhibit a pKa between these two values. Ultimately, it would 
be wise to synthesize both the monofluorinated and difluorinated derivatives of Ratio-pHCL-1 
to ensure the response pKa of the final probe is within the designated biological range. 
 Surprisingly, we also found that Ratio-pHCL-1 can penetrate cells even though it is a 
high MW compound. Especially for intratumoral studies, it would be beneficial to attach a 
charged functional group on the compound such as a sulfonate to ensure that the compound 
remains in the extracellular matrix and does not penetrate cells.8 This would give a much more 
accurate representation of the acidity of the tumor microenvironment. Examples of potential 







Scheme 5-2. Design of future Ratio-pHCL compounds. 
 
 
 We can also use the general strategy of fluorophore conjugation to provide ratiometric 
detection of reactive species, enzymes, and small molecules. Fluorophores appended to the 
chemiluminescent scaffold could be protected with reactive triggers, such as our current handles 
for H2S,9 HNO,10 ONOO-,11 or hypoxia.12,13 Such probes would then undergo selective reactions 
with their respective analytes to generate the open fluorophore, and the ratio of emissions 
between the open fluorophore vs. the chemiluminescent scaffold could provide ratiometric 


































Scheme 5-3. Potential structures of ratiometric chemiluminescence probes for reactive species 
































































5.3 Future studies in photoactivatable chemiluminescence 
 Photoactivated chemiluminescence has huge potential for in vivo molecular imaging. A 
major drawback for currently utilized probes and sensors, is they have no targeting capability. 
All of the agents must be directly administered to the imaging site. This may be harmful for 
studies such as intratumoral imaging, where direct intratumoral injections may affect tumor 
structure and biology. A more advantageous option would be to have photoactivatable 
chemiluminescence agents that are administered via intravenous injection, and can localize to 
their target through homing strategies.14,15 Once the agent has localized, the compound can be 
uncaged using NIR light16,17 through tissue to elicit a chemiluminescence response. An example 
of a tumor homing photocaged ratiometric pH probe is shown scheme 5-4. 
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Figure A-23. 1H NMR spectrum (400 MHz, Acetone-D6) of 23. 
 





























































































NAME        LR-II-115-4
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20191204
Time              14.56
INSTRUM           spect
PROBHD   5 mm QNP 1H/29
PULPROG            zg30
TD                65536
SOLVENT         Acetone
NS                    8
DS                    2
SWH            5597.015 Hz
FIDRES         0.085404 Hz
AQ            5.8545494 sec
RG                63.34
DW               89.333 usec
DE                 6.50 usec
TE       0 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320010 MHz
NUC1                 1H
P1                11.25 usec
PLW1        10.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0









Figure A-24. 13C NMR spectrum (100 MHz, Acetone-D6) of 23. 
 









































































































NAME     LR-II-115-4-13C
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20191204
Time              15.07
INSTRUM           spect
PROBHD   5 mm QNP 1H/29
PULPROG          zgpg30
TD                65536
SOLVENT         Acetone
NS                  100
DS                    4
SWH           24038.461 Hz
FIDRES         0.366798 Hz
AQ            1.3631488 sec
RG                195.7
DW               20.800 usec
DE                 6.50 usec
TE       0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6228293 MHz
NUC1                13C
P1                10.00 usec
PLW1        35.00000000 W
======== CHANNEL f2 ========
SFO2        400.1316005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.17778000 W
PLW13        0.08942100 W
F2 - Processing parameters
SI                32768
SF          100.6127685 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0









Figure A-25. 1H NMR spectrum (400 MHz, CDCl3) of 24. 
 




































































































NAME     LR-II-117'-iso
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20191205
Time              17.45
INSTRUM           spect
PROBHD   5 mm QNP 1H/29
PULPROG            zg30
TD                65536
SOLVENT           CDCl3
NS                    8
DS                    2
SWH            5597.015 Hz
FIDRES         0.085404 Hz
AQ            5.8545494 sec
RG                78.13
DW               89.333 usec
DE                 6.50 usec
TE       0 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320010 MHz
NUC1                 1H
P1                11.25 usec
PLW1        10.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0









Figure A-26. 13C NMR spectrum (100 MHz, CDCl3) of 24. 
 
  


























































































































NAME     LR-II-117'-iso-13C
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20191205
Time              17.57
INSTRUM           spect
PROBHD   5 mm QNP 1H/29
PULPROG          zgpg30
TD                65536
SOLVENT           CDCl3
NS                  100
DS                    4
SWH           24038.461 Hz
FIDRES         0.366798 Hz
AQ            1.3631488 sec
RG                195.7
DW               20.800 usec
DE                 6.50 usec
TE       0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6228293 MHz
NUC1                13C
P1                10.00 usec
PLW1        35.00000000 W
======== CHANNEL f2 ========
SFO2        400.1316005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.17778000 W
PLW13        0.08942100 W
F2 - Processing parameters
SI                32768
SF          100.6127685 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
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Figure A-29. 1H NMR spectrum (400 MHz, CDCl3) of 26. 
 
  
































































































































NAME     LR-II-120-crude
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20191209
Time              10.54
INSTRUM           spect
PROBHD   5 mm QNP 1H/29
PULPROG            zg30
TD                65536
SOLVENT           CDCl3
NS                    8
DS                    2
SWH            5597.015 Hz
FIDRES         0.085404 Hz
AQ            5.8545494 sec
RG                86.96
DW               89.333 usec
DE                 6.50 usec
TE       0 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320010 MHz
NUC1                 1H
P1                11.25 usec
PLW1        10.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0











Figure A-30. 13C NMR spectrum (100 MHz, CDCl3) of 26. 
 


























































































































NAME     LR-II-120-crude-13C
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20191209
Time              11.05
INSTRUM           spect
PROBHD   5 mm QNP 1H/29
PULPROG          zgpg30
TD                65536
SOLVENT           CDCl3
NS                  100
DS                    4
SWH           24038.461 Hz
FIDRES         0.366798 Hz
AQ            1.3631488 sec
RG                195.7
DW               20.800 usec
DE                 6.50 usec
TE       0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6228293 MHz
NUC1                13C
P1                10.00 usec
PLW1        35.00000000 W
======== CHANNEL f2 ========
SFO2        400.1316005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.17778000 W
PLW13        0.08942100 W
F2 - Processing parameters
SI                32768
SF          100.6127685 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
PC                 1.40


























































































































NAME     LR-II-120-crude-13C
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20191209
Time              11.05
INSTRUM           spect
PROBHD   5 mm QNP 1H/29
PULPROG          zgpg30
TD                65536
SOLVENT           CDCl3
NS                  100
DS                    4
SWH           24038.461 Hz
FIDRES         0.366798 Hz
AQ            1.3631488 sec
RG                195.7
DW               20.800 usec
DE                 6.50 usec
TE       0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6228293 MHz
NUC1                13C
P1                10.00 usec
PLW1        35.00000000 W
======== CHANNEL f2 ========
SFO2        400.1316005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.17778000 W
PLW13        0.08942100 W
F2 - Processing parameters
SI                32768
SF          100.6127685 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0










Figure A-31. 1H NMR spectrum (400 MHz, CDCl3) of 27. 
 





























































































































NAME     LR-II-104-anhydridehydrolysis
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20191114
Time              17.19
INSTRUM           spect
PROBHD   5 mm QNP 1H/29
PULPROG            zg30
TD                65536
SOLVENT           CDCl3
NS                    8
DS                    2
SWH            5597.015 Hz
FIDRES         0.085404 Hz
AQ            5.8545494 sec
RG                70.82
DW               89.333 usec
DE                 6.50 usec
TE       0 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320010 MHz
NUC1                 1H
P1                11.25 usec
PLW1        10.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








Figure A-32. 13C NMR (100 MHz, CDCl3) of 27. 
 

































































































































NAME     LR-II-104-anhydridehydrolysis-13C'
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20191114
Time              17.31
INSTRUM           spect
PROBHD   5 mm QNP 1H/29
PULPROG          zgpg30
TD                65536
SOLVENT           CDCl3
NS                  100
DS                    4
SWH           24038.461 Hz
FIDRES         0.366798 Hz
AQ            1.3631488 sec
RG                195.7
DW               20.800 usec
DE                 6.50 usec
TE       0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6228293 MHz
NUC1                13C
P1                10.00 usec
PLW1        35.00000000 W
======== CHANNEL f2 ========
SFO2        400.1316005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.17778000 W
PLW13        0.08942100 W
F2 - Processing parameters
SI                32768
SF          100.6127685 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0








Figure A-33. 1H NMR spectrum (400 MHz, CDCl3) of 28. 
 







































































































































































































NAME      LR-II-121-iso
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20191210
Time              10.10
INSTRUM           spect
PROBHD   5 mm QNP 1H/29
PULPROG            zg30
TD                65536
SOLVENT           CDCl3
NS                    8
DS                    2
SWH            5597.015 Hz
FIDRES         0.085404 Hz
AQ            5.8545494 sec
RG                70.82
DW               89.333 usec
DE                 6.50 usec
TE       0 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320010 MHz
NUC1                 1H
P1                11.25 usec
PLW1        10.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0












Figure A-34. 13C NMR (100 MHz, CDCl3) of 28. 
 




































































































































































































NAME     LR-II-121-iso-13C
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20191210
Time              10.44
INSTRUM           spect
PROBHD   5 mm QNP 1H/29
PULPROG          zgpg30
TD                65536
SOLVENT           CDCl3
NS                  500
DS                    4
SWH           24038.461 Hz
FIDRES         0.366798 Hz
AQ            1.3631488 sec
RG                195.7
DW               20.800 usec
DE                 6.50 usec
TE       0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6228293 MHz
NUC1                13C
P1                10.00 usec
PLW1        35.00000000 W
======== CHANNEL f2 ========
SFO2        400.1316005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.17778000 W
PLW13        0.08942100 W
F2 - Processing parameters
SI                32768
SF          100.6127685 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0












Figure A-35. 1H NMR spectrum (400 MHz, Acetone-D6) of 29. 
 



































































































































































































NAME     LR-II-122-crude
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20191211
Time              16.02
INSTRUM           spect
PROBHD   5 mm QNP 1H/29
PULPROG            zg30
TD                65536
SOLVENT         Acetone
NS                    8
DS                    2
SWH            5597.015 Hz
FIDRES         0.085404 Hz
AQ            5.8545494 sec
RG               124.36
DW               89.333 usec
DE                 6.50 usec
TE       0 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320010 MHz
NUC1                 1H
P1                11.25 usec
PLW1        10.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0


















































































































































































































































NAME     LR-II-122-crude-13C
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20191211
Time              16.38
INSTRUM           spect
PROBHD   5 mm QNP 1H/29
PULPROG          zgpg30
TD                65536
SOLVENT         Acetone
NS                  433
DS                    4
SWH           24038.461 Hz
FIDRES         0.366798 Hz
AQ            1.3631488 sec
RG                195.7
DW               20.800 usec
DE                 6.50 usec
TE       0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6228293 MHz
NUC1                13C
P1                10.00 usec
PLW1        35.00000000 W
======== CHANNEL f2 ========
SFO2        400.1316005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.17778000 W
PLW13        0.08942100 W
F2 - Processing parameters
SI                32768
SF          100.6127685 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0












Figure A-37. 1H NMR spectrum (400 MHz, Acetone-D6) of Ratio-pHCL-1. 
 



























































































































































































































NAME     LR-II-132-iso-2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20200123
Time              15.22
INSTRUM           spect
PROBHD   5 mm QNP 1H/29
PULPROG            zg30
TD                65536
SOLVENT         Acetone
NS                    8
DS                    2
SWH            5597.015 Hz
FIDRES         0.085404 Hz
AQ            5.8545494 sec
RG                195.7
DW               89.333 usec
DE                 6.50 usec
TE       0 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1320010 MHz
NUC1                 1H
P1                11.25 usec
PLW1        10.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0














Figure A-38. 13C NMR spectrum (100 MHz, Acetone-D6) of Ratio-pHCL-1. 
 
  









































































































































































































































NAME     LR-II-132-iso-2-13C''
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20200123
Time              21.30
INSTRUM           spect
PROBHD   5 mm QNP 1H/29
PULPROG          zgpg30
TD                65536
SOLVENT         Acetone
NS                 5120
DS                    4
SWH           24038.461 Hz
FIDRES         0.366798 Hz
AQ            1.3631488 sec
RG                195.7
DW               20.800 usec
DE                 6.50 usec
TE       0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6228293 MHz
NUC1                13C
P1                10.00 usec
PLW1        35.00000000 W
======== CHANNEL f2 ========
SFO2        400.1316005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.17778000 W
PLW13        0.08942100 W
F2 - Processing parameters
SI                32768
SF          100.6127685 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0






























































































































A2-1. Deriving [At], [Bt], [Ct] in a linear reaction 
AàBàC reaction 
Where x=[A], y=[B], z=[C] 
Rate of formation of A: 
(1) ()
(*
= −𝑘+𝑥  integrate 0àt 
(2) −ln(𝑥*) = 𝑘+𝑡 + 	𝐶 when t = 0, x = a 
(3) −ln	(𝑥) = 𝑘+𝑡 − ln	(𝑎) rearrange 
(4) ln(𝑥) − ln(𝑎) = −𝑘+𝑡 rearrange 
(5) ln 2)
,
3 = −𝑘+𝑡 take e exponential, rearrange 
(6) 𝑥 = 𝑎𝑒%-!* 











 substitute (1) for ()
(*





= 𝑘+𝑥 − 𝑘/𝑦  substitute (6) for x 
(10) (0
(*





+ 𝑘/𝑦 = 𝑘+𝑎𝑒%-!* multiply both sides by 𝑒%-"* 
(12) [(0
(*
+ 𝑘/𝑦](𝑒%-"*) = 𝑘+𝑎(𝑒%-!*)(𝑒%-"*) 
(
(
(𝑥 × 𝑦) = 𝑥𝑑𝑦 + 𝑦𝑑𝑥 
(13) (
(*
[𝑦 × 𝑒-"*] = 𝑘+𝑎𝑒(-"%-!)* rearrange 
(14)	𝑑[𝑦 × 𝑒-"*] = 𝑘+𝑎𝑒(-"%-!)*𝑑𝑡 integrate 0àt 
(15) 𝑦𝑒-"* = 𝑘+𝑎
3($"%$!)'
-"%-!
+ 𝐶 at initial conditions when t = 0, y=0, substitute for t and y 
(16) 0 = 𝑘+𝑎
3(
-"%-!
+ 𝐶 rearrange 
(17) 𝐶 = %-!,
-"%-!
  substitute into (15) 





  simplify and divide expression by 𝑒-"* 
(19) 𝑦 = -!,
-"%-!
[𝑒-"* × 𝑒%-!* × 𝑒%-"* − 𝑒%-"*] 𝑒-"*and 𝑒%-"* cancel, leaving: 
(20) 𝑦 = -!,
-"%-!












A2-2. Alternate kinetic fits based on derived rate equation 
 
Figure A2-1. Kinetic model. (A) Reactions used to model the chemiluminescence emission. 
(B) Rate equation for the chemiluminescence emission. y-value represents [HyCL-4] 
generated after k1. (C) Example fit of the chemiluminescence response of 40 µM HyCL-4-AM 
in A549 cells at 1% O2. (D) Example fit of the chemiluminescence response of 40 µM HyCL-
4-AM in A549 cells at 20% O2. (E) Alternate Rate equation for the chemiluminescence 
emission. y-value represents [HyCL-4] generated after k1. (F) Example fit of the 
chemiluminescence response of 40 µM HyCL-4-AM in A549 cells at 1% O2. (G) Example fit 
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r2 = 0.996 r2 = 0.998A = 620.267
k1 = 0.0407 min–1
= 0.000679 s–1





k1 = 0.0323 min–1
= 0.000538 s–1




k1 = 0.00285 min-1
= 0.0000475 sec-1
A = 214,052
k2 = 0.0278 min-1
= 0.000463 min-1
B = 20.435
r2 = 0.998k1 = 0.0407 min-1
= 0.000678 sec-1
A = 50,340
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F G
